

API IMPURITIES AND METABOLITES

COMPOUND NAME	PRODUCT CODE	CAS NO.	MF/MW	SYNONYMS
ACECLOFENAC	RBPL-A0100			
Aceclofenac impurity A	RBPL-A0101	15307-86-5 (Free acid); 15307-79-6;	C ₁₄ H ₁₀ Cl ₂ NNaO ₂ ; 318.13	[2-[(2,6-Dichlorophenyl)amino] phenyl]acetic acid sodium salt; Diclofenac Sodium Salt ; Diclofenac free acid
Aceclofenac impurity B	RBPL-A0102	15307-78-5;	C ₁₅ H ₁₃ Cl ₂ NO ₂ ; 310.18	Methyl [2-[(2,6-dichlorophenyl) amino] phenyl]acetate; Diclofenac methyl ester
Aceclofenac impurity I	RBPL-A0103	15362-40-0	C ₁₄ H ₉ Cl ₂ NO; 278.13	1-(2,6-Dichlorophenyl)-1,3-dihydro-2H-indol-2-one; 1-(2,6-Dichlorophenyl)oxindole; N-(2,6-dichlorophenyl)-2-indolinone; NSC 621845; Diclofenac Lactam; USP Diclofenac Related Compound A; Diclofenac Amide
Aceclofenac impurity E	RBPL-A0104	139272-67-6	C ₁₈ H ₁₇ Cl ₂ NO ₄ ; 382.24	2-[(2,6-Dichlorophenyl)amino] benzeneacetic Acid 2-Ethoxy-2-oxoethyl Ester; Aceclofenac ethyl ester
Aceclofenac impurity D	RBPL-A0105	139272-66-5;	C ₁₇ H ₁₅ Cl ₂ NO ₄ ; 368.21	Methyl [[[2-[(2,6-dichlorophenyl) amino]phenyl] acetyl]oxy]acetate; Aceclofenac methyl ester
Aceclofenac impurity F	RBPL-A0106	100499-89-6	C ₂₃ H ₁₉ Cl ₂ NO ₄ ; 444.31	Aceclofenac Benzyl Ester; 2-[(2,6-Dichlorophenyl)amino]benzeneacetic Acid 2-Oxo-2-(phenylmethoxy)ethyl Ester;
Aceclofenac impurity G	RBPL-A0107	1215709-75-3	C ₁₈ H ₁₅ Cl ₂ NO ₆ ; 412.22	Acetic Aceclofenac; 2-[(2,6-Dichlorophenyl)amino]benzeneacetic Acid 2-(Carboxymethoxy)-2-oxoethyl Ester
Aceclofenac impurity C	RBPL-A0108	15307-77-4	C ₁₆ H ₁₅ Cl ₂ NO ₂ ; 324.20	2-[(2,6-Dichlorophenyl)amino] benzeneacetic Acid Ethyl Ester; [o-(2,6-Dichloroanilino)phenyl]acetic Acid Ethyl Ester; Ethyl 2-(2,6-Dichloroanilino) phenylacetate; Diclofenac Ethyl Ester
AZITHROMYCIN	RBPL-A0200			

API IMPURITIES AND METABOLITES

Azithromycin impurity E	RBPL-A0201	612069-27-9	$C_{36}H_{68}N_2O_{12}$; 720.93	Azithromycin-N,N'-Didesmethyl; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(3-Amino-3,4,6-trideoxy-β-D-xylo-hexopyranosyl)oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one; Aminoazithromycin A
Azithromycin impurity F	RBPL-A0202	612069-28-0	$C_{38}H_{70}N_2O_{13}$; 762.97	3'-N-Desmethyl-3'-N-formyl Azithromycin; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(methylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one; CP-64434
Azithromycin impurity I	RBPL-A0203	172617-84-4	$C_{37}H_{70}N_2O_{12}$; 734.96	3'-N-Demethylazithromycin
Azithromycin impurity L	RBPL-A0204	90503-06-3	$C_{38}H_{72}N_2O_{13}$; 764.98	Azithromycin 3'-N-Oxide; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethyloxidoamino)-α-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one;
Hydroxy Azithromycin	RBPL-A0205	756825-20-4	$C_{38}H_{72}N_2O_{13}$; 764.98	4'-Hydroxy Azithromycin; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[[3,6-Dideoxy-3-(dimethylamino)-β-D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
Azithromycin Impurity M	RBPL-A0206	765927-71-7	$C_{37}H_{68}N_2O_{13}$; 748.94	(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12, 14-heptamethyl-11-[[3,4,6-trideoxy-3-(formylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one; 3'-N,N-Di(desmethyl)-3'-N-formyl Azithromycin
ALBENDAZOLE	RBPL-A0300			
Albendazole impurity C	RBPL-A0301	75184-71-3	$C_{12}H_{15}N_3O_4S$; 297.33	Albendazole Sulfone; N-[6-(Propylsulfonyl)-1H-benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl [5-(propylsulfonyl)-1H-benzimidazol-2-yl]carbamate,

API IMPURITIES AND METABOLITES

Albendazole impurity B	RBPL-A0302	54029-12-8	C ₁₂ H ₁₅ N ₃ O ₃ S; 281.33	Albendazole Sulfoxide; Albendazole Oxide, Ricobendazole, RS-8852
Albendazole impurity D	RBPL-A0303	80983-34-2	C ₁₀ H ₁₃ N ₃ O ₂ S; 239.29	Desmethoxycarbonyl Albendazole Sulfone; 5-(Propylsulphonyl)-1Hbenzimidazol-2-amine
Albendazole impurity A	RBPL-A0305	80983-36-4	C ₁₀ H ₁₃ N ₃ S; 207.3	Amino Albendazole; 5-(Propylthio)-1H-benzimidazol-2-amine; Albendazole Amine; 5-(Propylsulphanyl)-1H-benzimidazol-2-amine; Desmethoxycarbonyl Albendazole.
ACEBUTALOL	RBPL-A0400			
Acebutalol impurity C	RBPL-A0401	40188-45-2	C ₁₂ H ₁₅ NO ₃ ; 221.25	N-(3-Acetyl-4-hydroxyphenyl)butanamide
Acebutalol impurity J	RBPL-A0402	57898-79-0	C ₁₇ H ₂₇ ClN ₂ O ₄ ; 358.	N-[3-Acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl) amino] propoxy] phenyl] propanamide
Acebutalol impurity A	RBPL-A0403	28197-66-2	C ₁₅ H ₁₉ NO ₄ ; 277.32	3'-Acetyl-4'-(2,3-epoxypropoxy)butyranilide; N-[3-Acetyl-4-(oxiranylmethoxy) phenyl] butanamide; Acebutolol EP Impurity A
AZELASTINE	RBPL-A0500			
Azelastine impurity A	RBPL-A0501	613-94-5	C ₇ H ₈ N ₂ O; 136.15	Benzoyl hydrazine
ABIRATERONE ACETATE	RBPL-A0600			
Abiraterone N-Oxide	RBPL-A0601	NA	C ₂₄ H ₃₁ NO ₂ ; 365.52	
Abiraterone Acetate-5,6-Epoxy	RBPL-A0602	NA	C ₂₆ H ₃₃ NO ₃ ; 407.56	5,6-Epoxy Abiaterone acetate
Abiraterone	RBPL-A0603	154229-19-3	C ₂₄ H ₃₁ NO; 349.51	(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol; CB 7598;
3-Keto Abiraterone	RBPL-A0604	154229-21-7	C ₂₄ H ₂₉ NO; 347.49	(10R,13S)-10,13-dimethyl-17-(pyridin-3-yl)-1,2,6,7,8,9,10,11,12,13,14,15-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
Abiraterone RC-I	RBPL-A0605	979-02-2	C ₂₃ H ₃₂ O ₃ ; 356.5	16-Dehydro Pregnenolone Acetate; 3β)-3-(Acetyloxy)pregna-5,16-dien-20-one; 3β-

API IMPURITIES AND METABOLITES

				Hydroxypregna-5,16-dien-20-one Acetate; (-)-16-Dehydropregnenolone Acetate; 16,17-Didehydropregnenolone Acetate; 16-DPA; 16-Dehydropregnenolone-3 β -acetate; 20-Oxopregna-5,16-dien-3 β -yl Acetate; 3 β -Acetoxypregna-5,16-dien-20-one; 3 β -Acetyloxy-pregna-5,16-dien-20-one; NSC 37741; Pregnadienolone Acetate;
Abiraterone Impurity B	RBPL-A0606	53-43-0	C ₁₉ H ₂₈ O ₂ ; 288.42	3 β -Hydroxy-5-androsten-17-one, 5-Androsten-3 β -ol-17-one, DHEA, Dehydroepiandrosterone, Dehydroisoandrosterone, Prasterone
APREPITANT	RBPL-A0700			
Aprepitant N-oxide	RBPL-A0703	172673-23-3	C ₂₃ H ₂₁ F ₇ N ₄ O ₄ ; 550.43	[2R-[2 α (R*),3 α]]-5-[[2-[1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-oxido-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one
ATORVASTATIN	RBPL-A0800			
Atorvastatin Impurity H	RBPL-A0801	125995-03-1	C ₃₃ H ₃₃ FN ₂ O ₄ ; 540.62	Atorvastatin lactone; 5-(4-Fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1H-pyrrole-3-carboxamide; Atorvastatin δ -Lactone
o-OH Atorvastatin lactone	RBPL-A0802	163217-74-1	C ₃₃ H ₃₃ FN ₂ O ₅ ; 556.62	2-Hydroxy Atorvastatin Lactone; 5-(4-Fluorophenyl)-N-(2-hydroxyphenyl)-2-(1-methylethyl)-4-phenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1H-pyrrole-3-carboxamide
p-OH Atorvastatin lactone	RBPL-A0803	163217-70-7	C ₃₃ H ₃₃ FN ₂ O ₅ ; 556.62	4-Hydroxy Atorvastatin Lactone; 5-(4-Fluorophenyl)-N-(4-hydroxyphenyl)-2-(1-methylethyl)-4-phenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1H-pyrrole-3-carboxamide;
Atorvastatin related compound D	RBPL-A0804	148146-51-4	C ₂₆ H ₂₂ FNO ₄ ; 431.46	Atorvastatin Epoxydione; 3-(4-Fluorobenzoyl)-2-(2-methyl-1-oxopropyl)-N,3-diphenyloxirane carboxamide; Impurity D

API IMPURITIES AND METABOLITES

Atovastatin related compound C	RBPL-A0805	693793-53-2 (ca salt); 693794-20-6 (FB)	$C_{66}H_{68}CaF_2N_4O_{10}$; 1191.3; $C_{33}H_{34}F_2N_2O_5$; 576.63	Difluoro Atorvastatin Calcium Salt; ($\beta R, \delta R$)-2,3-Bis(4-fluorophenyl)- β, δ -dihydroxy-5-(1-methylethyl)-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt; Impurity C
Atovastatin related compound A	RBPL-A0806	433289-83-9	$C_{33}H_{35}CaN_2O_5$; 579.7194	Atorvastatin Related Compound A, (Desfluoro impurity, or (3R,5R)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt); Desfluoro Atorvastatin Sodium Salt; calcium (3R,5R)-3,5-dihydroxy-7-(2-isopropyl-4,5-diphenyl-3-(phenylcarbamoyl)-1H-pyrrol-1-yl)heptanoate; Atorvastatin EP Impurity A; Desfluoro Atorvastatin Calcium Salt; ($\beta R, \delta R$)- β, δ -Dihydroxy-2-(1-methylethyl)-4,5-diphenyl-3-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
Atovastatin related compound B	RBPL-A0807	-	$C_{33}H_{34}N_2O_{5.1/2}Ca$; 557.63	(3S,5R)-Atorvastatin Calcium Salt; ($\beta S, \delta R$)-2-(4-Fluorophenyl)- β, δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt; Atorvastatin USP Related Compound B
Atovastatin related compound E	RBPL-A0808	501121-34-2 (free acid)	$C_{33}H_{34}N_2NaO_5$; 557.63	($\beta S, \delta S$)-2-(4-Fluorophenyl)- β, δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Sodium; 3S,5S-Atorvastatin Sodium
Atorvastatin Impurity I	RBPL-A0809	125971-95-1	$C_{40}H_{47}FN_2O_5$; 654.81	Atorvastatin Acetonide tert-Butyl Ester; (4R,6R)-6-[2-[2-(4-Fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]ethyl]-2,2-dimethyl-1,3-dioxane-4-acetic Acid 1,1-Dimethylethyl Ester; Atorvastatin Related Compound I USP; Atorvastatin EP Impurity I
ASPIRIN	RBPL-A0900			
Aspirin Impurity E	RBPL-A0901	552-94-3	$C_{14}H_{10}O_5$; 258.23	Salicylic acid; 2-Hydroxybenzoic acid 2-carboxyphenyl ester
Aspirin Impurity F	RBPL-A0902	1466-82-6	$C_{18}H_{14}O_7$	Acetyl salicylic acid
Aspirin Impurity A	RBPL-A0903	99-96-7	$C_7H_6O_3$; 138.12	p-Salicylic Acid; p-Salicylic Acid; 4-Hydroxybenzoic Acid; 4-Carboxyphenol; Paraben-acid; p-Carboxyphenol; p-Hydroxybenzoic Acid; NSC 4961; USP Salicylic

API IMPURITIES AND METABOLITES

				Acid Related Compound A
Aspirin Impurity B	RBPL-A0904	636-46-4	C ₈ H ₆ O ₅ ; 182.13	4-Hydroxyisophthalic Acid; 4-Hydroxy-1,3-benzenedicarboxylic Acid; 4-Hydroxy-m-phthalic Acid; Eupirina; NSC 2445; USP Salicylic Acid Related Compound B; Acetylsalicylic Acid EP Impurity B/ Salicylic Acid Related Compound B
Aspirin Impurity C (Acetylsalicylic Acid EP Impurity C)	RBPL-A0905	69-72-7	C ₇ H ₆ O ₃ ; 138.12	Salicylic Acid; 2-Hydroxybenzoic Acid; 2-Carboxyphenol; 2-Hydroxybenzenecarboxylic Acid; 2-Hydroxybenzoic Acid; o-Carboxyphenol; o-Hydroxybenzoic Acid; Rutranex; Saligel; Salonil; Salvona Nanosal; Stri-Dex; Trans-Ver-Sal; Verrugon; Acetylsalicylic Acid EP Impurity C (Aspirin Impurity C)/ Mesalazine EP Impurity H
AMOXICILLIN	RBPL-A1000			
Amoxicillin impurity A	RBPL-A1001	551-16-6	C ₈ H ₁₂ N ₂ O ₃ S; 216.26	6-Aminopenicillanic acid; 2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-APA ; Flucloxacillin impurity C; Amoxicillin related compound A
ARIPIRAZOLE	RBPL-A1100			
Aripiprazole Related Compound F (N-oxide)	RBPL-A1101	573691-09-5	C ₂₃ H ₂₇ Cl ₂ N ₃ O ₃ ; 464.38	7-[4-[4-(2,3-Dichlorophenyl)-1-oxido-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone; Aripiprazole-N-oxide
Aripiprazole-N,N'-dioxide	RBPL-A1102	573691-13-1	C ₂₃ H ₂₇ Cl ₂ N ₃ O ₄ ; 480.38	7-[4-[4-(2,3-Dichlorophenyl)-1,4-dioxido-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone
Aripiprazole impurity A (RC-A)	RBPL-A1103	22246-18-0	C ₉ H ₉ NO ₂ ; 163.17	3,4-Dihydro-7-hydroxyquinoline-2(1H)-one; 7-Hydroxycarbostyryl; 3,4-Dihydro-7-hydroxy-2(1H)-quinolinone; 3,4-Dihydro-7-hydroxy-carbostyryl; 7-Hydroxy-1,2,3,4-tetrahydro-2-quinolinone;
Aripiprazole impurity B (RC-C)	RBPL-A1104	119532-26-2	C ₁₀ H ₁₃ Cl ₃ N ₂ ; 267.58	N-(2,3-Dichlorophenyl)piperazine Hydrochloride; 1-(2,3-Dichlorophenyl)piperazine Hydrochloride; 4-(2,3-Dichlorophenyl)piperazine Hydrochloride; DCPH-Hydrochloride; USP Aripiprazole Related Compound C; Aripiprazole EP Impurity B;

API IMPURITIES AND METABOLITES

				Aripiprazole USP Related Compound C
ACETAZOLAMIDE	RBPL-A1200			
Acetazolamide impurity A	RBPL-A1201	60320-32-3	C ₄ H ₄ ClN ₃ OS; 177.61	N-(5-Chloro-1,3,4-thiadiazol-2-yl)acetamide; 2-Acetamido-5-chloro-1,3,4-thiadiazole; 2-(Acetylamino)-5-chloro-1,3,4-thiadiazole; 2-Amino-5-acetamido-1,3,4-thiadiazole; NSC 231656
Acetazolamide impurity B	RBPL-A1202	NA	C ₄ H ₅ N ₃ OS; 143.17	2-(Acetylamino)-1,3,4-Thiadiazole; N-1,3,4-thiadiazol-2-ylacetamide; [(1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)cyclopent-2-enyl]methanol hydrochloride
Acetazolamide impurity E	RBPL-A1203	827026-60-8 (free acid)	C ₄ H ₅ N ₃ O ₄ S ₂ ; 223.23	5-acetamido-1,3,4-thiadiazole-2-sulfonic acid
Acetazolamide impurity C	RBPL-A1204	32873-56-6	C ₄ H ₅ N ₃ OS ₂ ; 175.23	2-Acetamido-5-mercapto-1,3,4-thiadiazole; N-(4,5-Dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)acetamide; N-(5-Mercapto-1,3,4-thiadiazol-2-yl)acetamide; 2-Acetylamino-1,3,4-thiadiazoline-2-thione;
Acetazolamide Impurity G	RBPL-A1205	2349-67-9	C ₂ H ₃ N ₃ S ₂ ; 133.2	5-Amino-1,3,4-thiadiazole-2-thiol; 2-Amino-1,3,4-thiadiazol-5-thiol; 2-Amino-1,3,4-thiadiazole-5-mercaptan; 2-Amino-1,3,4-thiadiazole-5-thiol; 2-Amino-5-mercapto-1,3,4-thiadiazole; 2-Amino-5-mercapto-1,3,5-thiadiazole; 2-Amino-5-mercaptothiadiazoole; 2-Amino-Δ ² -1,3,4-thiadiazoline-5-thione; 2-Mercapto-5-amino-1,3,4-thiadiazole; 2-Thiol-5-amino-1,3,4-thiadiazole; 5-Amino-1,3,4-thiadiazole-2(3H)-thione; 5-Amino-1,3,4-thiadiazole-2-thiol; 5-Amino-1,3,4-thiadiazole-2-thione; 5-Amino-1,3,4-thiadiazoline-2-thione; 5-Amino-1,3,4-thidiazole-2-thiol; 5-Amino-2-mercapto-1,3,4-thiadiazole; 5-Amino-3H-1,3,4-thiadiazole-2-thione; 5-Thio-2-amino-[1,3,4]thiadiazole; 5-Thiol-2-amino-1,3,4-thiadiazole; ATT; NSC 209061; NSC 21402; WR 180; Acetazolamide EP Impurity G
AMLODIPINE	RBPL-A1300			

API IMPURITIES AND METABOLITES

Amlodipine impurity A	RBPL-A1301	88150-62-3	$C_{28}H_{27}ClN_2O_7$; 538.98	Phthalimide amlodipine; 4-(2-Chlorophenyl)-2-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy)methyl]-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic Acid 3-Ethyl 5-Methyl Ester; 4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-2-[(2-phthalimidoethoxy)methyl]-1,4-dihydropyridine; Phthaloyl Amlodipine
Amlodipine impurity G	RBPL-A1302	43067-01-2	$C_{17}H_{18}ClNO_4$; 335.78	4-(2-Chlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic Acid 3,5-Dimethyl Ester; 4-(2-Chlorophenyl)-3,5-di(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine; Dimethyl 4-(2-Chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Amlodipine impurity E	RBPL-A1303	140171-65-9	$C_{21}H_{27}ClN_2O_5$; 422.9	Amlodipine Diethyl Ester; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic Acid 3,5-Diethyl Ester; 3-Ethyl 5-Ethyl 4-(2-Chlorophenyl)-6-methyl-2-[[2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine-3,5-dicarboxylate]; RC E
ALFUZOSIN	RBPL-A1400			
Alfuzosin impurity A	RBPL-A1401	98902-29-5; 98902-36-4 (Base)	$C_{19}H_{24}ClN_5O_4$; 421.88	2,3,4,5-Tetradehydro Alfuzosin Hydrochloride; N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolinyl) methylamino] propyl]-2-furancarboxamide Hydrochloride;
Alfuzosin impurity B	RBPL-A1402	23680-84-4	$C_{10}H_{10}ClN_3O_2$; 239.66	4-Amino-2-chloro-6,7-dimethoxyquinazoline; 2-Chloro-6,7-dimethoxy-4-quinazolinamine; USP Doxazosine Related Compound C; Terazosin EP Impurity A; Alfuzosin EP Impurity B; Doxazosin EP Impurity F
ALLOPURINOL	RBPL-A1500			
Allopurinol impurity A	RBPL-A1501	22407-20-1	$C_4H_6N_4O$; 126.12	3-Amino-pyrazole-4-carboxylic acid amide
Allopurinol impurity D (RC-D)	RBPL-A1502	6994-25-8	$C_6H_9N_3O_2$; 155.15	3-Amino-4-carbethoxypyrazole, Ethyl 3-aminopyrazole-4-carboxylate
ACYCLOVIR	RBPL-A1600			

API IMPURITIES AND METABOLITES

Acyclovir impurity B	RBPL-A1601	73-40-5	C ₅ H ₅ N ₅ O; 151.13	Guanine; 2-Amino-1,9-dihydro-6H-purin-6-one; 2-Amino-6-hydroxy-1H-purine; 2-Amino-6-hydroxypurine; 2-Aminohypoxanthine; 9H-Guanine; 2-Amino-hypoxanthine; Acyclovir Impurity B; Acyclovir Impurity B, Acyclovir EP RRT - 0.4; Aciclovir EP Impurity B; (Valaciclovir Impurity A)
Acyclovir impurity L	RBPL-A1602	3056-33-5	C ₉ H ₉ N ₅ O ₃ ; 235.2	N2,9-Diacetylguanine; N-(9-Acetyl-6,9-dihydro-6-oxo-1H-purin-2-yl)acetamide; 2,9-Diacetylguanine; Acyclovir Diacetylguanine Impurity; Aciclovir EP Impurity L
ASENAPINE	RBPL-A2000			
Asenapine Amide	RBPL-A2001	NA	C ₁₇ H ₁₄ ClNO ₂ ; 299.75	(3aR,12bR)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrol-1-one
Asenapine Deschloro	RBPL-A2002	NA	C ₁₇ H ₁₇ NO; 251.33	(3aR,12bR)-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7] oxepino[4,5-c]pyrrole
Cis-Asenapine	RBPL-A2003	65621-78-5	C ₁₇ H ₁₆ ClNO; 285.77	(3aR,12bR)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole
Asenapine-N-oxide	RBPL-A2004	128949-51-9	C ₁₇ H ₁₆ ClNO ₂ ; 301.77	(3aR-trans)-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole 2-Oxide
Asenapine Desmethyl	RBPL-A2005	1170701-78-6	C ₁₆ H ₁₅ Cl ₂ NO; 308.20	(3aR,12bR)-rel-5-Chloro-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole hydrochloride
Asenapine Deschloro amide	RBPL-A2006			
AMIODARONE	RBPL-A2100			
Amiodarone N-Oxide	RBPL-A2101	318267-30-0	C ₂₅ H ₂₉ I ₂ NO ₄ ; 661.30	2-(4-(2-butylbenzofuran-3-carbonyl)-2,6-diiodophenoxy)-N,N-diethylethanamine oxide

API IMPURITIES AND METABOLITES

Amiodarone Impurity B	RBPL-A2102	96027-74-6 (Hcl); freebase: 83409-32-9	$C_{23}H_{26}ClI_2NO_3$; 653.72	2-Butyl-3-benzofuranyl-4-[2-(ethylamino)ethoxy]-3,5-diiodophenyl Ketone Hydrochloride; Amiodarone EP Impurity B ; Amiodarone USP Related Compound B; Desethyl Amiodarone Hydrochloride
Amiodarone Impurity E (RC-E)	RBPL-A2103	52490-15-0	$C_{19}H_{18}O_3$; 294.34	2-Butyl-3-(4-hydroxybenzoyl)benzofuran; (2-Butyl-benzofuran-3-yl)-(4-hydroxyphenyl)-methanone; (2-Butylbenzofuran-3-yl)-(4-hydroxyphenyl)ketone; USP Amiodarone Related Compound E;Amiodarone EP Impurity E
AMITRIPTYLINE	RBPL-A2200			
Amitriptyline N-Oxide	RBPL-A2201	4317-14-0	$C_{20}H_{23}NO$; 293.40	3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine N-Oxide; 10,11-Dihydro-N,N-dimethyl-5H-Dibenzo[a,d]cycloheptene-Δ5,γ-propylamine N-Oxide; Amitriptyline Oxide; Amitriptylinoxide; Equilibrin
Amitriptyline EP Impurity A (Dibenzosuberone)	RBPL-A2202	1210-35-1	$C_{15}H_{12}O$; 208.26	Dibenzosuberone; 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-one; 10,11-Dihydro-5H-dibenzo[a,d]cycloheptatrien-5-one; 10,11-Dihydrodibenzo[a,d]cyclohepten-5-one; 2,3:6,7-Dibenzosuberone; Dibenzo[a,d]cyclohepta[1,4]dien-5-one; Dibenzo[a,d]cycloheptadien-5-one; Dibenzocycloheptenone; Dibenzosuberan-5-one; Dibenzosuberone; NSC 49727; USP Amitriptyline Related Compound A; Amitriptyline EP Impurity A
AMISULPRIDE	RBPL-A2300			
Amisulpride N-Oxide	RBPL-A2301	71676-01-2	$C_{17}H_{27}N_3O_5S$; 385.49	4-Amino-N-[(1-ethyl-1-oxido-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide N-Oxide; Amisulpride EP Impurity F
Amisulpride Impurity A	RBPL-A2302	26116-12-1	$C_7H_{16}N_2$; 128.22	2-(Aminomethyl)-1-ethylpyrrolidine; (1-Ethyl-2-pyrrolidinyl)methylamine; (1-Ethylpyrrolidin-2-yl)methanamine; (±)-2-(Aminomethyl)-1-ethylpyrrolidine; 1-(1-Ethylpyrrolidin-2-yl)methanamine; 1-Ethyl-2-(aminomethyl)pyrrolidine; 1-Ethyl-2-pyrrolidinemethanamine; 1-Ethyl-2-pyrrolidinemethylamine; 2-(Aminomethyl)-1-

API IMPURITIES AND METABOLITES

				ethyl-pyrrolidine; 2-(Aminomethyl)-N-ethylpyrrolidine; N-Ethyl-2-(aminomethyl)pyrrolidine; N-Ethyl- α -aminomethylpyrrolidine; N-[(1-Ethylpyrrolidin-2-yl)methyl]amine; Amisulpride EP Impurity A
Amisulpride Impurity E	RBPL-A2303	71675-87-1	C ₁₀ H ₁₃ NO ₅ S; 259.28	2-Methoxy-4-amino-5-ethylsulfonylbenzoic Acid; 4-Amino-5-(ethylsulfonyl)-2-methoxybenzoic Acid; Amisulpride EP Impurity E
ASCORBIC ACID	RBPL-A2400			
Ascorbic Acid Impurity A	RBPL-A2401	98-01-1	C ₅ H ₄ O ₂ ; 96.08	Furfural; 2-Furancarboxaldehyde; 2-Furaldehyde; 2-Formylfuran; 2-Furaldehyde; 2-Furancarbaldehyde; 2-Furancarbaldehyde; 2-Furfural; 2-Furfuraldehyde; 2-Furylaldehyde; 2-Furylcarboxaldehyde; Artificial ant oil; Fural; Furaldehyde; Furan-2-carboxaldehyde; Furancarbaldehyde; Furfuraldehyde; Furfurole; Furfurole; Furfurylaldehyde; Furole; NSC 8841; Pyromucic aldehyde; α -Furole
Ascorbic Acid Impurity E	RBPL-A2402	144-62-7; Dihydrate: 6153-56-6	C ₂ H ₂ O ₄ ; 90.03	Oxalic Acid; Ethanedioic Acid; Aktisal; Aquisal; DeerClean; NSC 132055; NSC 151956; NSC 62774; NSC 76990; Ultraplast Activate S 52
Ascorbic Acid Impurity F	RBPL-A2403	89-65-6	C ₆ H ₈ O ₆ ; 176.12	D(-)-Isoascorbic Acid (Erythorbic Acid); Araboascorbic Acid; Araboascorbic Acid, D-; D(-)-Isoascorbic Acid; D-Araboascorbic Acid; D-Erythorbic Acid; D-Isoascorbic Acid; D-arabino-Ascorbic Acid; E 315; Erycorbin; Glucosaccharonic Acid; Isoascorbic Acid; Isovitamin C; Mercate 5; NSC 8117; Neo-Cebicure; Saccharosonic Acid
ANASTROZOLE	RBPL-A2500			
Anastrozole Impurity F	RBPL-A2501	6192-52-5; Free Base: 104-15-4	C ₇ H ₁₀ O ₄ S; 190.22	4-Methylbenzenesulfonic Acid Hydrate; 4-Methylbenzenesulfonic Acid Monohydrate; 4-Toluenesulfonic Acid Monohydrate; Tosic Acid Monohydrate; PTSA Monohydrate; p-Toluenesulfonic Acid Monohydrate; TsOH; p-tsa; Lisinopril EP Impurity B; Anastrozole EP Impurity F
ALMOTRIPTAN	RBPL-A2600			

API IMPURITIES AND METABOLITES

Almotriptan RC	RBPL-A2601	334981-10-1	C ₁₁ H ₁₆ N ₂ O ₂ S; 240.32	4-[(1-Pyrrolidinylsulfonyl)methyl]aniline; 1-[(4-Aminobenzenemethane) sulfonyl]pyrrolidine; 4-[(1-Pyrrolidinylsulfonyl) methyl]benzenamine; 1-[(4-Aminophenyl)methyl] sulfonyl]pyrrolidine; N-[(4-Aminobenzenemethane) sulfonyl] pyrrolidine
Almotriptan N-Oxide	RBPL-A2602	603137-43-5	C ₁₇ H ₂₅ N ₃ O ₃ S; 351.46	N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine oxide
ATOMOXETINE	RBPL-A2700			
Atomoxetine Impurity E	RBPL-A2701	17199-29-0	C ₈ H ₈ O ₃ ; 152.15	(S)-(+)-Mandelic Acid; (αS)-α-Hydroxybenzeneacetic Acid; L-Mandelic Acid; (+)-(S)-Mandelic Acid; (+)-L-Mandelic Acid; (+)-Mandelic Acid; (+)-α-Hydroxyphenylacetic Acid; (2S)-2-Hydroxy-2-(phenyl)ethanoic Acid; L-2-Phenylglycolic Acid; Atomoxetine EP Impurity E
Atomoxetine Impurity H (RC-A)	RBPL-A2702	42142-52-9	C ₁₀ H ₁₅ NO; 165.23	α-[2-(Methylamino)ethyl]benzyl Alcohol; (±)-N-Methyl-3-hydroxy-3-phenylpropylamine; 3-(Methylamino)-1-phenyl-1-propanol; 3-Hydroxy-N-methyl-3-phenylpropylamine; 3-Methylamino-1-phenylpropanol; N-(3-Hydroxy-3-phenylpropyl)methylamine; N-Methyl-3-hydroxy-3-phenylpropylamine; N-Methyl-3-phenyl-3-hydroxypropylamine; α-[2-(Methylamino)ethyl]benzenemethanol; N-Methyl-N-(3-hydroxy-3-phenylpropyl)amine; Fluoxetine EP Impurity A (Atomoxetine Related Compound A)
ADAPALENE	RBPL-A2800			
Adapalene Rel Comp. A	RBPL-A2801	33626-98-1	C ₁₂ H ₉ BrO ₂ ; 265.1	Methyl 6-Bromo-2-napthoate; Methyl 6-Bromonaphthalene-2-carboxylate; 6-Bromonaphthalene-2-carboxylic Acid Methyl Ester; USP Adapalene Related Compound A; Adapalene USP Related Compound A
ALVIMOPAN	RBPL-A2900			
Alvimopan Impurity I	RBPL-A2901	119193-19-0	C ₁₃ H ₁₉ NO; 205.3	(+)-(3R,4R)-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine; 3-[(3R,4R)-3,4-Dimethyl-4-piperidinyl]phenol; (3R-cis)-3-(3,4-dimethyl-4-

API IMPURITIES AND METABOLITES

				piperidiny)phenol; (+)-(3R,4R)-3,4-Dimethyl-4-(3-hydroxyphenyl) piperidine; (+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)piperidine;
AMILORIDE	RBPL-A3000			
Amiloride impurity A	RBPL-A3001	1458-01-1	C ₆ H ₇ ClN ₄ O ₂ ; 202.6	3,5-Diamino-6-chloropyrazine-2-carboxylic Acid Methyl Ester; Methyl 3,5-Diamino-6-chloropyrazinecarboxylate; 3,5-Diamino-6-chloro-2-pyrazinecarboxylic Acid Methyl Ester; USP Amiloride Related Compound A; Amiloride USP Related Compound A
AMPICILLIN	RBPL-A3100			
Ampicillin EP Impurity L	RBPL-A3101	875-74-1	C ₈ H ₉ NO ₂ ; 151.16	D-(-)-2-Phenylglycine; (-)-(R)-Phenylglycine; (-)-Phenylglycine; (2R)-Amino-2-phenylethanoic Acid; (R)-(-)-2-Phenylglycine; (R)-2-Amino-2-phenylacetic Acid; (R)-2-Amino-2-phenylethanoic Acid; (R)-2-Phenyl-2-aminoethanoic Acid; (R)-2-Phenylglycine; (R)-2-Phenylglycine; (R)-Phenylglycine; (R)-Phenylglycine; (R)-α-Phenylglycine; D-(-)-Aminophenylacetic Acid; D-(-)-Phenylglycine; D-(-)-α-Aminophenylacetic Acid; D-(-)-α-Phenylglycine; D-2-Phenylglycine; D-C-Phenylglycine; D-Phenylglycine; D-α-Aminophenylacetic Acid; D-α-Phenylglycine; D-2-Phenylglycine; (R)-α-Aminobenzeneacetic Acid; (αR)-α-Aminobenzeneacetic Acid; Cefalexin EP Impurity A; Ampicillin EP Impurity L; Cephalexin EP Impurity A
BECLOMETHASONE	RBPL-B0100			
Beclomethasone Impurity R	RBPL-B0101	NA	C ₂₂ H ₂₈ O ₅ ; 372.47	Beclomethasone Dipropionate - Impurity R ; 9,11β-Epoxy-17,21-dihydroxy-16β-methyl-9β-pregna-1,4-diene-3,20-dione; (9β,11β,16β)-9,11-Epoxy-17,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; Betamethasone 9-11-Epoxy;
Beclomethasone Impurity G	RBPL-B0102	1186048-33-8	C ₃₁ H ₄₁ FO ₈ ; 560.65	Betamethasone Tripropionate; Betamethasone 11,17,21-Tripropionate, (11β,16β)-9-Fluoro-16-methyl-11,17,21-tris(1-oxopropoxy)pregna-1,4-diene-3,20-dione; Betamethasone 11,17,21-Tripropionate

API IMPURITIES AND METABOLITES

Beclomethasone Impurity V	RBPL-B0103	205105-83-5	C ₂₅ H ₃₂ O ₆ ; 428.52	9,11-epoxide-21-propionate; (9β,11β,16β)-9,11-Epoxy-17-hydroxy-16-methyl-21-(1-oxopropoxy)pregna-1,4-diene-3,20-dione; Beclomethasone 9,11-Epoxy 21-Propionate
BETAXOLOL	RBPL-B0200			
Betaxolol HCl impurity A	RBPL-B0201	464877-45-0	C ₁₄ H ₂₄ ClNO ₂ ; 273.8; 237 (FB)	Des[4-(2-cyclopropylmethoxy)] Betaxolol Hydrochloride; (2RS)-1-(4-Ethylphenoxy)-3-[(1-methylethyl)amino]-2-propanol Hydrochloride;
Betaxolol HCl impurity B	RBPL-B0202	62572-94-5	C ₁₄ H ₂₃ NO ₃ ; 253.34	O-Desmethyl Metoprolol; 4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]-benzeneethanol; (+/-)-4-[2-Hydroxy-3-(isopropylamino) propoxy]phenylethyl Alcohol; 4-[2-Hydroxy-3-[(1-methylethyl) amino]propoxy]-benzeneethanol; (+/-)-O-Demethylmetoprolol; H 105/22; SL 80-0088; ; Metoprolol impurity H
BUPROPION	RBPL-B0300			
Bupropion-2-amino impurity	RBPL-B0301	119802-69-6	C ₉ H ₁₀ ClNO; 183.64	2-amino-1(3-chlorophenyl)-1-propanone; 3-Chloro Cathinone
BENDROFLUMETHIAZIDE	RBPL-B0400			
Bendroflumethiazide Impurity A	RBPL-B0401	654-62-6	C ₇ H ₈ F ₃ N ₃ O ₄ S ₂ ; 318.28	4-Amino-6-(trifluoromethyl)-1,3-benzenedisulfonamide; 5-Trifluoromethyl-2,4-disulfamoylaniline; NSC 44625; 5-Amino-α,α,α-trifluoro-toluene-2,4-disulfonamide; 2,4-Disulfamyl-5-trifluoromethylaniline
BRIMONIDINE	RBPL-B0500			
Brimonidine Impurity A	RBPL-B0501	91147-43-2	C ₁₁ H ₁₁ N ₅ ; 213.24	Desbromo Brimonidine; N-(4,5-Dihydro-1H-imidazol-2-yl)-6-quinoxalinamine
Brimonidine Impurity B	RBPL-B0502	50358-63-9	C ₈ H ₆ BrN ₃ ; 224.06	6-Amino-5-bromoquinoxaline; 5-Bromo-6-quinoxalinamine; 5-Bromo-6-aminoquinoxaline; Brimonidine EP Impurity B
Brimonidine Impurity C	RBPL-B0503	6298-37-9	C ₈ H ₇ N ₃ ; 145.16	6-Quinoxalinamine; 6-Amino-quinoxaline; (Quinoxalin-6-yl)amine; 6-Aminoquinoxaline; 6-Quinoxalylamine; NSC 41810; Brimonidine EP Impurity C

API IMPURITIES AND METABOLITES

BISOPROLOL	RBPL-B0700			
Bisoprolol Impurity L	RBPL-B0701	29122-74-5	C ₁₃ H ₁₉ NO ₃ ; 237.29	4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzaldehyde; p-[2-Hydroxy-3-(isopropylamino)propoxy]benzaldehyde; H 128/80; Metoprolol Impurity C; Bisoprolol EP Impurity L (Metoprolol EP Impurity C)
BORTEZOMIB	RBPL-B0800			
Bortezomib Impurity B	RBPL-B0801	114457-94-2	C ₁₄ H ₁₃ N ₃ O ₃ ; 271.27	N-(2-pyrazinylcarbonyl)-L-phenylalanine; 3-Phenyl-2-[(pyrazine-2-carbonyl)amino]propionic Acid;
BICALUTAMIDE	RBPL-B0900			
Bicalutamide Impurity I	RBPL-B0901	90357-53-2	C ₁₂ H ₉ F ₃ N ₂ O; 254.21	N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-methylacrylamide ; N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-methyl-2-propenamid
Bicalutamide EP Impurity A	RBPL-B0902	90357-05-4	C ₁₈ H ₁₅ F ₃ N ₂ O ₄ S; 412.38	Desfluoro Bicalutamide; (+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methyl-3-(phenylsulfonyl)propanamide; Bicalutamide EP Impurity A
Bicalutamide EP Impurity D	RBPL-B0903	654-70-6	C ₈ H ₅ F ₃ N ₂ ; 186.13	5-Amino-2-cyanobenzotrifluoride; 4-Amino-2-(trifluoromethyl)benzonitrile; 4-Amino-α,α,α-trifluoro-o-tolunitrile; 2-Trifluoromethyl-4-aminobenzonitrile; 4-Cyano-3-(trifluoromethyl)aniline; Bicalutamide EP Impurity D
BENZOTHIADIAZINE	RBPL-B1000			
Benzothiadiazine Related Compound A	RBPL-B1001	121-30-2	C ₆ H ₈ ClN ₃ O ₄ S ₂ ; 285.73	4-Amino-6-chloro-1,3-benzenedisulfonamide; 4-Amino-6-chloro-m-benzenedisulfonamide; 3-Chloro-4,6-disulfamoylaniline; 5-Chloro-2,4-disulfamoylaniline; Chloraminophenamide; Chloroaminophenamide; Idorese; Salamid; Salamide; NSC 93772; USP Benzothiadiazine Related Compound A; Hydrochlorothiazide EP Impurity B
BUPIVACAINE	RBPL-B1100			
Bupivacaine impurity F	RBPL-B1101	87-62-7	C ₈ H ₁₁ N; 121.18	2,6-Dimethylaniline; 2,6-Dimethylbenzenamine; 2,6-DMA; 2,6-Xylidine; 1-Amino-

API IMPURITIES AND METABOLITES

				2,6-dimethylbenzene; 2,6-Dimethylbenzenamine; 2,6-Dimethylphenylamine; 2,6-Xylylamine; 2-Amino-1,3-dimethylbenzene; 2-Amino-1,3-xylene; 2-Amino-m-xylene; NSC 7098; o-Xylidine; Bupivacaine Imp. F (EP); USP Lidocaine impurity A; Lidocaine EP Impurity A
CLARITHROMYCIN	RBPL-C0100			
14-hydroxy Clarithromycin	RBPL-C0101	116836-41-0	C ₃₈ H ₆₉ NO ₁₄ ; 763.95	14-OH Clarithromycin; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13,14-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13,14-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
Clarithromycin impurity D (N-Desmethyl)	RBPL-C0102	101666-68-6	C ₃₇ H ₆₇ NO ₁₃ ; 733.93	N-Desmethyl Clarithromycin; N-Demethyl-6-O-methylerythromycin; 3"-N-Demethylclarithromycin; N-(Desmethyl)clarithromycin; N-Demethylclarithromycin; Clarithromycin related compound D;
Clarithromycin impurity Q	RBPL-C0103	118074-07-0	C ₃₈ H ₆₉ NO ₁₄ ; 763.95	Clarithromycin N-Oxide; 6-O-Methylerythromycin N-Oxide; Clarithromycin related compound Q
Clarithromycin impurity I	RBPL-C0104	118058-74-5	C ₃₀ H ₅₅ NO ₁₀ ; 589.76	De(cladinosyl) Clarithromycin; 3-O-De(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)-6-O-methylerythromycin; 5-O-Desosaminyl-6-O-methylerythronolide A; 3-O-Decladinosyl-6-O-methylerythronolide A;
Clarithromycin impurity K	RBPL-C0105	127157-35-1	C ₃₀ H ₅₁ NO ₈ ; 553.73	3-O-De(cladinosyl)-8,9,10,11-tetradehydro-9-deoxo-11,12-dideoxy-9,12-epoxy Clarithromycin; 3-O-De(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)-8,9,10,11-tetradehydro-9-deoxo-11,12-dideoxy-9,12-epoxy-6-O-methylerythromycin;
Clarithromycin impurity L	RBPL-C0106	127253-05-8	C ₃₈ H ₇₀ N ₂ O ₁₃ ; 762.97	Clarithromycin (9Z)-Oxime; 6-O-Methylerythromycin (9Z)-9-Oxime;

API IMPURITIES AND METABOLITES

				(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R,Z)-6-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-10-(hydroxyimino)-7-methoxy-3,5,7,9,11,13-hexamethyloxa cyclotetradecan-2-one
Clarithromycin impurity M	RBPL-C0107	127182-43-8	C ₃₇ H ₆₈ N ₂ O ₁₃ ; 748	N-Desmethyl-6-O-methylerythromycin (9E)-Oxime; 3-N-Demethyl-6-O-methylerythromycin A (E)-9-oxime; Oxacyclotetradecane Erythromycin deriv.;
Clarithromycin impurity N	RBPL-C0108	144604-03-5	C ₃₈ H ₆₇ NO ₁₂ ; 729.94	(10E)-10,11-Didehydro-11-deoxy-6-O-methylerythromycin; Oxacyclotetradecane Erythromycin Derivative
Clarithromycin impurity C	RBPL-C0109	127253--06-9	C ₃₈ H ₇₀ N ₂ O ₁₃ ; 762.97	Clarithromycin 9-Oxime; 6-O-Methylerythromycin 9-Oxime; 6-O-Methylerythromycin A 9-Oxime; 9E-Oxime
Clarithromycin impurity E	RBPL-C0110	81103-14-2	C ₃₉ H ₇₁ NO ₁₃ ; 761.98	Clarithromycin impurity E (6,11-Di-O-methylerythromycin A)
Clarithromycin impurity H	RBPL-C0111	127140-69-6	C ₃₈ H ₆₇ NO ₁₄ ; 761.94	Clarithromycin EP impurity H; N-Demethyl-N-formyl Clarithromycin; 3-N-Demethyl-3'-N-formyl-6-O-methylerythromycin A; N-Demethyl-N-formyl-6-O-methylerythrrithrcin EP Impurity H; N-Demethyl-N-formyl Clarithromycin
Clarithromycin impurity J	RBPL-C0112	13127-18-9	C ₃₇ H ₆₈ N ₂ O ₁₃ ; 748.94	Erythromycin A Oxime (Roxithromycin Impurity C); 9-Erythromycin 9-Oxime; 9-Erythromycin A Oxime; Erythromycin Oxime; Roxithromycin Impurity C; Clarithromycin EP Impurity J
Clarithromycin impurity R	RBPL-C0113	992-62-1	C ₃₆ H ₆₅ NO ₁₃ ; 719.9	N-Demethyl-erythromycin; Des-N-methylerythromycin; Demethylerythromycin; USP Clarithromycin Impurity R; Erythromycin EP Impurity B
CAPACITABINE	RBPL-C0200			
Capacitabine related compound C	RBPL-C0201	921769-65-5	C ₁₆ H ₂₀ FN ₃ O ₇ ; 385.34	Capecitabine-2',3'-cyclic Carbonate

API IMPURITIES AND METABOLITES

Capacitabine Impurity C	RBPL-C0202	161599-46-8	C ₁₃ H ₁₆ FN ₃ O ₆ ; 329.28	2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine; 5'-Deoxy-5-fluoro-cytidine 2',3'-Diacetate; Capecitabine Diacetyl Amino Impurity (USP)
Capacitabine Impurity A (RC-A)	RBPL-C0203	66335-38-4	C ₉ H ₁₂ FN ₃ O ₄ ; 245.21	5'-Deoxy-5-fluoro Cytidine; 5-Fluoro-5'-deoxycytidine, 5'-DFCR; USP Capecitabine Related Compound A; Capecitabine EP Impurity A
Capacitabine Impurity B (RC-B)	RBPL-C0204	3094-09-5	C ₉ H ₁₁ FN ₂ O ₅ ; 246.19	5'-Deoxy-5-fluorouridine; 5-Fluorodesoxyuridine; 5'-DFUR; 5'-dFUr; Doxifluridine; Flutron; Furtulon; Ro 21-9738; USP Capecitabine Related Compound B
CITALOPRAM	RBPL-C0300			
Citalopram impurity D	RBPL-C0301	1188264-72-3	C ₁₉ H ₂₀ BrFN ₂ O;	N-desmethyl Citalopram; 1-(4-Fluorophenyl)-1-(3-methylamino-propyl)-1,3-dihydro-isobenzofuran-5-carbonitrile Hydrobromide; 1-(3-Methylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5- carbonitrile.
Citalopram N-oxide (RC-E)	RBPL-C0302	63284-72-0	C ₂₀ H ₂₁ FN ₂ O ₂ ; 340.3913	Citalopram USP Related Compound E; 3-(5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl)-N,N-dimethylpropan-1-amine oxide; 3-(5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl)-N,N-dimethylpropan-1-amine oxide; Citalopram N-oxide
Citalopram impurity C	RBPL-C0303	372941-54-3	C ₂₀ H ₁₉ FN ₂ O ₂ ; 338.38	3-Oxo Citalopram; 1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-3-oxo- 5-isobenzofuran carbonitrile; USP Citalopram Related Compound C
Citalopram impurity E	RBPL-C0304	NA	C ₁₉ H ₂₂ BrClFNO; 413.05	Citalopram 5-Chloro Analog HBr; Citalopram USP Related Compound G, 1-(4'-Fluorophenyl)-1-(3-dimethylaminopropyl)-5-chlorophthalane hydrobromide ;
Citalopram impurity G	RBPL-C0305	1329745-98-3 (base)	C ₂₅ H ₃₃ FN ₂ O ₂ ; 412.54	Citalopram Impurity G; 5-Dimethylaminobutyryl Citalopram; 4-(Dimethylamino)-1-[(1RS)-1-[3- (dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2- benzofuran-5-yl]butan-1-one
CLOPIDOGREL	RBPL-C0400			

API IMPURITIES AND METABOLITES

Clopidogrel impurity A	RBPL-C0401	144750-42-5	C ₁₅ H ₁₅ Cl ₂ NO ₂ S; 344.26	(S)-Clopidogrel Acid Hydrochloride; (S)-α-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic Acid Hydrochloride; SR 26334 Hydrochloride; related compound A
Clopidogrel impurity B	RBPL-C0402	144750-52-7	C ₁₆ H ₁₇ Cl ₂ NO ₂ S; 358.28	Clopidogrel Related Compound B; Methyl (+/-)-(o-Chlorophenyl)-4,5-dihydrothieno[3,2-c]pyridine-6(7H)acetate Hydrochloride; α-(2-Chlorophenyl)-4,7-dihydro-thieno[2,3-c]pyridine-6(5H)acetic Acid Methyl Ester Hydrochloride
Clopidogrel impurity C	RBPL-C0403	120202-71-3	C ₁₆ H ₁₈ ClNO ₆ S ₂ ; 419.9	Clopidogrel USP RC C; Clopidogrel Bisulfate R-Isomer; Methyl (-)-(R)-(o-chlorophenyl)[6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl]acetate hydrogen sulfate
COLCHICINE	RBPL-C0500			
Colchicine impurity E	RBPL-C0501	7336-33-6	C ₂₁ H ₂₃ NO ₆ ; 385.41	3-Demethyl Colchicine; N-[(7S)-5,6,7,9-Tetrahydro-3-hydroxy-1,2,10-trimethoxy-9-oxobenzo[a]heptalen-7-yl]-acetamide; O3-Demethylcolchicine; 3-Demethyl(-)-colchicine; O3-Demethylcolchicine
Colchicine impurity A	RBPL-C0502	7411-12-3	C ₂₁ H ₂₃ NO ₆ ; 385.41	N-Deacetyl-N-formyl Colchicine; N-[(7S)-5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]formamide; Gloriosine; N-Deacetyl-N-formylcolchicine; N-Formyl-N-deacetylcolchicine; N-Formyl-N-desacetylcolchicine; N-Formyldeacetylcolchicine
Colchicine impurity D (Colchicoside)	RBPL-C0503	477-29-7	C ₂₇ H ₃₃ NO ₁₁ ; 547.55	(S)-N-[3-(b-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2,10-trimethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-3-(b-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2,10-trimethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; 3-Demethylcolchicine glucoside
CLINDAMYCIN	RBPL-C0600			
Clindamycin sulphone	RBPL-C0601	887402-22-4	C ₁₈ H ₃₃ ClN ₂ O ₇ S; 456.99	Methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propylpyrrolidin-2-yl]carbonyl]amino]-1-thio-L-threo-?-D-galacto-octopyranoside hydrochloride

API IMPURITIES AND METABOLITES

Clindamycin sulphoxide	RBPL-C0602	22431-46-5	$C_{18}H_{33}ClN_2O_6S$; 440.98	7(S)-Chloro-7-deoxylincomycin Sulfoxide; 7-Chloro-1,6,7,8-tetradecoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-(methylsulfinyl)-L-threo- α -D-galactooctopyranose; 7(S)-Chloro-7-deoxylincomycin Sulfoxide; U 25026A
CLOMPIRAMINE	RBPL-C0700			
Clompiramine impurity G	RBPL-C0701	1425793-87-8	$C_{17}H_{16}ClN$; 269.77	N-Allyl-3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine; 3-Chloro-10,11-dihydro-5-(2-propen-1-yl)-5H-dibenz[b,f]azepine
Clomipramine Impurity B	RBPL-C0702	113-52-0 Free Base: 50-49-7	$C_{19}H_{25}ClN_2$; 316.87	Imipramine Hydrochloride; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine Hydrochloride; Chrytemin; Imiprin; G-22355; Tofranil
Clomipramine Impurity E	RBPL-C0703	494-19-9	$C_{14}H_{13}N$; 195.26	10,11-Dihydrodibenz[b,f]azepine; 2,2'-Iminobibenzyl; 2,2'-Iminodibenzyl; Iminobibenzyl; Iminodibenzyl; NSC 72110; Carbamazepine EP Impurity E
Clomipramine Impurity F	RBPL-C0704	32943-25-2	$C_{14}H_{12}ClN$; 229.7	3-Chloroiminodibenzyl; 3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepine; Carbamazepine 3-Chloroiminodibenzyl Impurity
Clomipramine N-Oxide	RBPL-C0705	14171-67-6	$C_{19}H_{23}ClN_2O$; 330.86	3-Chloro-10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine N-Oxide
CLOZAPINE	RBPL-C0800			
Clozapine impurity D	RBPL-C0801	65514-71-8	$C_{18}H_{21}ClN_4O$; 344.84	1-[2-[(2-Amino-4-chlorophenyl) amino]benzoyl]-4-methylpiperazine; [2-[(2-Amino-4-chlorophenyl)amino]phenyl]-(4-methyl-1-piperazinyl)methanone, 1-[2-[(2-Amino-4-chlorophenyl)amino]benzoyl]-4-methylpiperazine
Clozapine-N-oxide	RBPL-C0802	34233-69-7	$C_{18}H_{19}ClN_4O$; 342.82	8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; N-oxide in-4-ium-1-yl)-5H-benzo[b][1,4]benzodiazepine hyl-1-piperazinyl)-5H-dibenzo[b,e](1,4)diazepine; N-oxide-8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine N-Oxide

API IMPURITIES AND METABOLITES

CEFOPERAZONE	RBPL- C0900			
Cefoperazone Impurity C	RBPL-C0901	13183-79-4	C ₂ H ₄ N ₄ S; 116.14	5-Mercapto-1-methyltetrazole; 1-Methyl-5-mercaptotetrazole; 1-Methyltetrazole-5-thiol
Cefoperazone Impurity E	RBPL-C0902	957-68-6	C ₁₀ H ₁₂ N ₂ O ₅ S; 272.28	7-Aminocephalosporanic Acid; (6R,7R)-3-[(Acetyloxy)methyl]-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid; (7R)-7-Aminocephalosporanic Acid; 3-(Acetoxymethyl)-7-aminocephem-4-carboxylic Acid; 7-ACA; 7-ACS; 7β-Aminocephalosporanic Acid; Cefoperazone EP Impurity E
CARVEDILOL	RBPL-C0100			
Carvedilol impurty A	RBPL-C1001	1076199-79-5 (USP-1198090-73-1)	C ₃₆ H ₄₃ N ₃ O ₇ ; 629.74	1-[[4-(2-Hydroxy-3-[[2-(methoxyphenoxy)ethyl]amino]propyl]-9H-carbazol-4-yl]oxy]-3-[[2-(2-methoxyphenoxy) ethyl]amino]propan-2-ol; 1-(9H-Carbazol-4-yloxy)-3-[[2-hydroxy-3-[[2-(2-methoxyphenoxy) ethyl]amino]propyl] [2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; Carvedilol Related Compound A
Carvedilol impurty C	RBPL-C1002	72955-94-3	C ₃₁ H ₃₂ N ₂ O ₄ ; 496.6	Carvedilol USP Related Compound C ; (2RS)-1-[Benzyl[2-(2-methoxyphenoxy) ethyl]amino]-3-(9H-carbazol-4-yloxy) propan-2-ol ; (1-(9H-Carbazol-4-yloxy)-3-(benzyl (2-(2-methoxyphenoxy) ethyl) amino) propan-2-ol)
Carvedilol Impurity D (RC-D)	RBPL-C1003	51997-51-4	C ₁₅ H ₁₃ NO ₂ ; 239.27	4-(2,3-Epoxypropoxy)carbazole; 4-Oxiranylmethoxy-9H-carbazole; 4-(Oxiranylmethoxy)-9H-carbazole; Carvedilol EP Impurity D; Carvedilol USP-D
Carvedilol Impurity E (RC-E)	RBPL-C1004	64464-07-9 Free Base: 1836-62-0	C ₉ H ₁₄ ClNO ₂ ; 203.67	2-(2-Methoxyphenoxy)ethylamine Hydrochloride; Carvedilol EP Impurity E; Carvedilol Impurity E; Carvedilol USP E
CETRIZINE	RBPL-C1100			
Cetirizine-N-oxide	RBPL-C1101	1076199-80-8	C ₂₁ H ₂₅ ClN ₂ O ₄ ; 404.8	[2-[4-(4-Chlorophenyl)phenylmethyl]-1-oxido-1-piperazinyl]ethoxy]acetic Acid

API IMPURITIES AND METABOLITES

Cetirizine impurity A	RBPL-C1102	303-26-4	C ₁₇ H ₁₉ ClN ₂ ; 286.8	(RS)-1-[(4-Chlorophenyl)phenylmethyl]piperazine, 1-(4-Chlorobenzhydryl) piperazine, NSC 86164, Norchlorcyclizine; Hydroxyzine Related Compound A
CLOTRIMAZOLE	RBPL-C1200			
Clotrimazole impurity E	RBPL-C1201	5162-03-8 c	C ₁₃ H ₉ ClO; 216.66	(2-Chlorophenyl)(phenyl)methanone; 2-Benzoylphenyl Chloride; 2-CBP; 2-Chlorophenyl Phenyl Ketone; NSC 62529; o-Chlorobenzophenone
Clotrimazole EP Impurity D	RBPL-C1202	288-32-4	C ₃ H ₄ N ₂ ; 68.08	Imidazole; 1,3-Diaza-2,4-cyclopentadiene; 1,3-Diazole; 3-Azapyrrole; 1H-Imidazole; Ondansetron EP Impurity E; Clotrimazole EP Impurity D
Clotrimazole EP Impurity E	RBPL-C1203	5162-03-8	ClC ₆ H ₄ COC ₆ H ₅ ; 216.66	2-Chlorobenzophenone; (2-Chlorophenyl)phenylmethanone ; Clotrimazole Imp. E (EP)
CYCLOPHOSPHAMIDE	RBPL-C1300			
Cyclophosphamide RC-A	RBPL-C1301	821-48-7 Free Base: 334-22-5	C ₄ H ₁₀ Cl ₃ N; 178.49	Bis(2-chloroethyl)amine Hydrochloride; 2-Chloro-N-(2-chloroethyl)ethanamine Hydrochloride; USP Cyclophosphamide Related Compound A
CELECOXIB	RBPL-C1400			
Celecoxib impurity A	RBPL-C1401	170570-01-1	C ₁₇ H ₁₄ F ₃ N ₃ O ₂ S; 381.38	4-[5-(3-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
CIPROFLAXACIN	RBPL-C1500			
Ciprofloxacin Impurity F	RBPL-C1501	226903-07-7	C ₁₇ H ₁₉ N ₃ O ₄ ; 329.35	1-cyclopropyl-6-hydroxy-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid
Ciprofloxacin Impurity A	RBPL-C1502	86393-33-1	C ₁₃ H ₉ ClFNO ₃ ; 281.67	7-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic Acid; 1-Cyclopropyl-1,4-dihydro-4-oxo-6-fluoro-7-chloro-3-quinolinecarboxylic Acid; 7-Chloro-1-cyclopropyl-6-fluoro-3-carboxy-1,4-dihydro-4-oxoquinoline; Fluoroquinolonic Acid; Ciprofloxacin EP Impurity A; Enrofloxacin impurity A

API IMPURITIES AND METABOLITES

CITICOLINE	RBPL- C1600			
Citicoline Na impuity B	RBPL-C1601	63-37-6	C ₉ H ₁₄ N ₃ O ₈ P; 323.2	Cytidine 5'-Monophosphate; 5'-Cytidylic Acid; Cytidine 5'-Phosphate; Cytidine 5'-Phosphoric Acid; Cytidine Monophosphate; Cytidine Mono(dihydrogen phosphate)(Ester); Cytidylic Acid; Cytosine 5'-Monophosphate
Citicoline impuity B	RBPL-C1602	58-96-8	C ₉ H ₁₂ N ₂ O ₆ ; 244.2	Uridine; 1-β-D-Ribofuranosyluracil; β-Uridine; 1-β-D-Ribofuranosyluracil; 1-β-D-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione; NSC 20256; β-Uridine
CHLORPROMAZINE	RBPL- C1700			
Chlorpromazine impurity E	RBPL-C1701	92-39-7	C ₁₂ H ₈ ClNS; 233.72	2-Chloro Phenothiazine; 2-Chloro-10H-phenothiazine; NSC 170953; NSC 17469; NSC 67188; Chlorpromazine EP Impurity E
Chlorpromazine N-Oxide	RBPL-C1702	1672-76-0	C ₁₇ H ₁₉ ClN ₂ OS; 334.87	3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine Oxide
CARBAMAZAPINE	RBPL-C1800			
Carbamazapine impurity D	RBPL-C1801	256-96-2	C ₁₄ H ₁₁ N; 193.24	Iminostilbene; 5H-Dibenz[b,f]azepine; 2,2'-Iminostilbene; 5-Azadibenzo[a,e]cycloheptatriene; 5H-Dibenzo[b,f]azepine; NSC 123458; RP 9989; Carbamazepine EP Impurity D
Carbamazapine impurity E	RBPL-C1802	494-19-9	C ₁₄ H ₁₃ N; 195.26	10,11-Dihydrodibenz[b,f]azepine; 2,2'-Iminobibenzyl; 2,2'-Iminodibenzyl; Iminobibenzyl; Iminodibenzyl; NSC 72110; Carbamazepine EP Impurity E
Carbamazapine impurity C	RBPL-C1803	1219170-51-0	C ₁₆ H ₁₃ N ₃ O ₂ ; 279.29	N-Carbamoyl Carbamazepine; 5H-Dibenzo[b,f]azepin-5-ylcarbonylurea; Carbamazepine EP Impurity C
CARPROFEN	RBPL-C1900			
Carprofen RC A (Carbazole)	RBPL-C1901	86-74-8	C ₁₂ H ₉ N; 167.21	9H-Carbazole; Carbazole; 9-Azafluorene; Chlorophenesin carbamate; Dibenzo[b,d]pyrrole; Dibenzopyrrole; Diphenylenimine; NSC 3498; SKF 20091; USP Carprofen Related Compound A

API IMPURITIES AND METABOLITES

CEFDINIR	RBPL-C2100			
7AVNA	RBPL-C2101	79349-82-9	C ₉ H ₁₀ N ₂ O ₃ S; 226.25	7-Amino-3-vinyl-3-cephem-4-carboxylic Acid; (6R,7R)-7-Amino-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid; (6R-trans)-7-Amino-3-ethenyl-8-oxo-5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid; 7-AVCA;
CAFFIENE	RBPL-C2500			
Caffeine impurity C	RBPL-C2501	519-32-4	C ₈ H ₁₀ N ₄ O ₂ ; 194.19	Isocaffeine; 3,9-Dihydro-1,3,9-trimethyl-1H-purine-2,6-dione; 1,3,9-Trimethylxanthine; 9-Methyltheophylline; NSC 28332; EP Impurity C for Caffeine
CLOMIPHENE	RBPL-C2600			
Clomiphene N-oxide	RBPL-C2601	97642-74-5	C ₂₆ H ₂₈ ClNO ₂ ; 421.96	2-[4-(2-Chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-ethanamine N-Oxide; Clomifenoxide; Clomiphene N-Oxide
CYPROHEPTADINE	RBPL-C2700			
Cyproheptadine N-oxide	RBPL-C2701	100295-63-4	C ₂₁ H ₂₁ NO; 303.4	Cyproheptadine N-Oxide; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methyl-piperidine 1-Oxide;
Cyproheptadine Related Compound C	RBPL-C2702	3967-32-6	C ₂₁ H ₂₃ NO; 305.41	5-(1-Methyl-4-piperidyl)-5H-dibenzo[a,d]cyclohepten-5-ol; 5-(1-Methylpiperidin-4-yl)-5H-dibenzo[a,d]cyclohepten-5-ol; Cyproheptadine Related Compound C
CHLORAMPHENICOL	RBPL-C2900			
Chloramphenicol Impurity B	RBPL-C2901	555-16-8		4-Itrobenzaldehyde
CEFPROZIL	RBPL-C3000			
Cefprozil impurity A (USP RC-I) (Amoxicilling impurity I)	RBPL-C3001	22818-40-2	C ₈ H ₉ NO ₃ ; 167.16	4-Hydroxy-D-(-)-2-phenylglycine; (αR)-α-Amino-4-hydroxybenzeneacetic Acid; R)-(4-Hydroxyphenyl)glycine; (R)-2-(4-Hydroxyphenyl)glycine; (R)-Ethyl 2-Amino-2-(4-hydroxyphenyl)acetate; (αR)-α-Amino-4-hydroxybenzeneacetic acid; 4-Hydroxy-D-phenylglycine; D-(-)-2-(4-Hydroxyphenyl)glycine; D-(-)-2-(p-Hydroxyphenyl)glycine;

API IMPURITIES AND METABOLITES

				D-(-)-4-Hydroxyphenylglycine; D-(-)-Amino(4-hydroxyphenyl)acetic Acid; D-(-)-p-Hydroxyphenylglycine; D-(-)-α-(4-Hydroxyphenyl)glycine; D-(-)-α-Amino-4-hydroxyphenylacetic Acid; D-(-)-α-Amino-p-hydroxyphenylacetic Acid; D-2-(4-Hydroxyphenyl)glycine; D-2-Amino-2-(p-hydroxyphenyl)acetic Acid; D-4-Hydroxyphenylglycine; D-p-Hydroxyphenylglycine; D-α-Amino-4-hydroxyphenylacetic Acid; D-α-Amino-p-hydroxyphenylacetic Acid; D-α-p-Hydroxyphenylglycine; p-Hydroxy-(R)-phenylglycine; p-Hydroxy-D-phenylglycine; Cefadroxil EP Impurity A(Amoxicillin EP Impurity A)
CLADRIBINE	RBPL-C3100			
Cladribine Impurity C	RBPL-C3101	1839-18-5	C ₅ H ₄ ClN ₅ ; 169.57	2-Chloroadenine; 2-Chloro-9H-purin-6-amine; 6-Amino-2-chloropurine; NSC 7362;
Cladribine Impurity E	RBPL-C3102	533-67-5	C ₅ H ₁₀ O ₄ ; 134.13	2-Deoxy-D-ribose; 2-Deoxy-D-erythro-pentose; 2-Deoxy-D-arabinose; D-(-)-2-Deoxyribose; Deoxyribose; Thymine
Cladribine Impurity G	RBPL-C3103	99-75-2	C ₉ H ₁₀ O ₂ ; 150.17	Methyl p-Toluate; 4-(Methoxycarbonyl)toluene; 4-Methylbenzoic Acid Methyl Ester; Methyl 4-Methylbenzoate; Methyl 4-Toluate; Methyl p-Methylbenzoate; Methyl p-Toluate; Methyl p-Toluenecarboxylate; NSC 24761; p-(Methoxycarbonyl)toluene; p- Carbomethoxytoluene
CARBOPLATIN	RBPL-C3200			
Carboplatin Impurity A	RBPL-C3201	15663-27-1	Cl ₂ H ₆ N ₂ Pt; 300.05	Cisplatin; Briplatin, Cismaplat, Cisplatyl, Lederplatin, Neoplatin, Platamine, Platinex, Platiblastin, Platinol, Platinoxan
Carboplatin Impurity B	RBPL-C3202	5445-51-2	C ₆ H ₈ O ₄ ; 144.13	1,1-Cyclobutanedicarboxylic Acid; Cyclobutane-1,1-dicarboxylic acid;
CARBOXYLIC ACID	RBPL-C3300			
Cyclobutanecarboxylic acid	RBPL-C3301	3721-95-7	C ₅ H ₈ O ₂ ; 100.12	Cyclobutane-1-carboxylic Acid; NSC 4535

API IMPURITIES AND METABOLITES

Carboxylic acid impurity G	RBPL-C3302	109-01-3	C ₅ H ₁₂ N ₂ ; 100.16	Cyclizine impurity A; 1-MethylpiperazineCyclizine Related Compound A
Carboxylic acid impurity H	RBPL-C3303	350-03-8	C ₇ H ₇ NO; 121.14	3-Acetylpyridine; 1-(3-Pyridinyl)ethanone; 3-Pyridinyl Methyl Ketone; Methyl 3-Pyridyl Ketone; NSC 761; β-Acetylpyridine; Imatinib EP Impurity H
CANAGLIFLOZIN	RBPL-C3400			
Canagliflozin Impurity 8	RBPL-C3401	90-80-2	C ₆ H ₁₀ O ₆ ; 178.14	D-Glucono-1,5-lactone; D-Gluconic acid δ-Lactone; D-Gluconic Acid Lactone; D-Gluconic Acid δ-Lactone; 1,5-Gluconolactone; D-(+)-Gluconic acid δ-lactone; D-(+)-Glucono-1,5-lactone; D-(+)-Glucono-δ-lactone; D-Gluconic acid 1,5-Lactone; D-Glucono-δ-lactone; E 575; Fujiglucon; Gluconolactone; Lysactone; δ-Gluconolactone
Canagliflozin Impurity 14	RBPL-C3402	58861-48-6	C ₁₀ H ₇ FS; 178.23	2-(4-Fluorophenyl)-thiophene;
CLONAZEPAM	RBPL-C3500			
Clonazepam Impurity A (RC-B)	RBPL-C3501	2011-66-7	C ₁₃ H ₉ ClN ₂ O ₃ ; 276.68	2-Amino-5-nitro-2'-chlorobenzophenone; 2-Amino-2'-chloro-5-nitrobenzophenone; (2-Amino-5-nitrophenyl)-(2-chlorophenyl)methanone; USP Clonazepam Related Compound B; Clonazepam EP Impurity A
CEPHALEXIN	RBPL-C3600			
Cephalexin Impurity B	RBPL-C3601	22252-43-3	C ₈ H ₁₀ N ₂ O ₃ S; 214.24	7-Aminodesacetoxycephalosporanic Acid; 6R,7R)-7-Amino-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid; 7-Amino-3-deacetoxycephalosporanic Acid; Deacetoxycephalosporanic Acid; 7-ADCA; Cefadroxil EP Impurity B
Cephalexin EP Impurity A	RBPL-C3602	875-74-1	C ₈ H ₉ NO ₂ ; 151.16	D-(-)-2-Phenylglycine; (-)-(R)-Phenylglycine; (-)-Phenylglycine; (2R)-Amino-2-phenylethanoic Acid; (R)-(-)-2-Phenylglycine; (R)-2-Amino-2-phenylacetic Acid; (R)-2-Amino-2-phenylethanoic Acid; (R)-2-Phenyl-2-aminoethanoic Acid; (R)-2-Phenylglycine; (R)-2-Phenylglycine; (R)-Phenylglycine; (R)-Phenylglycine; (R)-α-Phenylglycine; D-(-)-Aminophenylacetic Acid; D-(-)-Phenylglycine; D-(-)-α-

API IMPURITIES AND METABOLITES

				Aminophenylacetic Acid; D-(-)- α -Phenylglycine; D-2-Phenylglycine; D-C-Phenylglycine; D-Phenylglycine; D- α -Aminophenylacetic Acid; D- α -Phenylglycine; D-2-Phenylglycine; (R)- α -Aminobenzeneacetic Acid; (α R)- α -Aminobenzeneacetic Acid; Cefalexin EP Impurity A; Ampicillin EP Impurity L
CINNARIZINE	RBPL-C3700			
Cinnarizine EP Impurity A	RBPL-A3701	841-77-0	$C_{17}H_{20}N_2$; 252.35	1-Benzhydrylpiperazine; 1-(Diphenylmethyl)piperazine; 4-(Diphenylmethyl)piperazine; 4-Benzhydrylpiperazine; Benzhydrylpiperazine; N-(Diphenylmethyl)piperazine; N-Benzhydrylpiperazine; NSC 35536; Norcyclizine; Cinnarizine EP Impurity A
CHLORPHENAMINE	RBPL-C3800			
Chlorphenamine EP Impurity B	RBPL-C3801	1202-34-2	$C_{10}H_9N_3$; 171.2	2,2'-Dipyridylamine; 2,2'-Iminodipyridine; 2,2'-Bipyridylamine; 2,2'-Iminodipyridine; 2-(2-Pyridylamino)pyridine; Bis(2-pyridyl)amine; Bis(o-pyridyl)amine; Bis(pyridin-2-yl)amine; Di-2-pyridylamine; Di- α -pyridylamine; Dipyridin-2-ylamine; N-(2-Pyridinyl)-2-pyridinamine; NSC 7494; USP Chlorpheniramine Related Compound B; Chlorpheniramine EP Impurity B
CROMOGLICIC ACID	RBPL-C3900			
Cromoglicate Sodium Imp. A (EP)	RBPL-C3901	699-83-2	$C_8H_8O_3$; 152.15	2',6'-Dihydroxyacetophenone; 1-(2,6-Dihydroxyphenyl)ethanone; 2-Acetyl-1,3-benzenediol; 2-Acetylbenzene-1,3-diol; 2-Acetylresorcinol; NSC 615; γ -Resacetophenone
CYCLOBENZAPRINE	RBPL-C4000			
Cyclobenzaprine N-Oxide	RBPL-C4001	6682-26-4	$C_{20}H_{21}NO$; 291.4	3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine N-Oxide
DICLOFENAC	RBPL-D0100			

API IMPURITIES AND METABOLITES

Diclofenac Free Acid	RBPL-D0108	15307-86-5	C ₁₄ H ₁₁ Cl ₂ NO ₂ ; 296.15	Diclofenac acid; [o-(2,6-dichloroanilino)phenyl]acetic Acid; 2-(2,6-Dichloroanilino)phenylacetic Acid; 2-(2,6-Dichlorophenylamino)phenylacetic Acid; 2-[(2,6-Dichlorophenyl)amino]benzeneacetic Acid; 2-[2-(2,6-Dichlorophenylamino)phenyl]acetic Acid; Dichlofenac; Diclac; Diclofenac; Diclofenamic Acid; Dicloftil; Diclomelan; Dicloreuma; Flector; Flector EP Tissugel; N-(2,6-Dichlorophenyl)-o-aminophenylacetic Acid; Ortofen; Pennsaid; Transfenac; Voltaflan; Voltaren Dolo; Zorvolex; [o-(2,6-Dichloroanilino)phenyl]acetic Acid
Diclofenac impurity A	RBPL-D0101	15362-40-0	C ₁₄ H ₉ Cl ₂ NO; 278.13	Diclofenac Amide; 1-(2,6-Dichlorophenyl)-1,3-dihydro-2H-indol-2-one; 1-(2,6-Dichlorophenyl)oxindole; N-(2,6-dichlorophenyl)-2-indolinone; NSC 621845; Diclofenac Lactam; USP Diclofenac Related Compound A
Diclofenac isopropyl impurity	RBPL-D0102	66370-79-4	C ₁₇ H ₁₇ Cl ₂ NO ₂ ; 338.24	Isopropyl 2-(2-((2,6-Dichlorophenyl)amino)phenyl)acetate; Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 1-methylethyl ester
Diclofenac methyl ester impurity	RBPL-D0103	15307-78-5	C ₁₅ H ₁₃ Cl ₂ NO ₂ ; 310.18	2-[(2,6-Dichlorophenyl) amino] benzeneacetic Acid Methyl Ester; 2-[(2,6-Dichlorophenyl) amino] benzeneacetic Acid Methyl Ester; [o-(2,6-Dichloroanilino)phenyl]acetic Acid Methyl Ester; Methyl 2-(2,6-Dichloroanilino)phenylacetate;
Diclofenac impurity F	RBPL-D0104	560075-65-2	C ₁₄ H ₁₀ Cl ₃ NO; 314.59	2,6-Dichloro-N-(4-chlorophenyl)-benzeneacetamide
Diclofenac Impurity C Ethyl ester	RBPL-D0105	15307-77-4	C ₁₆ H ₁₅ Cl ₂ NO ₂ ; 324.20	2-[(2,6-Dichlorophenyl) amino] benzeneacetic Acid Ethyl Ester; [o-(2,6-Dichloroanilino)phenyl]acetic Acid Ethyl Ester; Ethyl 2-(2,6-Dichloroanilino)phenylacetate; Aceclofenac impurity C
Diclofenac Impurity D (RC D)	RBPL-D0106	127792-45-4	C ₁₄ H ₁₀ BrClNNaO ₂ ; 362.58	Diclofenac Monobromo Sodium Salt Impurity; 2-[(2-Bromo-6-chlorophenyl)amino]benzeneacetic Acid Sodium Salt; 2-[(2-Bromo-6-chlorophenyl)amino] phenylacetic Acid Sodium Salt; Diclofenac Impurity D; Diclofenac EP Impurity D

API IMPURITIES AND METABOLITES

Diclofenac impurity B	RBPL-D0107	22121-58-0	C ₁₃ H ₉ Cl ₂ NO; 266.13	N-(2,6-Dichlorophenyl)anthranilaldehyde; 2-(2,6-Dichloroanilino)benzaldehyde
Diclofenac impurity E (RC-E)		59-48-3	C ₈ H ₇ NO; 133.15	Oxindole (2-Indolone); 1,3-Dihydro-2H-indol-2-one; 2-Indolinone; Oxindole; 1,3-Dihydroindol-2-one; 2-Oxindole; 2-Oxo-2,3-dihydroindole; 2-Oxoindole; 2-Oxoindoline; Indol-2(3H)-one; Indoline-2-one; NSC 274863; Oxindol;
DOMPERIDONE	RBPL-D0200			
Domperidone impurity A	RBPL-D0201	53786-28-0	C ₁₂ H ₁₄ ClN ₃ O; 251.71	5-Chloro-1-(4-piperidyl)-2-benzimidazolinone; Des[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl] Domperidone; 4-(6-Chloro-1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)piperidine; 5-Chloro-1-(4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-(piperidin-4-yl)-1H-benzimidazol-2(3H)-one; 5-Chloro-1-piperidin-4-yl-1,3-dihydrobenzimidazol-2-one; R 29676
Domperidone impurity B	RBPL-D0202	1346598-11-5	C ₁₃ H ₁₄ ClN ₃ O ₂ ; 279.72	4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-formylpiperidine; 4-(6-Chloro-1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)piperidine-1-carbaldehyde; 5-Chloro-1-(4-formylpiperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-(4-formylpiperidinyl)-1H-benzimidazol-2(3H)-one;
DESVENLAFAXINE	RBPL-D0300			
Desvenlafaxine-N-oxide	RBPL-D0301	NA	C ₁₆ H ₂₅ NO ₃ ; 279.37	4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol N-oxide
DROTAVERINE	RBPL-D0400			
Drotaverine-N-oxide	RBPL-D0401	NA	C ₂₄ H ₃₁ NO ₅ ; 412.5	(Z)-1-{3,4-Diethoxybenzylidene}-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoliny-N-oxide;
DESLORATIDINE	RBPL-D0500			

API IMPURITIES AND METABOLITES

Desloratidine dehydro	RBPL-D0502	117811-20-8	C ₁₉ H ₁₇ ClN ₂ ; 308.80468	Dehydro Desloratadine; Dehydro Desloratadine; Desloratadine Impurity C; Desloratadine Dehydro Impurity; 8-Chloro-11-(piperidin-4-ylidene)-11H-benzo[5,6]cyclohepta[1,2-b]pyridine
Desloratidine deschloro impurity	RBPL-D0501	38092-95-4	C ₁₉ H ₂₀ N ₂ ; 276.38	4-(5,6-Dihydro-11H-benzo[5,6]cyclohepta [1,2-b]pyridin-11-ylidene)-piperidine
DIPYRIDAMOLE	RBPL-D0600			
Dipyridamole impurity A	RBPL-D0601	16982-40-4	C ₂₅ H ₄₀ N ₈ O ₂ ; 484.64	2,2'-[[4,6,8-Tri(piperidin-1-yl) pyrimido [5,4-d] pyrimidin-2-yl]nitrilo]diethanol; Dipyridamole Tripiperidine; 2,4,8-Tripiperidino-6-diethanolaminopyrimido[5,4-d]pyrimidine; AWD 568; RA 134
Dipyridamole impurity B	RBPL-D0602	16908-47-7	C ₂₃ H ₄₀ N ₈ O ₆ ; 524.61	2,2',2'',2''',2''''-[8-(Piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,4,6-triyl]trinitrilo]hexaethanol ; Dipyridamole USP RC B
Dipyridamole impurity E	RBPL-D0603	NA	C ₂₄ H ₄₀ N ₈ O ₄ ; 504.63	Dipyridamole USP RC E ; 2,4-Di[di(2-hydroxyethyl)amino]-6,8-di(piperidin-1-yl)-pyrimido[5,4-d]pyrimidine
DUTASTERIDE	RBPL-D0700			
Dutasteride impurity C	RBPL-D0701	157307-36-3	C ₂₁ H ₃₁ NO ₃ ; 345.48	Dutasteride Ethyl Ester ; Ethyl 3-oxo-4-aza-5α-androst-1-ene-17β-carboxylate ;
DORZALAMIDE	RBPL-D0800			
Dorzalamide HCl impurity D	RBPL-D0801	164455-27-0	C ₈ H ₁₂ N ₂ O ₄ S ₃ · HCl; 296.39 36.46	N-Desethyl Dorzolamide HCl; Dorzolamide related compound D
DIPHENHYDRAMINE	RBPL-D0900			
Diphenhydramine impurity A	RBPL-D0901	N/A	C ₁₆ H ₁₉ NO HCl; 241.34 36.46	2-(diphenylmethoxy)-N-methylethanamine.
DARIFENACIN	RBPL-D1000			
7-bromoethyl darifenacin	RBPL-D1001	NA	C ₁₀ H ₁₁ BrO; 227.1	7-(2-Bromoethyl)-2,3-dihydrobenzofuran

API IMPURITIES AND METABOLITES

DONEPEZIL	RBPL-D1100			
Donepezil benzyl bromide	RBPL-D1101	844694-85-5	C ₃₁ H ₃₆ BrNO ₃ ; 550.53	Donepezil Benzyl Bromide (Donepezil Impurity); 4-[(2,3-Dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1,1-bis(phenylmethyl) Piperidinium Bromide; Donepezil Impurity; Impurity III
Donepezil dihydro	RBPL-D1102	120011-70-3	C ₂₄ H ₃₀ ClNO ₃ ; 415.95	Donepezil Hydrochloride; 2,3-Dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidiny]methyl]-1H-inden-1-one; Impurity VIII
Donepezil N-oxide	RBPL-D1103	120013-84-5	C ₂₄ H ₂₉ NO ₄ ; 395.49	rac-(cis/trans) Donepezil N-Oxide; 2,3-Dihydro-5,6-dimethoxy-2-[[cis/trans-1-oxido-1-(phenylmethyl)-4-piperidiny]methyl]-1H-inden-1-one; (cis/trans)-2,3-Dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidiny]methyl]-1H-Inden-1-one N-Oxide, Impurity VII
DIAZEPAM	RBPL- D1200			
Diazepam impurity D	RBPL-D1201	1022-13-5	C ₁₄ H ₁₂ ClNO; 245.7	5-Chloro-2-(methylamino)benzophenone; 2-(Methylamino)-5-chlorobenzophenone; Ro 5-4365; [5-Chloro-2-(methylamino)phenyl]phenylmethanone; USP Temazepam Impurity A
DARBIGATRAN	RBPL- D1300			
Dabigatran Impurity P	RBPL-D1301	212322-56-0	C ₁₈ H ₂₂ N ₄ O ₃ ; 342.39	N-[3-Amino-4-(methylamino)benzoyl]-N-2-pyridinyl-β-alanine Ethyl Ester; Ethyl 3-(3-amino-4-(methylamino)-N-pyridin-2-yl)benzamido)propanoate
DULOXETINE	RBPL- D1400			
Duloxetine impurity B	RBPL-D1401	116539-55-0	C ₈ H ₁₃ NOS; 171.26	(S)-1-β-Hydroxy-1-(2-thienyl)-3-methylaminopropane; (S)-α-[2-(Methylamino)ethyl]-2-thiophenemethanol; (1S)-(-)-3-(Methylamino)-1-(thien-2-yl)propan-1-ol; (S)-(-)-3-(N-Methylamino)-1-(2-thienyl)-1-propanol; (S)-3-Methylamino-1-(2-thienyl)-1-propanol; N-Methyl-(S)-(-)-3-Hydroxy-3-(2-thiophen)propylamine; Duloxetine EP Impurity B

API IMPURITIES AND METABOLITES

Duloxetine impurity D	RBPL-D1402	90-15-3	C ₁₀ H ₈ O; 144.17	1-Naphthol; 1-Naphthalenol; 1-Hydroxynaphthalene; 1-Naphthyl Alcohol; C.I. 76605; Durafur Developer D; Fouramine ERN; Fournine 99; Fournine ERN; Furro ER; NSC 9586; Nako TRB; Naphthol-1; Naphthyl-1-ol; Tertral ERN; Ursol ERN; Zoba ERN; α-Hydroxynaphthalene; α-Naphthol; α-Naphthyl Alcohol; Duloxetine EP Impurity D
Duloxetine impurity G	RBPL-D1403	321-38-0	C ₁₀ H ₇ F; 146.16	1-Fluoronaphthalene; NSC 4690; α-Fluoronaphthalene; Duloxetine USP Impurity G; Duloxetine EP Impurity G
DEXTROMETHORPHAN	RBPL-D1600			
Dextromethorphan N-Oxide	RBPL-D1601	1177494-18-6	C ₁₈ H ₂₅ NO ₂ ; 287.40	(9α,13α,14α)-3-Methoxy-17-MethylMorphinan17-Oxide; (9S,13S,14S)-3-Methoxy-17-MethylMorphinan 17-Oxide; (+)-DextroMethorphan N-Oxide
DIOSMIN	RBPL-D1800			
Diosmin Impurity A	RBPL-D1801	6100-74-9	C ₉ H ₁₀ O ₃ ; 166.17	Isoacetovanillone; 1-(3-hydroxy-4-methoxyphenyl)ethanone; 3'-hydroxy-4'-methoxyacetophenone; 2-Methoxy-5-acetylphenol; 3'-Hydroxy-4'-methoxyacetophenone; 4'-Methoxy-3'-hydroxyacetophenone; 5-Acetyl-2-methoxyphenol; Acetoisovanillone; I; Diosmin EP Impurity A
Diosmin Impurity B	RBPL-D1802	520-26-3	C ₂₈ H ₃₄ O ₁₅ ; 610.56	Hesperidine; (2S)-7-[[6-O-(6-Deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-1-benzopyran-4-one; (2S)-Hesperidin; Atripliside B; Cirantin; Hesperetin 7-Rutinoside; NSC 44184; Diosmin EP Impurity B
Diosmin Impurity C	RBPL-D1803	552-57-8	C ₂₇ H ₃₀ O ₁₄ ; 578.52	Isorhoifolin; 7-[[6-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-5-hydroxy-2-(4-hydroxyphenyl)-4H-1-Benzopyran-4-one; Diosmin EP Impurity C
Diosmin Impurity D	RBPL-D1804	1431536-92-3	C ₂₈ H ₃₁ IO ₁₅ ; 734.44	6-Iodo Diosmin; 7-[[6-O-(6-Deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-6-iodo-4H-1-benzopyran-4-one; Diosmin EP Impurity D

API IMPURITIES AND METABOLITES

Diosmin Impurity E	RBPL-D1805	480-36-4	C ₂₈ H ₃₂ O ₁₄ ; 592.55	Linarine ; 7-[[6-O-(6-Deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-5-hydroxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one; Acacetin 7-O-rutinoside; Acacetin 7-O-α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranoside; Acacetin-7-O-(6''-O-rhamnose)-β-D-glucoside; Acacetin-7-O-β-D-rutinoside; Acaciin; Buddleoflavonololide; Buddleoside; Linarigenin glycoside; Diosmin EP Impurity E
Diosmin Impurity F	RBPL-D1806	520-34-3	C ₁₆ H ₁₂ O ₆ ; 300.26	Diosmetin; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',5,7-Trihydroxy-4'-methoxyflavone; 4'-Methyluteolin; Diosmetine; Diosmetol; Luteolin 4'-Methyl Ether; Pillon; Diosmin EP Impurity F
Diosmin Impurity I		645-08-9	C ₈ H ₈ O ₄ ; 168.15	3-Hydroxy-4-methoxybenzoic acid
DASATINIB	RBPL-D1900			
Dasatinib N-oxide	RBPL-D1901	910297-52-8	C ₂₂ H ₂₆ ClN ₇ O ₃ S; 504	Dasatinib N-Oxide; N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide N-Oxide
DOXEPINE	RBPL-D2100			
Doxepine N-Oxide	RBPL-D2101	22684-91-9	C ₁₉ H ₂₁ NO ₂ ; 295.38	Doxepin N-Oxide; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine N-Oxide; N,N-Diethyldibenz[b,d]oxepin-11(6H),α-propylamine N-Oxide
DEXAMETHASONE	RBPL-D2200			
Dexamethasone Impurity B	RBPL-D2201	378-44-9	C ₂₂ H ₂₉ FO ₅ ; 392.46	Betamethasone; (11β,16β)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9α-Fluoro-16β-methylprednisolone; Betadexamethasone; Flubenisolone; Sch-4831; NCS-39470; Betamethasone Acetate EP Impurity A; Betamethasone Valerate EP Impurity A
Dexamethasone Impurity G	RBPL-D2202	1177-87-3	C ₂₄ H ₃₁ FO ₆ ; 434.5	21-O-Acetyl Dexamethasone; (11β,16α)-21-(Acetyloxy)-9-fluoro-11,17-dihydroxy-16-methyl-pregna-1,4-diene-3,20-dione; 9-Fluoro-11β,17,21-trihydroxy-16α-methyl-pregna-1,4-diene-3,20-dione 21-Acetate; Decadronal; Dectancyl; Dex-

API IMPURITIES AND METABOLITES

				Cortidelt Acetate; Dexamethasone; NSC 39471; Betamethasone Acetate EP Impurity B
DOCETAXEL	RBPL-D2300			
Docetaxel Impurity E	RBPL-D2301	32981-86-5	C ₂₉ H ₃₆ O ₁₀ ; 544.59	10-Deacetyl Baccatin III; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(Acetyloxy)-12-(benzoyloxy)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,6,9,11-tetrahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca[3,4]benz[1,2-b]oxet-5-one; 10-DAB; Paclitaxel - In House Impurity
Docetaxel Impurity F	RBPL-D2302	143527-70-2	C ₁₇ H ₂₃ NO ₅ ; 321.37	(4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic Acid; (4S,5R)-2,2-Dimethyl-4-phenyl-3,5-oxazolidinedicarboxylic Acid 3-(1,1-Dimethylethyl) Ester; (4S,5R)-N-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylic Acid;
DECITABINE	RBPL-D2400			
Decitabine RC-D	RBPL-D2401	1126-46-1	C ₈ H ₇ ClO ₂ ; 170.59	Methyl 4-Chlorobenzoate; p-Chloro-benzoic Acid Methyl Ester; 4-(Methoxycarbonyl)chlorobenzene; 4-Carbomethoxyphenyl Chloride; 4-Chlorobenzoic Acid Methyl Ester; 5-Chloro-2-benzoic Acid Methyl Ester; Methyl 4-Chlorobenzoate; Methyl p-Chlorobenzoate; NSC 8366; p-Chlorobenzoic Acid Methyl Ester
DEFERASIROX	RBPL-D2500			
Deferasirox Impurity A	RBPL-D2501	69-72-7	C ₇ H ₆ O ₃ ; 138.12	Salicylic Acid; 2-Hydroxybenzoic Acid; 2-Carboxyphenol; 2-Hydroxybenzenecarboxylic Acid; 2-Hydroxybenzoic Acid; o-Carboxyphenol; o-Hydroxybenzoic Acid; Rutranex; Saligel; Salonil; Salvona Nanosal; Stri-Dex; Trans-Ver-Sal; Verrugon; Acetylsalicylic Acid EP Impurity C (Aspirin Impurity C)/ Mesalazine EP Impurity H
Deferasirox Impurity C	RBPL-D2502	1218-69-5	C ₁₄ H ₉ NO ₃ ; 239.23	2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one; 2-(2-Hydroxyphenyl)benz[e][1,3]oxazin-4-one; 2-(2'-Hydroxyphenyl)-4H-1,3-

API IMPURITIES AND METABOLITES

				benzoxazin-4-one; 2-(o-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one
ETORICOXIB	RBPL- E0100			
Etoricoxib N-Oxide	RBPL-E0101	325855-74-1	C ₁₈ H ₁₅ ClN ₂ O ₃ S ; 374.85	Etoricoxib N1'-Oxide; 5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine 1'-Oxide
Etoricoxib Impurity E	RBPL-E0102	5470-70-2	C ₈ H ₉ NO ₂ ; 151.16	Methyl 6-Methylnicotinate; 6-Methyl-3-pyridinecarboxylic Acid Methyl Ester; 6-Methylnicotinic Acid Methyl Ester; 6-Methoxycarbonyl-2-methylpyridine; Methyl 6-Methyl-3-pyridinecarboxylate; Methyl 6-Methylaminonicotinate; NSC 27973;
ERYTHROMYCIN	RBPL-E0200			
Erythromycin Impurity H (N-oxide)	RBPL-E0201	992-65-4	C ₃₇ H ₆₇ NO ₁₄ ; 749.93	Erythromycin A N-oxide is a facile metabolite of erythromycin A
Erythromycin Impurity B (3'-N-desmethyl erythromycin A)	RBPL-E0202	992-62-1	C ₃₆ H ₆₅ NO ₁₃ ; 719.90	3'-Demethylerythromycin; N-Demethylerythromycin A
Erythromycin Impurity D (Anhydro)	RBPL-E0203	23893-13-2	C ₃₇ H ₆₅ NO ₁₂ ; 715.91	Anhydro Erythromycin A; 9-Deoxy-6,12-dideoxy-6,9:9,12-diepoxy-erythromycin; 6,9,12-Anhydroerythromycin A; Anhydroerythromycin; BRL 46355ER; EM 202; Erythromycin Anhydride, Impurity D; Erythromycin EP Impurity D
Erythromycin Impurity E	RBPL-E0204	33396-29-1	C ₃₇ H ₆₅ NO ₁₂ ; 715.92	Erythromycin A Enol Ether; 11-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-5-ethyl-3,4-dihydroxy-9-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one; Erythromycin EP Impurity E
Erythromycin Impurity F	RBPL-E0205	105822-69-7	C ₃₇ H ₆₅ NO ₁₂ ; 715.93	11-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-5-ethyl-3,4-dihydroxy-9-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one;

API IMPURITIES AND METABOLITES

Erythromycin Impurity L (N-desmethyl – N-formoyl erythromycin A)	RBPL-E0206	NA	$C_{37}H_{65}NO_{14}$; 747.91	N-[2-[[[(3R,4S,5S,6R,7R,9R, 11R,12R,13S,14R)- 14-ethyl-7,12,13- trihydroxy-4-(5- hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl)oxy-3,5,7,9,11,13- hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-3-hydroxy-6-methyl- tetrahydropyran-4-yl]-N-methyl-formamide; 3''-N-demethyl-3''-N-formyl erythromycin A
Erythromycin Impurity J (9-Oxime)	RBPL-E0207	13127-18-9	$C_{37}H_{68}N_2O_{13}$; 748.94	Erythromycin A Oxime (Roxithromycin Impurity C); 9-Erythromycin 9-Oxime; 9- Erythromycin A Oxime; Erythromycin Oxime; Roxithromycin Impurity C; Clarithromycin EP Impurity J
Erythrolasamine	RBPL-E0208			
EMTRICITABINE	RBPL-E0300			
Emtricitabine Sulfoxide	RBPL-E0301	152128-77-3	$C_8H_{10}FN_3O_4S$; 263.25	Emtricitabine S-Oxide ; (Mixture of Diastereomers); 4-Amino-5-fluoro-1-[(2R,5S)-2- (hydroxymethyl)-3-oxido-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; [2R-(2 α ,5 α)]-4- Amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone S- Oxide; [2R-(2 α ,5 α)]-4-Amino-5-fluoro-1-[2-(hydroxymethyl)-3-oxido-1,3- oxathiolan-5-yl]-2(1H)-pyrimidinone; Emtricitabine EP impurity G
Emtricitabine Impurity C	RBPL-E0302	134678-17-4	$C_8H_{11}N_3O_3S$; 229.26	Lamivudine; 4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)- pyrimidinone; (2R-cis)-4-Amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)- pyrimidinone; (-)-2'-Deoxy-3'-thiacytidine; (-)-BCH 189; 3TC; Eпивir HBV; Hepitec; Heptodin; Heptovir; L-SddC; Lamivir; Virolam; Zeffix; β -L-2',3'-Dideoxy-3'- thiacytidine; β -L-3'-Thia-2',3'-dideoxycytidine;
Emtricitabine Impurity E	RBPL-E0303	2022-85-7	$C_4H_4FN_3O$; 129.09	5-Fluoro Cytosine; 4-Amino-5-fluoro-2(1H)-pyrimidine; Flucytosine, 5-FC; NSC 103805 6-Amino-5-fluoro-2(1H)-pyrimidinone
Emtricitabine Impurity F	RBPL-E0304	51-21-8	$C_4H_3FN_2O_2$; 130.08	2,4-Dihydroxy-5-fluoropyrimidine, 5-FU, 5-Fluoro-2,4(1H,3H)-pyrimidinedione, 5- Fluorouracil;

API IMPURITIES AND METABOLITES

ENALAPRIL	RBPL-E0400			
Enalaprilat Impurity C	RBPL-E0401	84680-54-6	C ₁₈ H ₂₄ N ₂ O ₅ ; 348.4	Enalaprilat Dihydrate; N-[(1S)-1-(Carboxy)-3-phenylpropyl]-L-alanyl]-L-proline Dihydrate; Enalaprilic Acid Dihydrate; MK-422 Dihydrate; Vasotec IV Dihydrate; Enalapril EP Impurity C (Dihydrate)
Enalapril DKP Impurity D	RBPL-E0402	115729-52-7	C ₂₀ H ₂₆ N ₂ O ₄ ; 358.43	Enalapril Diketopiperazine; (αS,3S,8aS)-Hexahydro-3-methyl-1,4-dioxo-α-(2-phenylethyl)pyrrolo[1,2-a]pyrazine-2(1H)-acetic Acid Ethyl Ester; [3S-[2(R*),3α,8αβ]]-Hexahydro-3-methyl-1,4-dioxo-α-(2-phenylethyl)pyrrolo[1,2-a]pyrazine-2(1H)-acetic Acid Ethyl Ester; Enalapril DKP; Enalapril EP Impurity
Enalapril impurity B	RBPL-E0403	82717-96-2	C ₁₅ H ₂₁ NO ₄ ; 279.33	(+)-N-[1-(S)-Ethoxycarbonyl-3-phenylpropyl]-L-alanine; (αS)-α-[[[(1S)-1-carboxyethyl]amino]benzenebutanoic Acid; N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanine; Ramipril EP Impurity E/ Enapril Maleate EP Impurity B
ERLOTINIB	RBPL-E0500			
Erlotinib Hcl N-Oxide	RBPL-E0501	NA	C ₂₂ H ₂₃ N ₃ O ₅ ; 409.44	4-((3-ethynylphenyl)amino)-6,7-bis(2-methoxyethoxy)quinazoline1-oxide
Erlotinib impurity (3-Ethynylaniline)	RBPL-E0502	54060-30-9	C ₈ H ₇ N; 117.15	3-Ethynylaniline; (3-Ethynylphenyl)amine; (m-Aminophenyl)acetylene; 1-Amino-3-ethynylbenzene; 3-Acetylenylaniline-d4; 3-Amino-1-ethynylbenzene; 3-Ethynylaniline; 3-Ethynylbenzenamine; m-Ethynylaniline
Erlotinib Lactam impurity	RBPL-E0503	179688-29-0	C ₁₄ H ₁₈ N ₂ O ₅ ; 294.3	6,7-Di(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one; 6,7-Bis(2-methoxyethoxy)quinazolin-4(3H)-one; CP-380736
ENROFLOXACIN	RBPL-E0600			
Enrofloxacin EP Impurity A	RBPL-E0601	86393-33-1	C ₁₃ H ₉ ClFNO ₃ ; 281.67	7-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic Acid; 1-Cyclopropyl-1,4-dihydro-4-oxo-6-fluoro-7-chloro-3-quinolinecarboxylic Acid; 7-Chloro-1-cyclopropyl-6-fluoro-3-carboxy-1,4-dihydro-4-oxoquinoline; Fluoroquinolonic Acid; Ciprofloxacin EP Impurity A; Enrofloxacin impurity A
Enrofloxacin EP Impurity B	RBPL-E0602	85721-33-1	C ₁₇ H ₁₈ FN ₃ O ₃ ; 331.34	Ciprofloxacin; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-

API IMPURITIES AND METABOLITES

				quinolinecarboxylic Acid; Bay q 3939; Ciflavin; Ciprine; Cipro IV; Ciprobay 100; Ciprofloxacin
ENZALUTAMIDE	RBPL-E0700			
Enzalutamide Impurity A	RBPL-E0701	112704-79-7	C ₇ H ₄ BrFO ₂ ; 219.01	4-Bromo-2-fluorobenzoic Acid; 2-Fluoro-4-bromobenzoic Acid; NSC 190364
Enzalutamide Impurity B	RBPL-E0702	749927-69-3	C ₈ H ₇ BrFNO; 232.05	4-Bromo-2-fluoro-N-methylbenzamide
ENTACAPONE	RBPL-E0800			
Entacapone Impurity C	RBPL-E0801	116313-85-0	C ₇ H ₅ NO ₅ ; 183.12	3,4-Dihydroxy-5-nitrobenzaldehyde; 3-Nitro-4,5-dihydroxybenzaldehyde; Entacapone EP Impurity C
FAMOTIDINE	RBPL-F0100			
Famotidine impurity B	RBPL-F0101	109467-08-5 (Dimaleate) ; 89268-62-2	C ₁₆ H ₂₃ N ₁₁ O ₂ S ₅ ; 561.75	3,5-Bis[2-[[[2-[(diaminomethylene) amino]thiazol-4-yl]methyl]sulfonyl]ethyl]-4H-1,2,4,6-thiatriazine 1,1-Dioxide Dimaleate; [[[2-[(Diaminomethylene)amino]thiazol-4-yl]methyl]sulphonyl]ethyl]-4H-1,2,4,6-thiatriazine 1,1-dioxide; Famotidine Related Compound B
Famotidine impurity E	RBPL-F0102	129083-44-9	C ₁₀ H ₁₄ N ₈ S ₄ ; 374.53	Bis[(2-guanidino-4-thiazolyl)methyl]disulfide
FOSINOPRIL	RBPL-F0200			
Fosinopril impurity A (RCA)	RBPL-F0201	95399-71-6	C ₂₃ H ₃₄ NO ₅ P; 435.49	(4S)-4-Cyclohexyl-1-[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline; trans-4-Cyclohexyl-1-[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline; Fosfenopril; Fosinoprilic Acid; SQ 27519; Fosinoprilat; Fosinopril related compound A
FINGOLIMOD	RBPL-F0300			
Fingolimod N-Oxide	RBPL-F0301	NA	C ₁₈ H ₃₁ NO ₃	Fingolimod N-Oxide

API IMPURITIES AND METABOLITES

FINOFIBRATE	RBPL-F0400			
Finofibrate impurity A	RBPL-F0401	42019-78-3	C ₁₃ H ₉ ClO ₂ ; 232.67	4-Chloro-4'-hydroxybenzophenone; (4-Chlorophenyl)(4-hydroxyphenyl)methanone; 4-(4-chlorobenzoyl)phenol; Fenofibrate Related Compound A;
Finofibrate impurity B	RBPL-F0402	42017-89-0	C ₁₇ H ₁₅ ClO ₄ ; 318.75	Fenofibric Acid; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methyl-propanoic Acid; FNF Acid; NSC 281318; Procetofenic Acid;
Finofibrate impurity G	RBPL-F0403	217636-48-1	C ₂₄ H ₂₇ ClO ₆ ; 446.92	Fenofibric Acid 1,1-Dimethyl-2-(1-methylethoxy)-2-oxoethyl Ester; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic Acid 1,1-Dimethyl-2-(1-methylethoxy)-2-oxoethyl Ester; Fenofibrate Impurity G; USP Fenofibrate Related Compound C
Finofibrate impurity C	RBPL-F0404	217636-47-0	C ₁₇ H ₁₅ ClO ₃ ; 302.75	3-[4-(4-Chlorobenzoyl)phenoxy]-2-butanone
Finofibrate impurity F	RBPL-F0405	154356-96-4	C ₁₆ H ₁₅ ClO ₂ ; 274.74	(4-Chlorophenyl)[4-(1-methylethoxy) phenyl]methanone; 3-[4-(4-Chlorobenzoyl)phenoxy]-2-propane;
FINASTERIDE	RBPL-F0500			
Finasteride impurity A	RBPL-F0501	98319-24-5	C ₂₃ H ₃₈ N ₂ O ₂ ; 374.56	1,2-dihydro finasteride; Dihydro Finasteride; Dihydroproscar; (5α,17β)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrostane-17-carboxamide; [4aR-(4aα,4bβ,6aα,7α,9aβ,9bα, 11aβ)]- N-(1,1-Dimethylethyl) hexadecahydro-4a,6a-dimethyl-2-oxo-1H-indeno[5,4-f]quinoline-7-carboxamide; 1,2-Dihydrofinasteride; 3-Oxo-4-aza-5α-androstan-17β-carboxylic acid N-(tert-butyl)amide; N-(tert-Butyl)-3-oxo-4-aza-5α-androstane-17β-carboxamide;
Finasteride impurity B	RBPL-F0502	103335-41-7	C ₂₀ H ₂₉ NO ₃ ; 331.45	3-Oxo-4-aza-5α-androst-1-ene-17β-carboxylic Acid Methyl Ester; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-Tetradecahydro-4a,6a-dimethyl-2-oxo-1H-indeno[5,4-f]quinoline-7-carboxylic Acid Methyl Ester; (5α,17β)-3-Oxo-4-azaandrost-1-ene-17-carboxylic Acid Methyl Ester;

API IMPURITIES AND METABOLITES

				Methyl 3-Oxo-4-aza-5 α -androst-1-ene-17 β -carboxylate; Finasteride Impurity;
FLUTICASONE	RBPL-F0600			
Fluticasone related compound A	RBPL- F0601	948566-12-9	C ₂₄ H ₃₀ F ₂ O ₆ S; 484.55	Fluticasone 17 β -Carbonylsulfenic Acid 17-Propionate;(6 α ,11 β ,16 α ,17 α)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androst-1,4-diene-17-carbo(thioperoxoic) Acid; Fluticasone EP Impurity B;
Fluticasone related compound C	RBPL- F0602	80474-24-4	C ₂₄ H ₂₉ F ₃ O ₅ S; 486.54	Fluticasone Acetate; (6 α ,11 β ,16 α ,17 α)-17-(Acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-androst-1,4-diene-17-carbothioic Acid S-(Fluoromethyl) Ester;
Fluticasone related compound D	RBPL- F0603	73205-13-7	C ₂₅ H ₃₂ F ₂ O ₅ S; 482.58	Ticabesone Propionate; (6 α ,11 β ,16 α ,17 α)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-androst-1,4-diene-17-carbothioic Acid S-Methyl Ester
FEXOFENADINE	RBPL- F0700			
Fexofenadine impurity A	RBPL- F0701	76811-98-8	C ₃₂ H ₃₇ NO ₄ ; 499.64	Fexofenadine impurity A; 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl]- α , α -dimethylphenylacetic acid; Fexofenadinone; 2-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl]phenyl]-2,2-dimethylacetic Acid; 4-[1-Oxo-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]- α , α -dimethyl benzene acetic Acid; USP Fexofenadine Related Compound A
Fexofenadine impurity C	RBPL- F0702	185066-37-9	C ₃₁ H ₃₉ NO ₂ ; 457.64	Fexofenadine Impurity-C ; (1R)-4-[4-(hydroxydiphenylmethyl) piperidin-1-yl]-1-[4-(1-methylethyl)phenyl]butan-1-ol; Decarboxy Fexofenadine; 4-(Hydroxy diphenylmethyl)- α -[4-(1-methylethyl) phenyl]-1-piperidinebutanol
Fexofenadine N-Oxide	RBPL-F0703	1422515-52-3	C ₃₂ H ₃₉ NO ₅ ; 517.67	Fexofenadine N-Oxide; Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-oxido-1-piperidinyl]butyl]- α , α -dimethy
FLUCONAZOLE	RBPL- F1000			

API IMPURITIES AND METABOLITES

Fluconazole N-oxide	RBPL-F1001	NA	C ₁₃ H ₁₂ F ₂ N ₆ O ₂ ; 322.27	Fluconazole mono-N-Oxide
Fluconazole Impurity E	RBPL-F1002	86404-63-9	C ₁₀ H ₇ F ₂ N ₃ O; 223.18	2,4-Difluoro-α-(1H-1,2,4-triazolyl)acetophenone; 1-(2,4-Difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)-ethanone; 2',4'-Difluoro-2-(1H-1,2,4-triazol-1-yl)acetophenone; ((2S, 3R)-2-(2,4-Difluorophenyl) -3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol); USP Voriconazole Related Compound C; Voriconazole EP Impurity A; Voriconazole USP Related Compound C
FUROSEMIDE	RBPL-F1100			
Furosemide Impurity E	RBPL-F1101	50-84-0	C ₇ H ₄ Cl ₂ O ₂ ; 191.01	2,4-dichlorobenzoic acid ; NSC 578; Furosemide EP Impurity E
FLUTAMIDE	RBPL-F1200			
2-Hydroxy-flutamide	RBPL-F1201	52806-53-8	C ₁₁ H ₁₁ F ₃ N ₂ O ₄ ; 292.21	Hydroxyflutamide; 2-Hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-propanamide, 2-Hydroxyflutamide, Hydroxyniptholide, Sch 16423, a,a,a-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide
FOLIC ACID	RBPL-F1300			
Folic acid related compound A	RBPL-F1301	1492-18-8		Folinic Acid Calcium Salt; L-N-[p-[[[(2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridiny]methyl]amino]benzoyl]glutamic Acid Calcium Salt; Calcium 5-formyltetrahydrofolate; Calcium L-Folate; Calcium Folate; Calcium Leucovorin; Folidan; Folinic Acid Calcium Salt; Lederfoline; Leucovorin Calcium; Leucovorin Calcium Salt; NSC 3590; Rescuvolin; Wellcovorin; USP Folic Acid Related Compound A
GALANTHAMINE	RBPL-G0100			
Galanthamine impurity B	RBPL-G0101	1668-85-5	C ₁₇ H ₂₁ NO ₃ ; 287.35	Epi Galanthamine; (4aS,6S,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol; 2-Epigalanthamine; (-)-Epigalanthamine; 3-Epigalanthamine; SPH 1068;

API IMPURITIES AND METABOLITES

Galanthamine impurity D	RBPL-G0102	664995-65-7	C ₁₇ H ₁₉ NO ₂ ; 269.34	Anhydro Galanthamine; (4aS,8aS)-9,10,11,12-Tetrahydro-3-methoxy-11-methyl-4aH-benzofuro[3a,3,2-ef][2]benzazepine; R 116937; Tetrahydrogalantamine;
O-desmethyl Galanthamine	RBPL-G0103	60755-80-8	C ₁₆ H ₁₉ NO ₃ ; 273.33	(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepine-3,6-diol; 10-Methyl-galantham-1-ene-3β,6-diol; Sanguinine;
GABAPENTINE	RBPL-G0200			
Gabapentine impurity A	RBPL-G0201	64744-50-9	C ₉ H ₁₅ NO; 153.22	Gabapentine lactam; 3-Azaspiro-[4,5]decan-3-one; Gabapentin Lactam; Gabapentin Related Compound A
GLIMIPRIDE	RBPL-G0300			
Glimipride impurity B	RBPL-G0301	119018-29-0	C ₁₆ H ₂₁ N ₃ O ₄ S; 351.42	4-[2-[(3-Ethyl-4-methyl-2-oxo-3-pyrrolin-1-yl)carboxamido]ethyl]benzenesulfonamide; Des[(trans-4-methylcyclohexyl) amino]carbonyl Glimepiride; N-[2-[4-(Aminosulfonyl)phenyl]ethyl]-3-ethyl-2,5-dihydro-4-methyl -2-oxo-1H-pyrrole-1-carboxamide; USP Glimepiride Related Compound B
GUAIFENESIN	RBPL-G0500			
Guaifenesin impurity B	RBPL-G0501	14007-09-1	C ₁₀ H ₁₄ O ₄ ; 198.22	2-(2-Methoxyphenoxy)-1,3-propanediol
GEFITINIB	RBPL-G0600			
Gefitinib Morpholine N-oxide	RBPL-G0601	847949-51-3	C ₂₂ H ₂₄ ClFN ₄ O ₄ ; 462.91	N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-oxido-4-morpholinyl)propoxy]-4-quinazolinamine
GEMCITABINE	RBPL-G0700			
Gemcitabine impurity A	RBPL-G0701	71-30-7	C ₄ H ₅ N ₃ O; 111.1	Cytosine; 6-Amino-2(1H)-pyrimidinone; 4-Amino-1H-pyrimidin-2-one; 4-Amino-2(1H)-pyrimidinone; 4-Amino-2-hydroxypyrimidine; 4-Aminouracil; Cytosinimine; NSC 27787

API IMPURITIES AND METABOLITES

GRANISETRON	RBPL-G0800			
Granisetron impurity D (RC D)	RBPL-G0801	50890-83-0	C ₉ H ₈ N ₂ O ₂ ; 176.17	1-Methylindazole-3-carboxylic Acid (Granisetron Impurity D); 1-Methyl-1H-indazole-3-carboxylic Acid; 3-Carboxy-1-methylindazole; Granisetron EP Impurity D;
Granisetron impurity H	RBPL-G0802	4498-67-3	C ₈ H ₆ N ₂ O ₂ ; 162.15	Indazole-3-carboxylic Acid; 1H-Indazole-3-carboxylic Acid; 3(1H)-Indazolecarboxylic Acid; 3-Carboxy-1H-indazole; 3-Carboxyindazole; NSC 520610
HYDROCHLORTHIAZIDE	RBPL-H0200			
Hydrochlorthiazide impurity A	RBPL-H0201	58-94-6	C ₇ H ₆ ClN ₃ O ₄ S ₂ ; 295.72	Chlorothiazide; 6-Chloro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Chlorthiazide; Chlotride; Diuril; Saluric; Urinex; Hydrochlorothiazide EP Impurity A
Hydrochlorthiazide impurity B	RBPL-H0202	121-30-2	C ₆ H ₈ ClN ₃ O ₄ S ₂ ; 285.73	4-Amino-6-chloro-1,3-benzenedisulfonamide; 4-Amino-6-chloro-m-benzenedisulfonamide; 3-Chloro-4,6-disulfamoylaniline; 5-Chloro-2,4-disulfamoylaniline; Chloraminophenamide; Chloroaminophenamide; Idorese; Salmid; Salmide; NSC 93772; USP Benzothiadiazine Related Compound A; Hydrochlorothiazide EP Impurity B
HALOPERIDOL	RBPL-H0300			
Haloperidol N-Oxide (Impurity – H (EP))	RBPL-H0301	148406-51-3	C ₂₁ H ₂₃ ClFNO ₃ ; 391.86	cis/trans-Haloperidol N-Oxide; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-oxido-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone N-Oxide; (Impurity – H (EP))
Haloperidol impurity I	RBPL-H0302	3874-54-2	C ₁₀ H ₁₀ ClFO; 200.64	4-Chloro-4'-fluorobutyrophenone; 4-Chloro-1-(4-fluorophenyl)-1-butanone; 4-Chloro-4'-fluoro-butyrophenone; 1-Chloro-4-(4-fluorophenyl)-4-oxobutane; 3-(4-Fluorobenzoyl)propyl Chloride; 3-(4-Fluorophenylcarbonyl)-1-chloropropane; 3-Chloropropyl 4-Fluorophenyl Ketone; 4-(4-Fluorophenyl)-4-oxobutyl Chloride; 4-(p-Fluorophenyl)-4-oxobutyl Chloride; NSC 87082

API IMPURITIES AND METABOLITES

HYOSCINE BUTYLBROMIDE	RBPL-H0400			
Hyoscine butylbromide Impurity B	RBPL-H0401	552-63-6	C ₉ H ₁₀ O ₃ ; 166.17	Tropic Acid; α-(Hydroxymethyl)-benzeneacetic Acid; (±)-Tropic Acid; (±)-2-Phenyl-3-hydroxypropionic Acid; (±)-3-Hydroxy-2-phenylpropionic Acid; 2-Phenyl-3-hydroxypropanoic Acid; 2-Phenyl-3-hydroxypropionic Acid; 2-Phenylhydracrylic Acid; 3-Hydroxy-2-phenylpropionic Acid; DL-Tropic Acid; NSC 20990; Tropic Acid; Ipratropium EP Impurity C
Hyoscine butylbromide Impurity C	RBPL-H0402	155-41-9	C ₁₈ H ₂₄ BrNO ₄ ; 398.29	Scopolamine Methyl Bromide; (1α,2β,4β,5α,7β)-7-[(2S)-3-Hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane; 6β,7β-Epoxy-3α-hydroxy-8-methyl-1αH,5αH-tropanium Bromide (-)-Tropate; [7(S)-(1α,2β,4β,5α,7β)]-7-(3-Hydroxy-1-oxo-2-phenylpropoxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane Bromide; (1α,2β,4β,5α,7β)-7-[(2S)-3-Hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane Bromide; N-Methylscopolammonium Bromide; 3-Oxa-9-azatricyclo[3.3.1.0 ^{2,4}]nonane, 3-oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane deriv.; (-)-Tropic Acid Ester with 6β,7β-Epoxy-3α-hydroxy-8-methyl-1αH,5αH-tropanium Bromide (8CI); (-)-Scopolamine Methobromide; (-)-Scopolamine Methyl Bromide; Ampyrox; Blocan; Diopal; Epoxymethamine Bromide; Epoxytropine Tropate M
HYDROCORTISONE ACETATE	RBPL-H0500			
Hydrocortisone Acetate EP Impurity C	RBPL-H0501	52-21-1	C ₂₃ H ₃₀ O ₆ ; 402.48	Methylprednisolone Acetate EP Impurity E ; Prednisolone Acetate; (11β)-21-(Acetyloxy)-11,17-dihydroxypregna-1,4-diene-3,20-dione; 11β,17α,21-Trihydroxypregna-1,4-diene-3,20-dione 21-acetate; 21-(Acetoxy)-11β,17α-dihydroxypregna-1,4-diene-3,20-dione; Cormalone; Cortipred; Deltilen; Econopred; Falcon; Meticortelone Acetate; Predalone 50; Prediacortin; Predicort; Prednelan N; Prednidoren; Prenema; Supercortyl
IMATINIB	RBPL-I0100			

API IMPURITIES AND METABOLITES

Imatinib impurity E	RBPL-I0101	1365802-18-1	C ₅₂ H ₄₈ N ₁₂ O ₂ ; 873.02	Imatinib dimer; Des(methylpiperazinyl-N-methyl) Imatinib Dimer Impurity; 1,4-Bis-[4-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]carbamoyl]benzylpiperazine
Imatinib (Pyridine) N-oxide	RBPL-I0102	571186-92-0	C ₂₉ H ₃₁ N ₇ O ₂ ; 509.60	N-[4-Methyl-3-[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl)methyl]benzamide; CGP 7238
Imatinib piperazine N-Oxide	RBPL-I0103	571186-91-9	C ₂₉ H ₃₁ N ₇ O ₂ ; 509.62	4-[[4-Methyl-4-oxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; CGP 71422; Imatinib EP Impurity J
Imatinib (Piperidine)-N,N-dioxide	RBPL-I0104	571186-93-1	C ₂₉ H ₃₁ N ₇ O ₃ ; 525.60	4-[[4-Methyl-1,4-dioxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide
Imatinib impurity A	RBPL-I0105	55314-16-4	C ₁₀ H ₁₂ N ₂ O; 176.22	3-Dimethylamino-1-(3-pyridyl)-2-propen-1-one; 1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one; 3-(Dimethylamino)-1-(3-pyridinyl)-2-propen-1-one; 3-Dimethylamino-1-(pyridin-3-yl)propenone; Imatinib EP Impurity A
Imatinib impurity C	RBPL-I0106	404844-02-6	C ₂₈ H ₂₉ N ₇ O; 479.58	N-Desmethyl Imatinib; N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperazinylmethyl)-benzamide; N-Desmethyl Gleevec; CGP-74588; Norimatinib; STI 509-00; Imatinib EP Impurity C
Imatinib impurity F	RBPL-I0107	152460-10-1	C ₁₆ H ₁₅ N ₅ ; 277.32	N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine; 4-Methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]aniline; 4-Methyl-N3-[4-(3-pyridinyl)-2-pyrimidinyl]-1,3-benzenediamine; Imatinib Impurity F
Imatinib Carboxylic acid	RBPL-I0108	106261-49-8 Free Base: 106261-48-7	C ₁₃ H ₂₀ Cl ₂ N ₂ O ₂ ; 307.22	4-(4-Methylpiperazinomethyl)benzoic Acid, Dihydrochloride; Imatinib Carboxylic Impurity; Imatinib Mesylate intermediate; 4-((4-methylpiperazin-1-yl)methyl)benzyl chloride; 4-[[4-methyl-1-piperazinyl)methyl]benzoic acid dihydrochloride.
IBUPROFEN	RBPL-I0200			
Ibuprofen impurity L	RBPL-I0201	53949-53-4	C ₁₃ H ₁₈ O ₃ ; 222.28	1-Hydroxy Ibuprofen (Ibuprofen Impurity L) (Mixture of Diastereomers), 4-(1-Hydroxy-2-methylpropyl)-α-methylbenzeneacetic Acid; 2-[4-(1-Hydroxy-2-methylpropyl)phenyl] propionic Acid;

API IMPURITIES AND METABOLITES

Ibuprofen impurity E	RBPL-I0202	38861-78-8	C ₁₂ H ₁₆ O; 176.25	1-(4-Isobutylphenyl) ethanone; 1-[4-(2-Methylpropyl)phenyl] ethanone; 1-Acetyl-4-isobutylbenzene; 1-[4-(2-Methylpropyl) phenyl]-1-ethanone; 1-[4-(2-Methylpropyl)phenyl]ethanone; 4-(2-Methylpropyl)acetophenone; NSC 173015; p-Acetylisobutyl benzene; p-Isobutylacetophenone; p-Isobutylphenyl Methyl Ketone; 4-IBAP; Ibuprofen Related Compound C;
Ibuprofen impurity A	RBPL-I0203	66622-47-7	C ₁₃ H ₁₈ O ₂ ; 206.28	m-Isobutyl Ibuprofen; α-Methyl-3-(2-methylpropyl)benzeneacetic Acid, α-(3-Isobutylphenyl)propionic Acid; α-Methyl-3-(2-methylpropyl)phenylacetic Acid; 2-(3-Isobutylphenyl)propionic Acid; Ibuprofen EP Impurity A
Ibuprofen impurity N	RBPL-I0204	3585-52-2	C ₁₁ H ₁₄ O ₂ ; 178.23	p-Ethylhydratropic Acid; 4-Ethyl-α-methylbenzeneacetic Acid; 2-(4-Ethylphenyl)propionic Acid; 2-(p-Ethylphenyl)propionic Acid; Ibuprofen EP Impurity N
Ibuprofen impurity B	RBPL-I0205	3585-49-7	C ₁₃ H ₁₈ O ₂ ; 206.28	(2RS)-2-(4-Butylphenyl)propanoic Acid; 4-Butyl-α-methylbenzeneacetic acid, p-Butylhydratropic acid, Ibuprofen impurity B
Ibuprofen impurity J	RBPL-I0206	65813-55-0	C ₁₃ H ₁₆ O ₃ ; 220.26	1-Oxo Ibuprofen; α-Methyl-4-(2-methyl-1-oxopropyl)benzeneacetic Acid; 2-(4-Isobutyrylphenyl)propionic Acid; Ibuprofen Impurity J; Ibuprofen EP Impurity J
ITRACONAZOLE	RBPL-I0300			
Itraconazole impurity C	RBPL-I0301	74855-91-7	C ₃₄ H ₃₆ Cl ₂ N ₈ O ₄ ; 691.61	Propyl Itraconazole; cis-4-[4-[4-[4-[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl] -1-piperazinyl]phenyl]-2,4-dihydro-2-propyl-3H-1,2,4-triazol-3-one;
INDAPAMIDE	RBPL- I0600			
Indapamide Impurity B	RBPL- I0601	63968-75-2	C ₁₆ H ₁₄ ClN ₃ O ₃ S; 363.82	Dehydro Indapamide; 3-(Aminosulfonyl)-4-chloro-N-(2-methyl-1H-indol-1-yl)benzamide; 4-Chloro-3-sulfamoyl-N-(2-methyl-1H-indol-1-yl)benzamide; USP Indapamide Related Compound A; Indapamide USP Related Compound A; Indapamide EP Impurity B

API IMPURITIES AND METABOLITES

IRINOTECAN	RBPL-I0700			
Irinotecan Impurity D	RBPL-I0701	NA	$C_{33}H_{45}ClN_4O_9 \cdot 3H_2O$; 677.18	(R)-Irinotecan Hydrochloride Trihydrate; (4R)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester [1,4'-Bipiperidine]-1'-carboxylic Acid Hydrochloride Trihydrate; (R)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride trihydrate; USP Irinotecan Related Compound D;
Irinotecan RC-B	RBPL-I0702	86639-52-3	$C_{22}H_{20}N_2O_5$; 392.4	SN-38; (4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione; 7-Ethyl-10-hydroxycamptothecin; 10-Hydroxy-7-ethylcamptothecin; SN 38 Lactone; USP Irinotecan Related Compound B; Irinotecan USP Related Compound B
Irinotecan RC-E	RBPL-I0703	78287-27-1	$C_{22}H_{20}N_2O_4$; 376.41	7-Ethyl Camptothecin; (4S)-4,11-Diethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 7-Ethyl-20(S)-camptothecin; SN 22; USP Irinotecan Related Compound E; Irinotecan USP Related Compound E
KETORALAC	RBPL-K0100			
Ketoralac impurity D	RBPL-K0101	1391053-45-4	$C_{16}H_{14}NNaO_4$; 307.0821; 285 (without sodium)	1-Methoxy Ketoralac ; Ketoralac 1-Methoxy Impurity ; (1RS)-5-Benzoyl-1-methoxy-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid sodium salt
Ketoralac impurity B	RBPL-K0102	113502-52-6	$C_{14}H_{11}NO_2$; 225.24	5-Benzoyl-2,3-dihydro-1H-pyrrolizin-1-one; USP Ketoralac Related Compound C;
KETOCONAZOLE	RBPL- K0200			
Ketoconazole-N-Oxide	RBPL- K0201	254912-65-7	$C_{26}H_{28}Cl_2N_4O_5$; 547.43	1-(4-(((2R,4S)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-acetylpiperazine 1-oxide ; Ketoconazole N-Oxide
LIFLUNOMIDE	RBPL-L0200			

API IMPURITIES AND METABOLITES

Liflunomide impurity E	RBPL-L0201	208401-20-1	C ₁₂ H ₉ F ₃ N ₂ O ₂ ; 270.21	5-Desmethyl-3-methyl Leflunomide; 3-Methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; N-[4-(Trifluoromethyl)phenyl]-3-methylisoxazole-4-carboxamide
Leflunomide impurity A (RC-A)	RBPL-L0202	455-14-1	C ₇ H ₆ F ₃ N; 161.12	4-(Trifluoromethyl)aniline; USP Leflunomide Related Compound A; 4-(Trifluoromethyl)benzenamine; 4-Amino- α,α,α -benzotrifluoride; 4-Aminobenzotrifluoride; NSC 10337; p-(Trifluoromethyl)aniline; p-Amino- α,α,α -trifluorotoluene; p-Aminobenzotrifluoride; p-Trifluoromethylphenylamine; α,α,α -Trifluoro-p-toluidine; Leflunomide EP Impurity A; Leflunomide USP Related Compound A
Leflunomide impurity B	RBPL-L0203	163451-81-8	C ₁₂ H ₉ F ₃ N ₂ O ₂ ; 270.21	A 77-1726; N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide, 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-beuteamide, LEF-M; Teriflunomide; Leflunomide EP Impurity B; Aubagio; A1726; (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide; Femorix; HMR 1726; SU 20
Leflunomide impurity D	RBPL-L0204	42831-50-5	C ₅ H ₅ NO ₃ ; 127.1	5-Methylisoxazole-4-carboxylic Acid; 5-Methyl-4-isoxazolecarboxylic Acid; Leflunomide EP Impurity D
Leflunomide impurity H	RBPL-L0205	24522-30-3	C ₁₀ H ₇ F ₃ N ₂ O; 228.17	2-Cyano-N-[4-(trifluoromethyl)phenyl]acetamide; 2-Cyano- α,α,α -trifluoro-p-acetotoluidide; Leflunomide EP Impurity H
LAMOTRIGINE	RBPL-L0300			
Lamotrigine impurity F	RBPL-L0301	252186-79-1	C ₁₆ H ₉ Cl ₄ N ₅ O; 429.09	3-(2,3-Dichlorobenzamido) Lamotrigine; N-[5-Amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-3-yl]-2,3-dichlorobenzamide; Lamotrigine related compound D
Lamotrigine impurity G	RBPL-L0302	38943-76-9	C ₉ H ₅ Cl ₂ N ₃ O ₂ ; 258.06	6-(2,4-dichlorophenyl)-1,2,4-triazine-3,5-diamine
Lamotrigine N-Oxide	RBPL-L0303	136565-76-9	C ₉ H ₇ Cl ₂ N ₅ O; 272.09	Lamotrigine N2-Oxide; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine 2-Oxide;
Lamotrigine impurity E	RBPL-L0304	50-45-3	C ₇ H ₄ Cl ₂ O ₂ ; 191.01	2,3-Dichlorobenzoic Acid; Lamotrigine USP Related Compound B/ Lamotrigine EP

API IMPURITIES AND METABOLITES

				Impurity E
LANSOPRAZOLE	RBPL-L0400			
Lansoprazole sulphone	RBPL-L0401	953787-54-7	C ₁₆ H ₁₄ F ₃ N ₃ O ₄ S; 401.36	Lansoprazole Sulfone N-Oxide; 2-[[[3-Methyl-1-oxido-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfonyl]-1H-benzimidazole
Lansoprazole sulphone N-oxide	RBPL-L0402	953787-54-7	C ₁₆ H ₁₄ F ₃ N ₃ O ₄ S; 401.36	2-[[[3-Methyl-1-oxido-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfonyl]-1H-benzimidazole
Lansoprazole impurity C	RBPL-L0403	103577-40-8	C ₁₆ H ₁₄ F ₃ N ₃ OS; 353.36	Lansoprazole sulphide; 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]-1H-benzimidazole; AG 1777; H 225/18; K 1252
Lansoprazole chloro	RBPL-L0404	127337-60-4	C ₉ H ₁₀ Cl ₂ F ₃ NO; 276.08	Lansoprazole chloro; 2-Chloromethyl-3-met; Lansoprazole intermediate; 2-Chloromethyl-3-Methyl-4-; Lansoprazole Intermediate 1; 2-ChloroMethyl-3-Methyl-4-(2; lansoprazole chloro compound; Lansoprazole Chloro IMPurity;
2-mercapto-1H-Benzimidazole	RBPL-L0405	97963-62-7	C ₈ H ₆ F ₂ N ₂ OS; 216.21	5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole
S-Lansoprazole	RBPL-L0406	138530-95-7	C ₁₆ H ₁₄ F ₃ N ₃ O ₂ S; 369.36	2-[(S)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
Lansoprazole impurity D (1H-Benzimidazol-2-ol)	RBPL-L0407	615-16-7	C ₇ H ₆ N ₂ O; 134.14	2-Hydroxybenzimidazole; 1,3-Dihydro-2H-benzimidazol-2-one; 2-Benzimidazolinone; 2,3-Dihydro-2-oxo-1H-benzimidazole; 2-Benzimidazolol; 2-Benzimidazolone; N,N'-(1,2-Phenyleneurea); NSC 10383; NSC 178108; o-Phenyleneurea; Lansoprazole EP Impurity D(Rabeprazole EP Impurity K)
Lansoprazole impurity E (Rabeprazole Mercapto Impurity ; 1H-Benzimidazole-2-thiol)	RBPL-L0408	583-39-1	C ₇ H ₆ N ₂ S; 150.2	2-Mercaptobenzimidazole; 1,3-Dihydro-2H-benzimidazole-2-thione; 2-Benzimidazolinethione; 1H-Benzimidazole-2-thiol; 2-Mercapto-1H-benzimidazole; 2-Thiobenzimidazole; Antigene MB; Antioxidant Rabeprazole Related Compound CMB; Permanax 21; Sandant MB; Sumilizer MB; Vulkanox; o-Phenyleneethiourea; Rabeprazole Related Compound C USP, Rabeprazole EP Impurity F; Lansoprazole

API IMPURITIES AND METABOLITES

				impurity E
LEVOFLOXACIN	RBPL-L0500			
Levofloxacin carboxylic acid	RBPL-L0501	100986-89-8	C ₁₃ H ₉ F ₂ NO ₄ ; 281.21	Levofloxacin Difluoro Impurity; (3S)-9,10-Difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid; Levofloxacin Q-Acid; Levofloxacin Related Compound B
Levofloxacin-N-oxide	RBPL-L0502	117678-38-3	C ₁₈ H ₂₀ FN ₃ O ₅ ; 377.36	(S)-4-(6-carboxy-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-10-yl)-1-methylpiperazine 1-oxide; 1-Methyl-4-[(9-fluoro-2,3-dihydro-6-carboxy-3α-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazin)-10-yl]piperazine 1-oxide
Levofloxacin Impurity B (RC-A) (N-desmethyl)	RBPL-L0503	117707-40-1	C ₁₇ H ₁₈ FN ₃ O ₄ ; 347.34	Levofloxacin Related Compound A; (3S)-9-Fluoro-2,3-dihydro-3-methyl-7-oxo-10-(1-piperazinyl)-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid Hydrochloride
Levofloxacin Impurity A	RBPL-L0504	117707-40-1	C ₁₇ H ₁₈ FN ₃ O ₄ ; 347.34	Levofloxacin USP Related Compound A ; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid ; N-Desmethyl Levofloxacin
LOPERAMIDE	RBPL-L0600			
Loperamide impurity B	RBPL-L0601	NA	C ₄₇ H ₅₃ ClN ₃ O ₃ ; 743.4	4-(4-chlorophenyl)-1,1-bis[4-(dimethylamino)-4-oxo-3,3-diphenylbutyl]-4-hydroxypiperidinium
Loperamide impurity F	RBPL-L0602	106900-12-3	C ₂₉ H ₃₃ ClN ₂ O ₃ ; 493.05	trans-4-(4-Chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutanamide 1-Oxide; Arestal; Loperamide Oxide; R 58425; Loperamide related compound A
Loperamide impurity G	RBPL-L0603	109572-89-6	C ₂₉ H ₃₃ ClN ₂ O ₃ ; 493.04	Loperamide cis-N-Oxide; cis-4-(4-Chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutanamide 1-Oxide

API IMPURITIES AND METABOLITES

Loperamide impurity A	RBPL-L0604	1391052-94-0	C ₃₅ H ₃₇ ClN ₂ O ₂ ; 553.143	Loperamide Impurity A; UNII-O0JEK28Z5J; O0JEK28Z5J; ZINC77286473; 4-Dechloro-4-(4-chlorophenyl) Loperamide; 4-(4-Chlorobiphenyl)-4-hydroxy-N,N-dimethyl- A, A-diphenyl-1-piperidinebutanamide;
Loperamide impurity C	RBPL-L0605	39512-49-7	C ₁₁ H ₁₄ ClNO; 211.69	4-(4-Chlorophenyl)-4-hydroxypiperidine; 4-(4-Chlorophenyl)-4-piperidinol; 4-(p-Chlorophenyl)-4-hydroxypiperidine; 4-Hydroxy-4-(p-chlorophenyl)piperidine; NSC 89568; Loperamide Impurity C
Loperamide impurity H	RBPL-L0606	61299-42-1	C ₂₉ H ₃₁ ClN ₂ O; 459.02	Dehydro Loperamide; 4-(4-Chlorophenyl)-3,6-dihydro-N,N-dimethyl- α,α -diphenyl-1(2H)-pyridinebutanamide; Loperamide Impurity H;
LORATIDINE	RBPL-L0700			
Loratidine-N-oxide	RBPL-L0701	165739-62-8	C ₂₂ H ₂₃ ClN ₂ O ₃ ; 398.88	4-(8-Chloro-5,6-dihydro-1-oxido-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; Sch 38554
Loratidine impurity D (Des)	RBPL-L0702	100643-71-8	C ₁₉ H ₁₉ ClN ₂ ; 310.82	8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo[5,6] cyclohepta[1,2-b]pyridine; Loratidine related compound A; Descarboethoxyloratidine; Desloratidine
Loratidine impurity B (RC-C)	RBPL-L0703	31251-41-9	C ₁₄ H ₁₀ ClNO; 243.69	8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one; USP Loratidine Related Compound C; Loratidine EP Impurity B; Loratidine USP Related Compound C
Loratidine impurity H	RBPL-L0704	29976-53-2	C ₈ H ₁₃ NO ₃ ; 171.19	N-Carboethoxy-4-piperidone; 1-(Carboethoxy)-4-piperidinone; 1-(Carboethoxy)-4-piperidone; 1-(Ethoxycarbonyl)-4-piperidone; 1-Carboethoxy-4-piperidone; 1-Carboethoxypiperidin-4-one; 1-Ethoxycarbonyl-4-oxopiperidine; 1-Ethoxycarbonyl-4-piperidinone; 4-Oxo-1-piperidinecarboxylic Acid Ethyl eEster; Ethyl 4-Oxo-1-piperidinecarboxylate; N-(Ethoxycarbonyl)-4-piperidone; N-Carboethoxy-4-piperidinone; N-Carboethoxy-4-piperidone; N-Ethoxycarbonyl-4-piperidinone; NSC 139022; Loratidine EP Impurity H

API IMPURITIES AND METABOLITES

LINEZOLID	RBPL-L0800			
Linezolid USP rel cpd A	RBPL-L0801	168828-84-0	C ₁₄ H ₁₆ FN ₅ O ₃ ; 321.31	Deacetamide Linezolid Azide; (5R)-5-(Azidomethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone; (R)-5-(Azidomethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone; Linezolid USP Related Compound A
LAMIVUDINE	RBPL-L0900			
Lamivudine EP Impurity C	RBPL-L0902	69-72-7	C ₇ H ₆ O ₃ ; 138.12	Salicylic Acid; 2-Hydroxybenzoic Acid; 2-Carboxyphenol; 2-Hydroxybenzenecarboxylic Acid; 2-Hydroxybenzoic Acid; o-Carboxyphenol; o-Hydroxybenzoic Acid; Rutranex; Saligel; Salonil; Salvona Nanosal; Stri-Dex; Trans-Ver-Sal; Verrugon; Acetylsalicylic Acid EP Impurity C (Aspirin Impurity C)/ Mesalazine EP Impurity H
Lamivudine R-Sulphoxide (G)	RBPL-L0903	160552-54-5	C ₈ H ₁₁ N ₃ O ₄ S; 245.26	Lamivudine (R)-Sulfoxide; Lamivudine (R)-S-Oxide; 4-Amino-1-[(2R,3R,5S)-2-(hydroxymethyl)-3-oxido-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; [2R-(2α,3β,5α)]-4-Amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone S-Oxide; 1,3-Oxathiolane, 2(1H)-pyrimidinone Deriv.; [2R-(2α,3β,5α)]-4-Amino-1-[2-(hydroxymethyl)-3-oxido-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; GI 138870X; Lamivudine EP Impurity H
LOSARTAN	RBPL- L0100			
Losartan impurity D	RBPL-L0101	83857-96-9	C ₈ H ₁₁ ClN ₂ O; 186.64	2-Butyl-5-chloro-1H-imidazole-4-carboxaldehyde; 2-Butyl-4-chloro-5-formylimidazole; 2-Butyl-4-chloroimidazole-5-carboxaldehyde; 2-Butyl-5-formyl-4-chloroimidazole; Losartan EP Impurity D; Losartan USP Related Compound A
LEVETIRACETAM	RBPL-L1100			
Levetiracetam related compound B	RBPL-L1101	7682-20-4	C ₄ H ₁₁ ClN ₂ O; 138.6	(S)-2-Aminobutyramide Hydrochloride; (S)-2-Aminobutanamide Monohydrochloride; USP Levetiracetam Related Compound B; Levetiracetam USP

API IMPURITIES AND METABOLITES

				Related Compound B
Levetiracetam Impurity C	RBPL-L1102	142-08-5	C ₅ H ₅ NO; 95.1	2-Hydroxypyridine; Pyridin-2-ol ; 2-Pyridinol
LETROZOLE	RBPL- L1400			
Letrozole N-Oxide	RBPL-L1401	NA	C ₁₇ H ₁₁ N ₅ O; 301.31	1-(bis(4-cyanophenyl)methyl)-1H-1,2,4-triazole 2-oxide
Letrozole RC-A	RBPL-L1402	112809-52-6	C ₁₇ H ₁₁ N ₅ ; 285.3	Iso Letrozole; 4,4'-(4H-1,2,4-Triazol-4-ylmethylene)bisbenzonitrile; USP Letrozole Related Compound A; Letrozole EP Impurity A
LIDOCAINE	RBPL-L1500			
Lidocaine impurity A	RBPL-L1501	87-62-7	C ₈ H ₁₁ N; 121.18	2,6-Dimethylaniline; 2,6-Dimethylbenzenamine; 2,6-DMA; 2,6-Xylidine; 1-Amino-2,6-dimethylbenzene; 2,6-Dimethylbenzenamine; 2,6-Dimethylphenylamine; 2,6-Xylylamine; 2-Amino-1,3-dimethylbenzene; 2-Amino-1,3-xylene; 2-Amino-m-xylene; NSC 7098; o-Xylidine; Bupivacaine Imp. F (EP); USP Lidocaine impurity A; Lidocaine EP Impurity A; (Bupivacaine impurity F)
Lidocaine impurity H	RBPL-L1502	1131-01-7	C ₁₀ H ₁₂ ClNO; 197.66	2-Chloro-2',6'-dimethylacetanilide; 2-Chloro-N-(2,6-dimethylphenyl)acetamide; 1-Chloroacetyl-amino-2,6-dimethylbenzene; 2-Chloro-2',6'-acetoxylidide; 2',6'-Dimethyl-2-chloroacetanilide; Chloroacetamido-2,6-xylidine; Chloroaceto-2,6-xylidide; N-(2,6-Dimethylphenyl)-2-chloroacetamide; N-(2,6-Xylyl)chloroacetamide; N-Chloroacetyl-2,6-dimethylaniline; NSC 37260; Lidocaine EP Impurity H
LEVONORGESTREL	RBPL-L1600			
Levonorgestrel Impurity L	RBPL-L1601	21800-83-9	C ₁₉ H ₂₆ O ₂ ; 286.41	D-Ethyl Gonendione; 13-Ethyl-gon-4-ene-3,17-dione; (+)-13-Ethylgon-4-ene-3,17-dione; (+)-13-β-Ethylgon-4-ene-3,17-dione; 18-Methyl-19-norandrost-4-ene-3,17-dione; 18-Methylestr-4-ene-3,17-dione; Levonorgestrel Impurity L (EP); Levonorgestrel EP Impurity L

API IMPURITIES AND METABOLITES

Levonorgestrel Impurity U	RBPL-L1602	68-22-4	C ₂₀ H ₂₆ O ₂ ; 298.42	Norethindrone; (17 α)-17-Hydroxy-19-norpregn-4-en-20-yn-3-one; 19-Nor-17 α -ethynyl-4-androsten-17 β -ol-3-one; 17 α -Ethynyl-19-nortestosterone; 19-Norethisterone; Levonorgestrel Impurity U (EP)
LACOSAMIDE	RBPL-L1700			
Lacosamide impurity G	RBPL-L1701	588-46-5	C ₉ H ₁₁ NO; 149.19	N-Benzylacetamide; Lacosamide Impurity B; N-(Phenylmethyl)-acetamide; N-(Phenylmethyl)acetamide; N-Acetylbenzylamine; N-Benzylacetamide; NSC 8065
LOVASTATIN	RBPL-L1800			
Lovastatin EP Impurity A	RBPL-L1801	73573-88-3	C ₂₃ H ₃₄ O ₅ ; 390.51	Mevastatin; Compactin, 6-Demethylvevinolin, CS-500, ML-236 B
METOPROLOL	RBPL-M0200			
Metoprolol epoxide (Metoprolol impurity A)	RBPL-M0201	56718-70-8	C ₁₂ H ₁₆ O ₃ ; 208.25	1-[2-(2-methoxyethyl)phenoxy]-2,3-epoxypropane; Metoprolol impurity stage-IA; 2-[[4-(2-Methoxyethyl)phenoxy]methyl-oxirane; [[4-(2-Methoxyethyl)phenoxy]methyl]-oxirane; MEEP; Metoprolol Impurity VII
Metoprolol impurity H (Betaxolol Impurity B)	RBPL-M0202	62572-94-5	C ₁₄ H ₂₃ NO ₃ ; 253.34	O-Desmethyl Metoprolol; 4-[2-Hydroxy-3-[(1-methylethyl) amino]propoxy]-benzeneethanol; (+/-)-4-[2-Hydroxy-3-(isopropylamino)propoxy] phenylethyl Alcohol; 4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]-benzeneethanol; (+/-)-O-Demethylmetoprolol; H 105/22; SL 80-0088;
Metoprolol impurity B	RBPL-M0203	56718-71-9	C ₉ H ₁₂ O ₂ ; 152.19	Metoprolol Impurity I; p-(2-Methoxyethyl)phenol; 4-(2-Methoxyethyl)phenol
Metoprolol impurity G	RBPL-M0204	501-94-0	C ₈ H ₁₀ O ₂ ; 138.16	Tyrosol; 4-Hydroxy-benzeneethanol; 2-(4-Hydroxyphenyl)ethanol; 2-(4-Hydroxyphenyl)ethyl Alcohol; NSC 59876;
Metoprolol impurity M	RBPL-M0205	73313-36-7	C ₉ H ₂₄ Cl ₂ N ₂ O; 247.21	1,3-Bis[(1-methylethyl)amino]-2-propanol Dihydrochloride;
Metoprolol impurity N	RBPL-M0206	6452-57-9	C ₆ H ₁₅ NO ₂ ; 133.19	3-Isopropylamino-1,2-propanediol; 3-[(1-Methylethyl)amino]-1,2-propanediol; 1,2-Dihydroxy-3-isopropylaminopropane;

API IMPURITIES AND METABOLITES

Metoprolol impurity O	RBPL-M0207	154784-36-8	C ₂₇ H ₄₁ NO ₆ ; 475.6	1,1'-[(1-Methylethyl)imino]bis[3-[4-(2-methoxyethyl)phenoxy]-2-propanol (Mixture of Diastereomers) (Metoprolol Impurity); Metoprolol Impurity VIII; Metoprolol Related compound D;
Metoprolol impurity C	RBPL-M0208	29122-74-5	C ₁₃ H ₁₉ NO ₃ ; 237.29; (C ₁₇ H ₂₃ NO ₇ ; 353.15) maleate	4-[2-Hydroxy-3-[(1-methylethyl)amino] propoxy]benzaldehyde; Metoprolol Related Compound C (Bisoprolol EP Impurity L)
Metoprolol impurity A	RBPL-M0209	109632-08-8	C ₁₄ H ₂₃ NO ₃ , 253.34	1-(Ethylamino)-3-[4-(2-methoxyethyl) phenoxy]-2-propanol; H 173/09; C-Desmethyl Metoprolol; Metoprolol related compound A
METOCLOPRAMIDE	RBPL-M0300			
Metoclopramide impurity H	RBPL-M0301	50-86-2	C ₉ H ₉ NO ₄ ; 195.17	N-Acetyl-4-aminosalicylic Acid; 4-Acetylamino-2-hydroxybenzoic Acid; 4-Acetamidosalicylic Acid; p-Acetamidosalicylic Acid; NSC 54182
MEFENAMIC ACID	RBPL-M0400			
Mefenamic acid impurity C	RBPL-M0401	118-91-2	C ₇ H ₅ ClO ₂ ; 156.57	2-Chlorobenzoic acid; o-Chlorobenzoic Acid; 2-CBA; NSC 15042; NSC 32737; o-Chlorobenzoic Acid;
Mefenamic acid impurity D	RBPL-M0402	65-85-0	C ₇ H ₆ O ₂ ; 122.12	Benzoic acid; Benzenecarboxylic Acid; Benzeneformic Acid; Benzenemethanoic Acid; Carboxybenzene; Draclyic Acid; E 210; HA 1; MENNO-Florades; NSC 149; Phenylcarboxylic Acid; Phenylformic Acid; Purox B; Retarder BA; Retardex; Salvo Liquid; Solvo Powder; Tenn-Plas; VevoVital;
MYCOPHENOLATE	RBPL-M0500			
Mycophenolate impurity F	RBPL-M0501	24280-93-1	C ₁₇ H ₂₀ O ₆ ; 320.34	Mycophenolic Acid; (4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic Acid;
Mycophenolate Mofetil N-Oxide	RBPL-M0502	224052-51-1	C ₂₃ H ₃₁ NO ₈ ; 449.49	Mycophenolate Mofetil N-Oxide (EP Impurity G); (4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic Acid 2-(4-Oxido-

API IMPURITIES AND METABOLITES

				4-morpholinyl)ethyl Ester; EP Impurity G; Mycophenolate Mofetil EP Impurity G
MONTELUKAST	RBPL-M0600			
Montelukast Sulfoxide	RBPL-M0601	909849-96-3	C ₃₅ H ₃₆ ClNO ₄ S ; 602.18	1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfinyl]methyl]cyclopropaneacetic Acid; Montelukast M2 ; Montelukast EP Impurity C), (USP Related Compound A)
Montelukast Sulphone	RBPL-M0602	1266620-74-9	C ₃₅ H ₃₆ ClNO ₅ S; 618.18	Montelukast Sulfone; 1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfonyl]methyl]cyclopropaneacetic Acid
Montelukast Ketone	RBPL-M0603	1258428-71-5	C ₂₉ H ₂₆ ClNO ₂ ; 455.98	Montelukast 3-Oxo Propanol Impurity ; (E)-1-[3-[2-(7-Chloroquinolin-2-yl)vinyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propan-1-one
Montelukast methylstyrene	RBPL-M0604	918972-54-0	C ₃₅ H ₃₄ ClNO ₂ S ; 568.17	Montelukast EP Impurity B ; Montelukast USP Related Compound F ; Montelukast Methylstyrene ; Anhydro Montelukast ; Dehydro Montelukast ; Styrene Montelukast ; [1-[[[(1R)-1-[3-[(E)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(prop-1-en-2-yl)phenyl]propyl]sulfonyl]methyl]cyclopropyl]acetic acid
Montelukast Michael Adduct	RBPL-M0605	1187586-61-3	C ₄₁ H ₄₆ ClNO ₅ S ₂ ; 732.39	Montelukast EP Impurity D ; Montelukast USP Related Compound C ; Montelukast Michael Adduct (R,R)-Isomer ; Montelukast Bis-Sulfide (Mixture of Diastereomers) ; 1-[[[(1R)-1-[3-[(1R)-1-[[[1-(Carboxymethyl)cyclopropyl]methyl]thio]-2-(7-chloro-2-quinolinyl)ethyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropaneacetic acid
Montelukast Sulfone N-Oxide	RBPL-M0606	N/A	C ₃₅ H ₃₅ ClNO ₆ S ; 633.19	(R,E)-2-(3-[1-(((1-(carboxymethyl)cyclopropyl)methyl)sulfonyl)-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl)styryl]-7-chloroquinoline 1-oxide
MOXIFLOXACIN	RBPL-M0700			

API IMPURITIES AND METABOLITES

Moxifloxacin impurity A	RBPL-M0701	151213-15-9	C ₂₀ H ₂₁ F ₂ N ₃ O ₃ ; 389.40	Moxifloxacin Difluoro Analog ; 1-Cyclopropyl-6,8-difluoro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 8-Desmethoxy-8-fluoro Moxifloxacin; Moxifloxacin Related Compound A
Moxifloxacin RC (Difluoro methoxy ethyl ester)	RBPL-M0702	112811-71-9	C ₁₆ H ₁₅ F ₂ NO ₄ ; 323.29	1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic Acid Ethyl Ester; Ethyl 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylate;
MODAFINIL	RBPL-M0800			
Modafinil impurity B	RBPL-M0801	118779-53-6	C ₁₅ H ₁₅ NO ₃ S; 289.35	Modafinil EP Impurity B; USP Modafinil Related Compound B; diphenyl methyl sulfonyl acetamide; 2-[(diphenylmethyl) sulfonylphenylmethyl)sulfonyl]hydrazylsulfonylacetamide; 2-(Benzhydrylsulfonyl) acetamide; Armodafinil sulfone; 2-[(diphenylmethyl)sulfonylphenylmethyl)sulfonyl]hydrazylsulfonylacetamide; 2-(Benzhydrylsulfonyl) cetamide; diphenylmethylsulfonyl cetamide
Modafinil acid sulphide	RBPL-M0802	63547-22-8	C ₁₅ H ₁₄ O ₂ S; 258.34	2-[(Diphenylmethyl)thio]acetic Acid; (Benzhydrylthio)acetic Acid; Benzhydrylsulfanyl-acetic Acid; AKOS BC-1797
MELOXICAM	RBPL-M0900			
Meloxicam impurity B	RBPL-M0901	7305-71-7	C ₄ H ₆ N ₂ S ; 114.17	2-Amino-5-methyl-thiazole ; Meloxicam impurity Related Compound-B
MEMANTINE	RBPL-M1000			
Memantine Impurity C	RBPL-M1001	19982-07-1	C ₁₄ H ₂₃ NO; 221.34	N-Acetyl Memantine; N-(3,5-Dimethyltricyclo[3.3.1.1 ^{3,7}]dec-1-yl)acetamide; N-(3,5-Dimethyl-1-adamantyl)acetamide; 1-Acetamido-3,5-dimethyladamantane
Memantine USP RC A	RBPL-M1002	702-79-4	C ₁₂ H ₂₀ ; 164.29	1,3-Dimethyladamantane; Memantine Related Compound A (1,3-Dimethyladamantane)

API IMPURITIES AND METABOLITES

Memantine USP RC B	RBPL-M1003	707-37-9	C ₁₂ H ₂₀ O; 180.29	3,5-Dimethyl-1-adamantanol; Memantine Related Compound B, 3,5-Dimethyltricyclo[3.3.1.1 ^{3,7}]decan-1-ol; 1,3-Dimethyl-5-adamantanol; 1,3-Dimethyl-5-hydroxyadamantane; 1-Hydroxy-3,5-dimethyladamantane; 3,5-Dimethyl-1-hydroxyadamantane; NSC 102294; Memantine USP Related Compound B (3,5-Dimethyladamantane-1-ol)
Memantine USP RC C	RBPL-M1004	707-36-8	C ₁₂ H ₁₉ Cl; 198.73	1-Chloro-3,5-dimethyladamantane; 1-Chloro-3,5-dimethyltricyclo[3.3.1.1 ^{3,7}]decane; 1,3-Dimethyl-5-chloroadamantane; 5-Chloro-1,3-dimethyladamantane; Memantine Related Compound C
Memantine USP RC D	RBPL-M1005	941-37-7	C ₁₂ H ₁₉ Br; 243.18	Memantine Impurity B; 1-Bromo-3,5-dimethyladamantane; 1-Bromo-3,5-dimethyltricyclo[3.3.1.1 ^{3,7}]decane; 1-Bromo-3,5-dimethyladamantane; 3,5-Dimethyl-1-bromoadamantane; NSC 102293;
METFORMIN	RBPL- M1200			
Metformin impurity A	RBPL-M1201	461-58-5	C ₂ H ₄ N ₄ ; 84.08	Cyanoguanidine; Metformin Related Compound A USP; N-Cyanoguanidine; 1-Cyanoguanidine; 2-Cyanoguanidine; CGNA; Dicyandiamide; Dicyanodiamide; Didin; Epicure DICY; Metformin Related Compound A USP; Metformin EP Impurity A; Metformin USP Related Compound A1 - Cyanoguanidine
Metformin Impurity C (RC-B)	RBPL-M1202	1985-46-2	C ₅ H ₁₀ N ₆ ; 154.17	N,N-Dimethylmelamine; Metformin Impurity C; 2,4-Diamino-6-(dimethylamino)-s-triazine; 2-(Dimethylamino)-4,6-diamino-s-triazine; 2,4-Diamino-6-dimethylamino-1,3,5-triazine; ENT 22312; N,N-Dimethyl-1,3,5-triazine-2,4,6-triamine; N2,N2-Dimethylmelamine; NSC 4417; USP Metformin Related Compound C; Metformin EP Impurity C
Metformin impurity D	RBPL-M1203	108-78-1	C ₃ H ₆ N ₆ ; 126.12	Melamine; 1,3,5-Triazine-2,4,6-triamine; 2,4,6-Triamino-s-triazine; Cyanurotriamide; NSC 2130
Metformin impurity F	RBPL-M1204	506-59-2 Free Base: 124-40-3	C ₂ H ₈ ClN; 81.54	Dimethylamine Hydrochloride; N-Methylmethanamine Hydrochloride; Dimethylamine Hydrochloride; Dimethylammonium Chloride; N-

API IMPURITIES AND METABOLITES

				Methylmethanamine Hydrochloride; Imatinib EP Impurity I
MELPHALAN	RBPL-M1600			
Melphalan impurity I	RBPL-M1601	949-99-5	C ₉ H ₁₀ N ₂ O ₄ ; 210.19	4-Nitro-L-phenylalanine; (S)-4-Nitrophenylalanine; 3-(4-Nitrophenyl)-L-alanine; L-4-Nitrophenylalanine L-p-Nitrophenylalanine; NSC 152925; p-Nitro-L-phenylalanine; p-Nitrophenylalanine
Melphalan impurity K	RBPL-M1602	109-89-7	C ₄ H ₁₁ N; 73.14	N-Ethylethanamine; Diethylamine, N,N-Diethylamine
METHOTREXATE	RBPL-M1700			
Methotrexate Impurity B	RBPL-M1701	54-62-6	C ₁₉ H ₂₀ N ₈ O ₅ ; 440.41	Aminopterin; N-[4-[[[(2,4-Diamino-6-pteridiny)methyl]amino]benzoyl]-L-glutamic Acid; 4-Aminofolic Acid, 4-Aminopteroyl-L-glutamic Acid, 4-Amino-PGA; NSC 739; USP Methotrexate Related Compound B; Methotrexate EP Impurity B
MINOXIDIL	RBPL-M1800			
Minoxidil Impurity B	RBPL-M1801	156-83-2	C ₄ H ₅ ClN ₄ ; 144.56	6-Chloro-pyrimidine-2,4-diamine; 6-Chloro-pyrimidine-2,4-diylldiamine, 4-Chloro-2,6-diaminopyrimidine; NSC 8818; Minoxidil EP Impurity B
MESALAZINE	RBPL-M1900			
Mesalazine impurity H (Sulfasalazine impurity H)	RBPL-M1901	69-72-7	C ₇ H ₆ O ₃ ; 138.12	Salicylic Acid; 2-Hydroxybenzoic Acid; 2-Carboxyphenol; 2-Hydroxybenzenecarboxylic Acid; 2-Hydroxybenzoic Acid; o-Carboxyphenol; o-Hydroxybenzoic Acid; Rutranex; Saligel; Salonil; Salvona Nanosal; Stri-Dex; Trans-Ver-Sal; Verrugon; Acetylsalicylic Acid EP Impurity C (Aspirin Impurity C)/ Mesalazine EP Impurity H
MICONAZOLE	RBPL-M2000			
Miconazole EP Impurity D	RBPL-M2001	24168-96-5; Free base; 27523-40-6	C ₁₈ H ₁₅ Cl ₄ N ₃ O ₄ ; 479.14	Isoconazole Nitrate; 1-[2-(2,4-Dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]-imidazole Mononitrate; Adestan G 100; Fazol; Gyno-Travogen; R 15454; Travogen; Travogyn; Miconazole Impurity D (Nitrate);

API IMPURITIES AND METABOLITES

				Miconazole EP Impurity D; 1-[2-(2,4-Dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]-1H-imidazole;
Miconazole EP Impurity B	RBPL-M2002	27220-47-9	C ₁₈ H ₁₅ Cl ₃ N ₂ O; 381.68	Econazole; 1-[2-[(4-Chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole (±)-Econazole; 1-[2,4-Dichloro-β-[(p-chlorobenzyl) oxy]phenethyl]imidazole; NSC 187789
Miconazole Nitrate Impurity A	RBPL-M2003	24155-42-8	C ₁₁ H ₁₀ Cl ₂ N ₂ O; 257.12	rac-1-(2,4-Dichlorophenyl)-2-(1-imidazolyl)ethanol; α-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol; (+/-)-α-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol; α-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol; Econazole EP Impurity A
METHYLPREDNISOLONE ACETATE	RBPL-M2100			
Methylprednisolone Acetate EP Impurity E	RBPL-M2101	52-21-1	C ₂₃ H ₃₀ O ₆ ; 402.48	Prednisolone Acetate; (11β)-21-(Acetyloxy)-11,17-dihydroxypregna-1,4-diene-3,20-dione; 11β,17α,21-Trihydroxypregna-1,4-diene-3,20-dione 21-acetate; 21-(Acetoxy)-11β,17α-dihydroxypregna-1,4-diene-3,20-dione; Cormalone; Cortipred; Deltilen; Econopred; Falcon; Meticortelone Acetate; Predalone 50; Prediacortin; Predicort; Prednelan N; Prednidoren; Prenema; Supercortyl; Hydrocortisone Acetate EP Impurity C
NIMSULIDE	RBPL-N0100			
Nimsulide impurity D	RBPL-N0101	5422-92-4	C ₁₂ H ₁₀ N ₂ O ₃ ; 230.22	4-nitro-2-phenoxyaniline; 4-Nitro-2-phenoxybenzenamine; 2-Amino-5-nitrodiphenyl Ether; 2-Phenoxy-4-nitroaniline; NSC 10867
NORADRENALIN	RBPL-N0200			
Noradrenalin impurity E	RBPL-N0201	99-40-1	C ₈ H ₇ ClO ₃ ; 186.59	Chloro Acetyl Catechol; 2-Chloro-3,4-dihydroxyacetophenone; 1-Chloroacetyl-3,4-dihydroxybenzene; 2-Chloro-1-(3,4-dihydroxyphenyl)-1-ethanone; 3,4-Dihydroxyphenacyl chloride; Chloro Acetyl Catechol;

API IMPURITIES AND METABOLITES

Noradrenalin impurity F	RBPL-N0202	20455-68-9	C ₁₄ H ₁₆ ClN; 233.74	N-benzyl-1-phenylmethanamine; dibenzylammoniumchloride;n-(phenylmethyl)-benzene methanamin hydrochloride;Dibenzylamine Hcl;Dibenzylamine Hydrochloride
Noradrenalin impurity A	RBPL-N0203	51-43-4	C ₉ H ₁₃ NO ₃ ; 183.2	L-(-)-Epinephrine; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; (R)-Epinephrine; Renoform; Renostypticin; Adnephrine; Adrenal; Adrenalin; Adrenaline; l-Epinephrine; Levoepinephrine;
Noradrenalin impurity C	RBPL-N0204	62-31-7; Free Base: 51-61-6	C ₈ H ₁₂ ClNO ₂ ; 189.64	Dopamine Hydrochloride; 4-(2-Aminoethyl)-1,2-benzenediol Hydrochloride; 4-(2-Aminoethyl)pyrocatechol Hydrochloride; 2-(3,4-Dihydroxyphenyl)ethyl-1,1,2,2-amine Hydrochloride; ASL-279; Cardiosteril; Dopastat; Dynatra; Inovan; Inotropin
NAPROXEN	RBPL-N0300			
Naproxen impurity B	RBPL-N0301	89617-86-7	C ₁₄ H ₁₃ ClO ₃ ; 264.7	(2S)-2-(5-Chloro-6-methoxynaphthalen-2-yl)propanoic acid ; (αS)-5-Chloro-6-methoxy-α-methyl-2-naphthaleneacetic Acid; (S)-5-Chloro-6-methoxy-α-methyl-2-naphthaleneacetic Acid;
Naproxen impurity D	RBPL-N0302	116883-62-6	C ₁₄ H ₁₃ IO ₃ ; 356.16	(S)-5-Iodo-6-methoxy-α-methyl-2-naphthaleneacetic Acid;
Naproxen impurity K	RBPL-N0303	77301-42-9	C ₁₃ H ₁₄ O ₂ ; 202.25	(1RS)-1-(6-Methoxy-2-naphthyl)ethanol (Naproxen Impurity K); 6-Methoxy-α-methyl-2-Naphthalenemethanol; (+/-)-1-(6-Methoxynaphthyl)ethanol; 1-(6'-Methoxy-2-naphthyl)ethanol; 2-(1-Hydroxyethyl)-6-methoxynaphthalene; α-(6-Methoxy-2-naphthyl)ethanol; Naproxen Impurity K
Naproxen impurity L	RBPL-N0304	3900-45-6	C ₁₃ H ₁₂ O ₂ ; 200.23	6'-Methoxy-2'-acetophenone (Naproxen Impurity L); 1-(6-Methoxy-2-naphthalenyl)ethanone; 2-Acetyl-6-methoxynaphthalene; 6-Acetyl-2-methoxynaphthalene; 6-Methoxy-2-acetylnaphthalene; 6-Methoxy-2-naphthyl Methyl Ketone; NSC 105564; Naproxen Impurity L; Naproxen USP Related Compound L
Naproxen impurity N	RBPL-N0305	5111-65-9	C ₁₁ H ₉ BrO; 237.09	2-Bromo-6-methoxynaphthalene (Naproxen Impurity N); 2-Methoxy-6-bromonaphthalene; 6-Methoxy-2-bromonaphthalene; Naproxen Impurity N;

API IMPURITIES AND METABOLITES

				Naproxen EP Impurity N
Racemic Naproxen	RBPL-N0306	23981-80-8	C ₁₄ H ₁₄ O ₃ ; 230.26	rac-Naproxen; (RS)-Naproxen; (+/-)-2-(6-Methoxy-2-naphthalenyl)propionic Acid; (+/-)-2-(6-Methoxy-2-naphthyl)propionic Acid; (+/-)-6-Methoxy- α -methyl -2-naphthaleneacetic Acid; (+/-)-Naproxen; 2-(6-Methoxy-2-naphthyl)propanoic Acid; dl-Naproxen
Naproxen impurity O	RBPL-N0307	2471-70-7	C ₁₂ H ₁₀ O ₃ ; 202.21	6-Methoxy-2-naphthoic Acid; 2-Methoxy-6-naphthalenecarboxylic Acid; 6-Methoxy-2-naphthalenecarboxylic Acid; Naproxen Impurity O; Naproxen USP Related Compound A
NIZATIDINE	RBPL-N0400			
Nizatidine impurity H	RBPL-N0401	27366-72-9	C ₄ H ₁₁ ClN ₂ S; 154.66	2-(Dimethylamino)ethanethioamide Hydrochloride; Nizatidine EP Impurity H; Nizatidine EP Impurity H
Nizatidine impurity G	RBPL-N0402	1193434-63-7	C ₂₀ H ₃₃ N ₇ O ₂ S ₄ ; 531.78	N'-[2-[[[2-[(Dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl] Nizatidine
Nizatidine EP Impurity B	RBPL-N0403	61832-41-5	C ₄ H ₈ N ₂ O ₂ S; 148.18	N-Methyl-1-(methylthio)-2-nitro-ethenamine; 1-(Methylamino)-1-(methylthio)-2-nitroethene; 2-(Methylthio)-2-(methylamino)-1-nitroethene; 1-(Methylthio)-2-nitro-N-methylethyleneamine; Ranitidine EP Impurity K;
NEBIVOLOL	RBPL-N0500			
Nebivolol Impurity A	RBPL-N0501	118457-16-2	C ₂₂ H ₂₅ F ₂ NO ₄ ; 405.45	Nebivolol Impurity A; (1S)-1-[(2S)-6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl]-2-[[[(2S)-2-[(2S)-6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl]-2-hydroxyethyl]amino]ethan-1-ol
Nebivolol Impurity B	RBPL-N0502	119365-25-2	C ₂₂ H ₂₅ F ₂ NO ₄ ; 405.45	(S)-1-[(S)-6-fluorochroman-2-yl]-2-[(R)-2-[(S)-6-fluorochroman-2-yl]-2-hydroxyethyl]amino]ethan-1-ol; [2S-[2R*[R*[S*(R*)]]]]- α , α' -[Iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol

API IMPURITIES AND METABOLITES

NARATRIPTAN	RBPL-N0600			
Naratriptan N-Oxide	RBPL-N0601	1159977-52-2	C ₁₇ H ₂₅ N ₃ O ₃ S ; 351.46	N-Nethyl-3-(1-methyl-1-oxido-4-piperidinyl)-1H-indole-5-ethanesulfonamide
	RBPL-N0602			
OLANZAPINE	RBPL-O0100			
Olanzapine impurity D ((RC-C) (N-oxide)	RBPL-O0101	174794-02-6	C ₁₇ H ₂₀ N ₄ OS; 328.43	Olanzapine Related CoMpoUND C; Olanzapine N-oxide ; 2-Methyl-4-(4-methyl-4-oxido-1-piperazinyl)-10H-thieno[2,3-β][1,5]benzodiazepine; 2-Methyl-4-(4-methyl-4-oxido-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-Methyl-4-(4-Methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine 4'-N-oxide;
OMEPRAZOLE	RBPL-O0200			
Omeprazole related compound B	RBPL-O0201	37052-78-1	C ₈ H ₈ N ₂ OS; 180.23	5-Methoxy-2-mercaptobenzimidazole; omeprazole imp A; 1,3-Dihydro-5-methoxy-2H-benzimidazole-2-thione; 2-Mercapto-5-methoxy-1H-benzimidazole; 2-Mercapto-5-methoxybenzimidazole; 5-Methoxy-1H-benzimidazole-2-thiol; 5-Methoxy-2-benzimidazolethiol;
Omeprazole impurity C	RBPL-O0202	73590-85-9	C ₁₇ H ₁₉ N ₃ O ₂ S; 329.42	Omeprazole Sulfide; Ufiprazole; 6-Methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole; 2-[[[(3,5-Dimethyl-4-methoxy-2-pyridyl)methyl]thio]-5-methoxy benzimidazole; Pyrimetazole
Omeprazole impurity F&G	RBPL-O0203	125656-82-8+125656-83-9	C ₁₆ H ₁₃ N ₃ O ₂ S	8(9)-Methoxy-1,3-dimethyl-12-thioxopyrido[1',2':3,4]imidazo[1,2-a]benzimidazol-2-(12H)-one; (Mixture of Regioisomers)
Omeprazole impurity I	RBPL-O0205	158812-85-2	C ₁₇ H ₁₉ N ₃ O ₅ S; 377.41	Omeprazole Sulfone N-Oxide; 5-Methoxy-2-[[[(4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole; Esomeprazole Impurity Impurity I
4-Hydroxy omeprazole sulphide	RBPL-O0206	103876-98-8	C ₁₆ H ₁₇ N ₃ O ₂ S; 315.39	2-[[[(6-Methoxy-1H-benzimidazol-2-yl)thio]methyl]-3,5-dimethyl-4-pyridinol; Omeprazole Pyridone

API IMPURITIES AND METABOLITES

Omeprazole Related Compound A (Impurity D) (Sulphone)	RBPL-O0207	88546-55-8	C ₁₇ H ₁₉ N ₃ O ₄ S ; 361.42	omeprazole sulphone; 5-Methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole; Esomeprazole EP Impurity D
Omeprazole impurity E (N-oxide)	RBPL-O0208	176219-04-8	C ₁₇ H ₁₉ N ₃ O ₄ S ; 361.42	6-Methoxy-2-[[[4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; omeprazole-N-oxide
Omeprazole impurity B	RBPL-O0209	110374-16-8	C ₁₆ H ₁₇ N ₃ O ₂ S ; 315.39	4-Desmethoxy Omeprazole ; 2-[(RS)-[(3,5-dimethylpyridin-2-yl)methyl]sulphinyl]-5-methoxy-1H-benzimidazole
Omeprazole impurity H	RBPL-O0210	863029-89-4	C ₁₆ H ₁₆ ClN ₃ O ₂ S; 349.84	4-Desmethoxy-4-chloro Omeprazole; 2-[[[4-Chloro-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-methoxy-1H-benzimidazole; 5-Methoxy-2-[[[4-Chloro-3,5-dimethyl-pyridine-2-yl)methyl]sulfinyl]-1H-benzimidazole; Esomeprazole Impurity H; Omeprazole EP Impurity H;
OFLAXACIN	RBPL-O0300			
Oflaxacin impurity E	RBPL-O0301	82419-52-1	C ₁₇ H ₁₈ FN ₃ O ₄ ; 347.34	Desmethyl Ofloxacin Hydrochloride; 9-Fluoro-2,3-dihydro-3-methyl-7-oxo-10-(1-piperazinyl)-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid; Ofloxacin related compound A
Oflaxacin N-oxide	RBPL-O0302	104721-52-0	C ₂₀ H ₂₄ FN ₃ O ₇ ; 437.42	Ofloxacin N-Oxide Acetic Acid Salt (Mixture of Diastereomers); 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-4-oxido-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid Acetic Acid Salt
ONDANSETRON	RBPL-O0400			
Ondansetron impurity D	RBPL-O0401	99614-64-9	C ₁₄ H ₁₃ NO; 211.26	9-Methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one; 1,2,3,4-Tetrahydro-9-methyl-3-methylene-9H-carbazol-4-one;
Ondansetron impurity E	RBPL-O0402	288-32-4	C ₃ H ₄ N ₂ ; 68.08	Imidazole; 1,3-Diaza-2,4-cyclopentadiene; 1,3-Diazole; 3-Azapyrrole; 1H-Imidazole; Ondansetron EP Impurity E; Clotrimazole EP Impurity D
Ondansetron impurity F	RBPL-O0403	693-98-1	C ₄ H ₆ N ₂ ; 82.1	2-Methylimidazole; 1H-2-Methylimidazole; 2-Methyl-1H-imidazole; 2MZ; 2MZ-H; 2MZ-PW; Actiron 2MI; Curezol 2MZ; Curezol 2MZ-P; Denka CN 25; Epicure MI 2;

API IMPURITIES AND METABOLITES

				Epikure MI 2; Imicure AMI 2; NSC 21394
Ondansetron RC C	RBPL-O0404	27387-31-1	C ₁₃ H ₁₃ NO; 199.25	1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one; 2,3-Dihydro-9-methylcarbazol-4(1H)-one; USP Ondansetron Related Compound C; Ondansetron EP Impurity C
OXYBUTYNIN	RBPL-O0500			
Oxybutynin RC A	RBPL-O0501	4335-77-7	C ₁₄ H ₁₈ O ₃ ; 234.29	Phenylcyclohexylglycolic Acid; α-Cyclohexylmandelic acid, 2-Cyclohexyl-2-hydroxy-2-phenylacetic acid; α-Cyclohexylmandelic acid
Phenylcyclohexylglycolic Acid Propargyl Ester	RBPL-O0502	81039-74-9	C ₁₇ H ₂₀ O ₃ ; 272.34	alpha-Cyclohexyl-alpha-hydroxybenzeneacetic acid 2-propynyl ester; Propargyl (RS)-2-Cyclohexyl-2-hydroxy-2-phenylacetate
OLOPATADINE	RBPL-O0600			
Olopatadine Related Compound C	RBPL-O0601	55453-87-7	C ₁₆ H ₁₂ O ₄ ; 268.26	Isoxepac; 6,11-Dihydro-11-oxo-dibenz[b,e]oxepin-2-acetic Acid; Artil; 11-Oxo-6,11-dihydrodibenz[b,e]oxepin-2-acetic Acid; NSC 300907; Olopatadine USP Related Compound C
OLMESARTAN	RBPL-O0700			
Olmesartan impurity A	RBPL-O0701	144689-24-7	C ₂₄ H ₂₆ N ₆ O ₃ ; 446.5	Olmesartan Acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid; CS 088; RNH 6270; Olmesartan EP Impurity A;
Olmesartan impurity B	RBPL-O0702	849206-43-5	C ₂₄ H ₂₄ N ₆ O ₂ ; 428.49	Olmesartan Lactone Impurity; 3,6-Dihydro-6,6-dimethyl-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4H-Furo[3,4-d]imidazol-4-one; Olmesartan EP Impurity B
OSIMERTINIB	RBPL-O0800			
Osimertinib N-Oxide	RBPL-O0801	1975982-94-5	C ₂₈ H ₃₃ N ₇ O ₃ ; 515.61	Osimertinib Impurity M

API IMPURITIES AND METABOLITES

Osimertinib N'-Oxide	RBPL-O0802		C ₂₈ H ₃₃ N ₇ O ₃ ; 515.61	Osimertinib Impurity L
Osimertinib N,N'-Dioxide	RBPL-O0803	NA	C ₂₈ H ₃₃ N ₇ O ₄ ; 531.61	Osimertinib Impurity Q
OXALIPLATIN	RBPL-O900			
Oxaliplatin impurity A (Oxalic acid)	RBPL-O0901	144-62-7	C ₂ H ₂ O ₄ ; 90.03	Oxalic Acid; Ethanedioic Acid; Aktisal; Aquisal; DeerClean; NSC 132055; NSC 151956; NSC 62774; NSC 76990; Ultraplact Activate S 52
Oxaliplatin RC-A	RBPL-O0902	6153-56-6	HO ₂ CCO ₂ H · 2H ₂ O; 126.07	Ethanedioic acid dihydrate, Oxalic acid dehydrate; Oxaliplatin Related Compound A
OSELTAMIVIR	RBPL-O1000			
Oseltamivir impurity H	RBPL-O1001	814-29-9	C ₁₂ H ₂₇ OP; 218.32	Tributylphosphine Oxide; Butyphos; NSC 41935; NSC 65484; TBPO; Trisbutylphosphine Oxide
OXCARBAZEPINE	RBPL-O1100			
Oxcarbazepine EP Impurity A	RBPL-O1101	28721-07-5	C ₁₅ H ₁₂ N ₂ O ₂ ; 252.27	Oxcarbazepine; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; Aurene; GP 47680; Oxacarbazepine; Oxecarb; Oxetol; Trileptal
Oxcarbazepine EP Impurity E	RBPL-O1102	256-96-2	C ₁₄ H ₁₁ N; 193.24	Iminostilbene; 5H-Dibenz[b,f]azepine; 2,2'-Iminostilbene; 5-Azadibenzo[a,e]cycloheptatriene; 5H-Dibenzo[b,f]azepine; NSC 123458; RP 9989; Carbamazepine EP Impurity D
Oxcarbazepine EP Impurity H	RBPL-O1103	4698-11-7	C ₁₅ H ₁₃ NO; 223.27	10-Methoxy Iminostilbene; 10-Methoxy-5H-dibenz[b,f]azepine
PIOGLITAZONE	RBPL-P0100			
Pioglitazone-N-oxide	RBPL-P0101	145350-09-0	C ₁₉ H ₂₀ N ₂ O ₄ S; 372.44	5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione N-Oxide

API IMPURITIES AND METABOLITES

Pioglitazone related compound C	RBPL-P0102	952188-00-0	C ₂₈ H ₃₁ N ₃ O ₃ S, 489.63	5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-3-[2-(5-ethyl-2-pyridinyl)ethyl]-2,4-thiazolidinedione; N-[Ethyl-(2-pyridyl-5-ethyl) Pioglitazone; Pioglitazone Impurity
PARACETAMOL	RBPL-P0200			
Paracetamol impurity J	RBPL-P0201	539-03-7	C ₈ H ₈ ClNO; 169.61	4'-Chloroacetanilide; N-(4-Chlorophenyl)acetamide; N-(p-Chlorophenyl)acetamide; N-Acetyl-4-chloroaniline; N-Acetyl-p-chloroaniline; p-Chloroacetanilide; NSC 40563; NSC 444; Acetaminophen Related Compound J;
Paracetamol impurity F	RBPL-P0202	100-02-7	C ₆ H ₅ NO ₃ ; 139.11	4-nitro phenol; p-Nitrophenol; 1-Hydroxy-4-nitrobenzene; 4-Hydroxy-1-nitrobenzene; 4-Hydroxynitrobenzene; NSC 1317; Niphen; p-Hydroxynitro benzene;
Paracetamol impurity K	RBPL-P0203	51-78-5	C ₆ H ₇ NO.HCl; 109.13; 145.59	4-Amino phenol HCl; 4-Hydroxyaniline hydrochloride
Paracetamol impurity A (RC C)	RBPL-P0204	614-80-2	C ₈ H ₉ NO ₂ ; 151.16	2-Acetamidophenol; N-(2-Hydroxyphenyl)acetamide; 2'-Hydroxyacetanilide; 2-(Acetylamino)phenol; 2-(N-Acetylamino)phenol; 2-Acetaminophenol; 2-Hydroxyacetanilide; o-(Acetylamino)phenol; NSC 3989; USP Acetaminophen Related Compound C; Paracetamol EP Impurity A;
PROPAFENONE	RBPL-P0300			
Propafenone impurity A	RBPL-P0301	3516-95-8	C ₁₅ H ₁₄ O ₂ ; 226.27	2'-Hydroxy-3-phenylpropiophenone; 1-(2-Hydroxy-phenyl)-3-phenyl-propan-1-one;
Propafenone impurity C	RBPL-P0302	22525-95-7	C ₁₈ H ₁₈ O ₃ ; 282.33	2'-(2,3-Epoxypropoxy)-3-phenyl-propiophenone; 1-[2-(Oxiranylmethoxy)phenyl]-3-phenyl-1-propanone; 2-[[2-(3-Phenylpropanoyl) phenoxy]methyl]oxirane;
Propafenone impurity E	RBPL-P0304	165279-79-8	C ₁₈ H ₁₉ ClO ₃ ; 318.79	Depropylamino Chloro Propafenone; 1-[2-(3-Chloro-2-hydroxypropoxy)phenyl]-3-phenyl-1-propanone;

API IMPURITIES AND METABOLITES

Propafenone impurity F	RBPL-P0305	1329643-40-4	C ₃₃ H ₃₂ O ₅ ; 508.6	1,1'-[Hydroxypropane-1,3-diylbis(oxy-2,1-phenylene)]bis(3-phenylpropan-1-one); 1-(2-{2-hydroxy-3-[2-(3- phenylpropanoyl) phenoxy]propoxy}phenyl)-3-phenylpropan-1-one.
Propafenone impurity H	RBPL-P0306	27439-12-9	C ₁₅ H ₁₂ O ₂ ; 224.2	(2R)-2-Phenyl-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-phenyl-, (2R)-
PROMETHAZINE	RBPL-P0400			
Promethazine impurity D	RBPL-P0401	7640-51-9	C ₁₇ H ₂₀ N ₂ OS; 300.42	Promethazine sulphoxide; N,N,α-Trimethyl-10H-phenothiazine-10-ethanamine 5-Oxide; N-[2-(Dimethylamino) propyl]phenothiazine S-Oxide; Promethazine 5-Oxide; Promethazine 5-Sulfoxide; Romergan Sulfoxide;
Promethazine impurity A	RBPL-P0402	92-84-2	C ₁₂ H ₉ NS; 199.27	Thiodiphenylamine; 10H-Phenothiazine
Promethazine impurity B	RBPL-P0403	5568-90-1	C ₁₇ H ₂₁ ClN ₂ S; 320.88	Iso Promethazine Hydrochloride; N,N,β-Trimethyl-10H-phenothiazine-10-ethanamine Hydrochloride; 10-[2-(Dimethylamino)-1-methylethyl] phenothiazine Monohydrochloride; Promethazine EP Impurity B;
Promethazine impurity C	RBPL-P0404	60113-77-1	C ₁₆ H ₁₉ ClN ₂ S; 306.85	rac N-Demethyl Promethazine Hydrochloride; N,α-Dimethyl-10H-phenothiazine-10-ethanamine Hydrochloride; Nor1-Promethazine Monohydrochloride; Promethazine EP Impurity C;
PACLITAXEL	RBPL-P0500			
Paclitaxel related compound B	RBPL-P0501	78454-17-8	C ₄₅ H ₄₉ NO ₁₃ ; 811.87	7-Epi 10-Desacetyl Paclitaxel; 10-Deacetyl-7-epi-taxol; 10-Deacetyl-7-epitaxol; 10-Desacetyl-7-epipaclitaxel; 7-Epi-10-deacetyl-taxol; 7-epi-10-Deacetyl-taxol; Ormosin VI
PROPRANOLOL	RBPL-P0600			
Propranolol impurity A	RBPL-P0601	36112-95-5	C ₁₃ H ₁₄ O ₃ ; 218.25	3-(1-Naphthalenyloxy)-1,2-propanediol; 1-(α-Naphthoxy)-2,3-propylene Glycol; 3-(α-Naphthoxy)-1,2-propanediol; 3-(α-Naphthoxy)-1,2-propylene Glycol;

API IMPURITIES AND METABOLITES

				Propranolol Glycol
Propranolol impurity C	RBPL-P0602	17216-10-3	C ₂₃ H ₂₀ O ₃ ; 344.4	1,3-Bis(1-naphthalenyloxy)-2-propanol;
PALONOSETRON	RBPL-P0700			
Dehydropalonosetron	RBPL-P0701	NA	C ₁₉ H ₂₃ ClN ₂ O; 330.85	2-(quinuclidin-3-yl)-2,4,5,6-tetrahydro-1H-benzo[de]isoquinolin-1-one hydrochloride; Palonosetron Impurity 1 HCl
PANTAPRAZOLE	RBPL-P0800			
Pantaprazole related compound A (Sulphone)	RBPL-P0801	127780-16-9	C ₁₆ H ₁₅ F ₂ N ₃ O ₅ S, 399.37	5-Difluoromethoxy-2-[[[(3,4-dimethoxy)-2-pyridyl]methylsulfonyl]-1H-benzimidazole; Pantoprazole Sulfone
Pantaprazole related compound B (Sulfide)	RBPL-P0802	102625-64-9	C ₁₆ H ₁₅ F ₂ N ₃ O ₃ S, 367.37	5-(Difluoromethoxy)-2-[[[(3,4-dimethoxy-2-pyridinyl)methyl]thio]-1H-benzimidazole; Pantoprazole Thioether; Pantoprazole Sulfide
Pantaprazole impurity C	RBPL-P0803	97963-62-7	C ₈ H ₆ F ₂ N ₂ OS; 216.21	5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole; 5-(Difluoromethoxy)-1,3-dihydro-2H-benzimidazole-2-thione; 5-Difluoromethoxy-2-mercaptobenzimidazole; SKA 47; USP Pantoprazole Related Compound C; Pantoprazole EP Impurity C;
Pantaprazole Sulfone N-oxide	RBPL-P0804	953787-55-8	C ₁₆ H ₁₅ F ₂ N ₃ O ₆ S; 415.37	Pantoprazole Sulfone N-Oxide; 6-(Difluoromethoxy)-2-[[[(3,4-dimethoxy-1-oxido-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole;
PAROXETINE	RBPL-P0900			
Paroxetine impurity I	RBPL-P0901	220548-73-2	C ₁₂ H ₁₇ ClFNO; 245.72	N-Desmethyl Paroxol Hydrochloride; (3S,4R)-4-(4-Fluorophenyl)-3-piperidinemethanol Hydrochloride; (3S-trans)-4-(4-Fluorophenyl)-3-piperidinemethanol Hydrochloride; (3S,4R)-(-)-4-(4-Fluorophenyl)-3-piperidinemethanol Hydrochloride; (3S,4R)-4-(4-Fluorophenyl)piperidine-3-methanol Hydrochloride

API IMPURITIES AND METABOLITES

Paroxetine HCl Anhydrous EP Impurity B	RBPL-P0902	533-31-3	C ₇ H ₆ O ₃ ; 138.12	Sesamol; 1,3-Benzodioxol-5-ol; 3,4-(Methylenedioxy)phenol; 4-Hydroxy-1,2-methylenedioxybenzene; 5-Hydroxy-1,3-benzodioxole; NSC 59256; Paroxetine Anhydrous EP Impurity B
Paroxetine USP RC F	RBPL-P0903	110429-36-2	C ₂₀ H ₂₂ FNO ₃ ; 343.39	N-Methyl Paroxetine; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxy)methyl-1-methylpiperidine; (3S,4R)-N-Methylparoxetine; USP Paroxetine Related Compound F; Paroxetine USP Related Compound F
PYRIDOXIN	RBPL-P1100			
Pyridoxin impurity B Hcl	RBPL-P1101	148-51-6 freebase: 61-67-6	C ₈ H ₁₂ ClNO ₂ ; 189.64	4-Deoxy Pyridoxine Hydrochloride ; 2,4-Dimethyl-3-hydroxy-5-hydroxymethylpyridine Hydrochloride; 4-Deoxypyridoxine Hydrochloride; 3-Hydroxy-5-hydroxymethyl-2,4-dimethylpyridine Hydrochloride; 4-Deoxypyridoxol Hydrochloride; 5-Hydroxy-4,6-dimethyl-3-pyridinemethanol Hydrochloride; 4-Desoxyadermin Hydrochloride; 4-Desoxypyridoxine Hydrochloride; 5-Hydroxymethyl-2,4-dimethylpyridin-3-ol Hydrochloride
PREGABALIN	RBPL-P1300			
Pregabalin	RBPL-P1300	148553-50-8	C ₈ H ₁₇ NO ₂ ; 159.23	N-methylpregabalin
Pregabalin Impurity C	RBPL-P1301	181289-15-6	C ₉ H ₁₇ NO ₃ ; 187.24	3-(2-Amino-2-oxoethyl)-5-methylhexanoic Acid; 3-(Carbamoylmethyl)-5-methylhexanoic Acid;
Pregabalin Impurity D (PG-3)	RBPL-P1302	75143-89-4	C ₉ H ₁₆ O ₄ ; 188.22	3-(2-Methylpropyl)pentanedioic Acid; 3-Isobutylglutaric Acid;
Pregabalin Impurity B (PG-4)	RBPL-P1303	61312-87-6	C ₈ H ₁₅ NO; 141.21	4-Isobutyl-2-pyrrolidinone (pregabalin lactam impurity); 4-(2-Methylpropyl)-2-pyrrolidinone; Pregabalin USP Related Compound C
Pregabalin Impurity E (PG-5)	RBPL-P1304	216576-74-8	C ₈ H ₁₅ NO ₂ ; 157.21	rac 4,5-Dehydro Pregabalin; 3-(Aminomethyl)-5-methyl-4-hexenoic Acid; 4,5-Dehydropregabalin;
Pregabalin Impurity A	RBPL-P1305	181289-23-6	C ₈ H ₁₅ NO; 141.21	(S)-Pregabalin Lactam; (S)-4-(2-Methylpropyl)-2-pyrrolidinone; (S)-4-

API IMPURITIES AND METABOLITES

				(Isobutyl)pyrrolidin-2-one
Pregabalin Impurity (PG-2)	RBPL-P1306	916982-10-0	C ₉ H ₁₅ NO ₂ ; 169.22	4-(2-Methylpropyl)piperidine-2,6-dione; 4-(2-Methylpropyl)-2,6-piperidinedione; 3-Isobutylglutarimide; 4-Isobutyl-2,6-dioxopiperidine; 4-Isobutylpiperidine-2,6-dione
PHENYTOIN	RBPL-P1400			
Phenytoin Impurity A	RBPL-P1401	119-61-9	C ₁₃ H ₁₀ O; 182.22	Benzophenone; Diphenylmethanone; Adjutan 6016; BLS 531; Benzoylbenzene; Darocur BP; Diphenyl Ketone; Kayacure BP; Kayacure BP 100; Lowlite 24; NSC 8077; Phenyl Ketone; Runtecure 1020; Speedcure BP; α-Oxodiphenylmethane; α-Oxoditane; Diphenhydramine EP Impurity E
Phenytoin Impurity B	RBPL-P1402	134-81-6	C ₁₄ H ₁₀ O ₂ ; 210.23	Benzil; Diphenylethanedione; 1,2-Diphenyl-1,2-ethanedione; 1,2-Diphenylethane-1,2-dione; 1,2-Diphenylethanedione; Bibenzoyl; Dibenzoyl; Diphenyl diketone; Diphenyl-α,β-diketone; Diphenylethanedione; Diphenylglyoxal; Esacure KBO; NSC 220315; NSC 4041; Wy 20910
Phenytoin Impurity C (RC-A)	RBPL-P1403	3060-50-2	C ₁₄ H ₁₃ NO ₂ ; 227.26	2,2-Diphenylglycine; α-Amino-α-phenylbenzeneacetic Acid; 2,2-Diphenyl Glycine; 2-Amino-2,2-diphenylacetic Acid; Amino(diphenyl)acetic Acid; NSC 33392; α,α-Diphenylglycine; α-Aminodiphenylacetic Acid; USP Phenytoin Related Compound A; Phenytoin USP Related Compound A 2,2-Diphenylglycine
PALLIPERIDONE	RBPL-P1500			
Palliperidone N-oxide	RBPL-P1501	761460-08-6	C ₂₃ H ₂₇ FN ₄ O ₄ ; 442.48	Paliperidone N-Oxide; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-oxido-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 9-Hydroxy Risperidone N-Oxide; Paliperidone USP Related Compound D
Paliperidone RC-B	RBPL-P1502	84163-13-3 Free Base: 84163-77-9	C ₁₂ H ₁₄ ClFN ₂ O; 256.7	6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole Hydrochloride; 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole Monohydrochloride; 4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidine Hydrochloride; 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole

API IMPURITIES AND METABOLITES

				Hydrochloride; 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole Monohydrochloride; 6-Fluoro-3-(4-piperidinyl)benzisoxazole Hydrochloride; 6-Fluoro-3-(piperidin-4-yl)benzo[d]isoxazole Hydrochloride; 6-Fluoro-3-(piperidinyl-4-yl)-benzisoxazole Hydrochloride; USP Paliperidone Related Compound B; Risperidone EP Impurity M; Paliperidone USP Related Compound B; Paliperidone impurity O (Iloperidone impurity 16);
PERINDOPRIL	RBPL-R1600			
Perindopril impurity A	RBPL-P1601	80875-98-5	C ₉ H ₁₅ NO ₂ ; 169.22	L-(2S,3aS,7aS)-Octahydroindole-2-carboxylic Acid; [2S-(2α,3αβ,7αβ)]-Octahydro-1H-indole-2-carboxylic Acid; (2S,3aS,7aS)-2-Carboxyoctahydroindole; (2S,3aS,7aS)-Perhydroindole-2-carboxylic Acid; USP Perindopril Related Compound A; Perindopril USP Related Compound A
PEMETREXED ACID	RBPL-P1700			
Pemetrexed acid ME	RBPL-P1701	155405-80-4	C ₁₆ H ₁₆ N ₄ O ₃ ; 312.32	4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic Acid Methyl Ester
Pemetrexed Diacid	RBPL-P1702	137281-23-3	C ₂₀ H ₂₁ N ₅ O ₆ ; 427.41	N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid; N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid; NSC 698037; Pemetrexed; Pemetrexed EP Impurity E
PIRFENIDONE	RBPL-P1800			
Pirfenidone impurity A	RBPL-P1801	1603-41-4	C ₆ H ₈ N ₂ ; 108.14	2-Amino-5-methylpyridine; 5-Methyl-2-pyridinamine; 5-Methyl-2-pyridylamine; NSC 1489; NSC 96444
Pirfenidone impurity B	RBPL-P1802	1003-68-5	C ₆ H ₇ NO; 109.13	2-Hydroxy-5-methylpyridine; 5-Methyl-2-oxopyridine; 5-Methyl-2-pyridinol; 5-Methyl-2-pyridone; 5-Methyl-2(1H)-pyridinone
Pirfenidone impurity C	RBPL-P1803	108-95-2	C ₆ H ₅ OH; 94.11	Hydroxybenzene; Phenol

API IMPURITIES AND METABOLITES

Pirfenidone impurity D	RBPL-P1804	108-86-1	C ₆ H ₅ Br; 157.01	1-Bromobenzene; Bromobenzene; Bromobenzol; Monobromobenzene; NSC 6529; Phenyl Bromide
PIPERACILLIN	RBPL-P1900			
Piperacillin EP Impurity A	RBPL-P1901	69-53-4	C ₁₆ H ₁₉ N ₃ O ₄ S; 349.4	Ampicillin; (2S,5R,6R)-6-[[[(2R)-2-Amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid; AY 6108; Albipen; Amfipen; Amplital; Penicline; (Ampicillin, Sultamicillin EP Impurity C)
Piperacillin EP Impurity E	RBPL-P1902	59702-31-7	C ₆ H ₁₀ N ₂ O ₂ ; 142.16	1-Ethyl-2,3-dioxopiperazine; 1-Ethyl-2,3-piperazinedione; N-Ethylpiperazine-2,3-dione; T 1982C; Piperacillin EP Impurity E; Piperacillin USP Related Compound E
Piperacillin Sodium EP Impurity G	RBPL-P1903	63422-71-9	C ₁₅ H ₁₇ N ₃ O ₅ ; 319.31	(R)-α-[[[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]benzeneacetic Acid; (αR)-α-[[[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]benzeneacetic Acid;
Piperacillin EP Impurity H	RBPL-P1904	551-16-6	C ₈ H ₁₂ N ₂ O ₃ S; 216.26	(Amoxicillin EP Impurity A, Sulbactam EP Impurity B); (+)-6-Aminopenicillanic Acid; (2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid; 6-APA; 6-APS; 6β-Aminopenicillanic acid; NSC 50071; [2S-(2α,5α,6β)]-6-Amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid; 6-Aminopenicillinate; USP Amoxicillin Related Compound A, Sulbactam Impurity B EP, Amoxicillin EP Impurity A
QUETIAPINE	RBPL-Q0100			
Quetiapine impurity S (S-oxide)	RBPL-Q0101	329216-63-9	C ₂₁ H ₂₅ N ₃ O ₃ S; 399.51	Quetiapine-S-oxide; 2-[2-[4-(5-Oxidodibenzo[b,f][1,4]thiazepin-11-yl)-1-piperazinyl]ethoxy]ethanol;
Quetiapine impurity F (II)	RBPL-Q0102	848814-27-7 (FB)	C ₂₁ H ₂₇ N ₃ O ₃ S; 401.52	2-(2-(4-(Dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol; 1-[2-[(2-Aminophenyl)thio]benzoyl]-4-[2-(2-hydroxyethoxy)ethyl]-piperazine; [2-[(2-Aminophenyl)thio]phenyl][4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-methanone
Quetiapine impurity D	RBPL-Q0103	945668-94-0	C ₃₀ H ₂₄ N ₄ S ₂ ; 504.67	Quetiapine Dimer; 11,11-(1,4-Piperazinediyl)bis-dibenzo[b,f][1,4]thiazepine;

API IMPURITIES AND METABOLITES

Quetiapine impurity G	RBPL-Q0104	3159-07-7	C ₁₃ H ₉ NOS; 227.28	Quetiapine Lactam; Quetiapine DBTO Metabolite; Quetiapine related compound G; Quetiapine related compound 01; Dibenzo[b,f][1,4]thiazepine-11-[10H]one; 4-(dibenzo[b,f][1,4]thiazepin-11-yl)-1-[2-(2-hydroxyethoxy)ethyl]piperazine-1-oxide
Quetiapine impurity P	RBPL-Q0105	1011758-03-4	C ₁₉ H ₂₁ N ₃ S; 323.46	11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine; N-ethyl Quetiapine
Quetiapine Impurity H (N-Oxide)	RBPL-Q0106	1076199-40-0	C ₂₁ H ₂₅ N ₃ O ₃ S; 399.51	2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol N-Oxide; Quetiapine-N-oxide
Quetiapine impurity I (rc 02)	RBPL-Q0107	329216-67-3 (base) ; 329218-14-6 (2HCl)	C ₁₉ H ₂₁ N ₃ OS; 339.45	Quetiapine Desethoxy Impurity (USP) ; Quetiapine Alcohol Impurity ; Quetiapine Ethanol Impurity ; 11-[4-(2-Hydroxyethyl)-1-piperazinyl]-dibenzo[b,f][1,4]thiazepine ;
Quetiapine impurity N	RBPL-Q0108	1800291-86-4	C ₂₉ H ₄₁ N ₃ O ₃ S ; 539.73	2-(2-(4-(2-(2-(4-(Dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethyl)piperazin-1-yl)ethoxy)ethanol; Quetiapine EP Impurity N
Quetiapine impurity R	RBPL-Q0109	2459-05-4	C ₆ H ₈ O ₄ ; 144.13	Fumaric Acid Monoethyl Ester; (2E)-2-Butenedioic Acid 1-Ethyl Ester; (2E)-2-Butenedioic Acid Monoethyl Ester; Fumaric Acid Ethyl Ester; (E)-4-Ethoxy-4-oxo-2-butenic Acid; Ethyl Hydrogen Fumarate; Monoethyl Fumarate; Monoethyl Fumerate; Monoethyl trans-2-Butenedioate; Quetiapine EP Impurity R;
QUINAPRIL	RBPL-Q0200			
Quinapril Impurity C (RC B)	RBPL-Q0201	82768-85-2	C ₂₃ H ₂₆ N ₂ O ₅ ; 410.46	(3S)-2-[(2S)-2-[[[(1S)-1-Carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid; Quinaprilat; Quinapril related compound B
Quinapril Impurity A	RBPL-Q0202	74163-81-8	C ₁₀ H ₁₁ NO ₂ ; 177.2	(S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid; (-)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid; L-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid; L-3-Carboxy-1,2,3,4-tetrahydroisoquinoline; L-Porretine; Quinapril EP Impurity A
ROXITHROMYCIN	RBPL-R0100			

API IMPURITIES AND METABOLITES

N,N-didesmethyl Roxithromycin	RBPL-R0101	231620-65-8	C ₃₉ H ₇₂ N ₂ O ₁₅ ; 809	
Roxithromycin impurity F	RBPL-R0102	118267-18-8	C ₄₀ H ₇₄ N ₂ O ₁₅ ; 823.02	N-Demethyl Roxithromycin; (9E)-9-[O-[(2-Methoxyethoxy)methyl]oxime]-N-demethyl Erythromycin; (E)-N-Demethylroxithromycin; RU 44981
Roxithromycin impurity B	RBPL-R0103	214902-82-6	C ₃₃ H ₆₂ N ₂ O ₁₂ ; 678.85	Decladinose Roxithromycin (Roxithromycin Impurity B); (9E)-3-O-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)erythromycin9-[O-[(2-Methoxyethoxy)methyl]oxime]; Decladinoseroxithromycin; (9E)-3-O-De(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)erythromycin 9-[O-[(2-Methoxyethoxy)methyl]oxime]; Roxithromycin Impurity B;
Roxithromycin impurity A	RBPL-R0104	114-07-8	C ₃₇ H ₆₇ NO ₁₃ ; 733.93	Erythromycin; E-Base; E-Mycin; Erythromycin A; Aknemycin; Aknin; Emgel; Ery-Derm; Erymax; Ery-Tab; Erythromid; ERYC;
Roxithromycin impurity C	RBPL-R0106	13127-18-9	C ₃₇ H ₆₈ N ₂ O ₁₃ ; 748.94	Erythromycin A Oxime (Roxithromycin Impurity C); 9-Erythromycin 9-Oxime; 9-Erythromycin A Oxime; Erythromycin Oxime; Roxithromycin Impurity C; Clarithromycin EP Impurity J
Roxithromycin N-Oxide	RBPL-R0105	1460313-73-8	C ₄₁ H ₇₆ N ₂ O ₁₆ ; 853.06	2-[[[(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl)oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-2-oxo-oxacyclotetradec-6-yl]oxy]-3-hydroxy-N,N,6-trimethyl-tetrahydropyran-4-amine oxide
RABEPRAZOLE	RBPL-R0200			
Rabeprazole impurity B (Sulfone N-Oxide)	RBPL-R0201	924663-37-6	C ₁₈ H ₂₁ N ₃ O ₅ S; 391.44	Rabeprazole sulphone N-oxide; 2-[[[4-(3-Methoxypropoxy)-3-methyl-1-oxido-2-pyridinyl]methyl]sulfonyl]-1H-benzimidazole;
Rabeprazole Impurity A (Sulphone)	RBPL-R0202	117976-47-3	C ₁₈ H ₂₁ N ₃ O ₄ S; 375.44	Rabeprazole sulphone; 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfonyl]-1H-benzimidazole; Rabeprazole Related Compound D; Dextrabeprazole impurity D

API IMPURITIES AND METABOLITES

Rabeprazole Sulfide	RBPL-R0203	117977-21-6	$C_{18}H_{21}N_3O_2S$; 343.44	Rabeprazole Sulfide ; 2-[[[3-Methyl-4-(3-methoxypropoxy)-2-pyridyl]methyl]thio]-1H-benzimidazole; 2-[[4-(3-Methoxypropoxy)-3-methylpyridine-2-yl]-methylthio]-1H-benzimidazole; Rabeprazole Thioether; USP Rabeprazole Related Compound E; Rabeprazole EP Impurity B; Dextrabeprazole impurity E
Rabeprazole RC-E	RBPL-R0204	117977-21-6	$C_{18}H_{21}N_3O_2S$; 343.44	Rabeprazole Sulfide; 2-[[[3-Methyl-4-(3-methoxypropoxy)-2-pyridyl]methyl]thio]-1H-benzimidazole; 2-[[4-(3-Methoxypropoxy)-3-methylpyridine-2-yl]-methylthio]-1H-benzimidazole; H 295/43; Rabeprazole Thioether; USP Rabeprazole Related Compound E; Rabeprazole EP Impurity B
Rabeprazole RC-C (Imp-F)	RBPL-R0205	583-39-1	$C_7H_6N_2S$; 150.2	2-Mercaptobenzimidazole; 1,3-Dihydro-2H-benzimidazole-2-thione; 2-Benzimidazolinethione; 1H-Benzimidazole-2-thiol; 2-Mercapto-1H-benzimidazole; 2-Thiobenzimidazole; Antigene MB; Antioxidant Rabeprazole Related Compound CMB; Permanax 21; Sandant MB; Sumilizer MB; Vulkanox; o-Phenylene thiourea; Rabeprazole Related Compound C USP, Rabeprazole EP Impurity F; Lansoprazole impurity E
Rabeprazole impurity K	RBPL-R0206	615-16-7	$C_7H_6N_2O$; 134.14	2-Hydroxybenzimidazole; 1,3-Dihydro-2H-benzimidazol-2-one; 2-Benzimidazolinone; 2,3-Dihydro-2-oxo-1H-benzimidazole; 2-Benzimidazolol; 2-Benzimidazolone; N,N'-(1,2-Phenyleneurea); NSC 10383; NSC 178108; o-Phenyleneurea; Lansoprazole EP Impurity D(Rabeprazole EP Impurity K)
RAMIPRIL	RBPL-R0300			
Ramipril impurity D	RBPL-R0301	108731-95-9	$C_{23}H_{30}N_2O_4$; 398.5	Ramipril Diketopiperazine; (α S,3S,5aS,8aS,9aS)-Decahydro-3-methyl-1,4-dioxo- α -(2-phenylethyl)-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazine-2-acetic Acid Ethyl Ester; [3S-[2(R*),3 α ,5a β ,8a β ,9a β]]-Decahydro-3-methyl-1,4-dioxo- α -(2-phenylethyl)-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazine-2-acetic Acid Ethyl Ester; Ramipril Related Compound D;

API IMPURITIES AND METABOLITES

Ramipril impurity B	RBPL-R0302	295328-72-2	C ₂₄ H ₃₄ N ₂ O ₅ ; 430.54	(2S,3aS,6aS)-Hexahydro-1-[(2S)-2-[[[(1S)-1-[(1-methylethoxy)carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]cyclopenta[b]pyrrole-2(2H)-carboxylic Acid; (2S,3aS,6aS)-Octahydro-1-[(2S)-2-[[[(1S)-1-[(1-methylethoxy)carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]cyclopenta[b]pyrrole-2-carboxylic Acid; Ramipril related compound B; Ramipril Isopropyl Ester
Ramipril Bicyclic acid (Pevindopril impurity A)	RBPL-R0303	80875-98-5	C ₉ H ₁₅ NO ₂ ; 169.22	L-(2S,3aS,7aS)-Octahydroindole-2-carboxylic Acid; [2S-(2α,3αβ,7αβ)]-Octahydro-1H-indole-2-carboxylic Acid; (2S,3aS,7aS)-2-Carboxyoctahydroindole; (2S,3aS,7aS)-Perhydroindole-2-carboxylic Acid; USP Perindopril Related Compound A; Perindopril USP Related Compound A
Ramipril RC-B (EP-B) (Impurity F)	RBPL-R0304	82717-96-2	C ₁₅ H ₂₁ NO ₄ ; 279.33	(+)-N-[1-(S)-Ethoxycarbonyl-3-phenylpropyl]-L-alanine; (αS)-α-[[[(1S)-1-carboxyethyl]amino]benzenebutanoic Acid; N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanine; Ramipril EP Impurity E/ Enapril Maleate EP Impurity B
Ramipril impurity M	RBPL-R0305	2743-38-6	C ₁₈ H ₁₄ O ₈ ; 358.3	Di-O-benzoyl L-Tartaric Acid; (2R,3R)-2,3-Bis(benzoyloxy)butanedioic Acid; (-)-Di-O-benzoyl-L-tartaric Acid; (-)-O,O'-Dibenzoyl-(2R,3R)-tartaric Acid; (2R,3R)-2,3-Bis(benzoyloxy)succinic Acid; NSC 118224; NSC 338494; Ramipril EP Impurity M;
RISPERIDONE	RBPL-R0400			
Risperidone impurity C	RBPL-R0401	144598-75-4	C ₂₃ H ₂₇ FN ₄ O ₃ ; 426.48	9-Hydroxy Risperidone; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; Invega; Paliperidone; R 76477; RO 76477
Risperidone-N-oxide	RBPL-R0402	832747-55-4	C ₂₃ H ₂₇ FN ₄ O ₃ ; 426.48	3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-oxido-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
Risperidone impurity E	RBPL-R0403	1346602-28-5	C ₂₄ H ₂₉ FN ₄ O ₂ ; 424.51	6-Methyl Risperidone; 3-[2-4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl-6,7,8,9-tetrahydro-2,6-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one;

API IMPURITIES AND METABOLITES

Risperidone impurity C	RBPL-R0404	144598-75-4	$C_{23}H_{27}FN_4O_3$; 426.48	Paliperidone; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 9-Hydroxyrisperidone; R 76477; RO 76477; Risperidone Imp. C (EP)
Risperidone impurity M	RBPL-R0405	84163-13-3 (HCl salt)	$C_{12}H_{14}ClFN_2O$; 256.7	6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole Hydrochloride; 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole Monohydrochloride; 4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidine Hydrochloride; 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole Hydrochloride; 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole Monohydrochloride; 6-Fluoro-3-(4-piperidinyl)benzisoxazole Hydrochloride; 6-Fluoro-3-(piperidin-4-yl)benzo[d]isoxazole Hydrochloride; 6-Fluoro-3-(piperidinyl-4-yl)-benzisoxazole Hydrochloride; USP Paliperidone Related Compound B; Risperidone EP Impurity M; Paliperidone USP Related Compound B; Paliperidone impurity O (Iloperidone impurity 16); Risperidone Amine Impurity (HCl Salt) ; Paliperidone USP RC
		84163-77-9 (base)	$C_{12}H_{13}FN_2O$; 220.24	6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole; 3-(4-Piperidinyl)-6-fluorobenzo[d]isoxazole; 4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidine; 4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidine
Risperidone impurity L	RBPL-R0406	63234-80-0	$C_{11}H_{15}ClN_2O$; 226.7	3-(2-Chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; Risperidone EP Impurity L
RANITIDINE	RBPL-R0500			
Ranitidine impurity B	RBPL-R0501	66356-53-4	$C_{10}H_{18}N_2OS$; 214.33	5-[[[2-Aminoethyl]thio]methyl]-N,N-dimethyl-2-furanmethanamine; 2-[[5-(Dimethylaminomethyl)-2-furanyl]methylthio]ethylamine;
Ranitidine-N-oxide	RBPL-R0502	73857-20-2	$C_{13}H_{22}N_4O_4S$; 330.4	N-[2-[[[5-[[Dimethyloxidoamino]methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine;
Ranitidine impurity I	RBPL-R0503	207592-21-0	$C_{27}H_{44}N_8O_6S_2$, 640.82	N1,N5-Bis[2-[[[5-[[dimethylamino]methyl]-2-furanyl]methyl]thio]ethyl]-N1',N5'-

API IMPURITIES AND METABOLITES

				dimethyl-2,4-dinitro-1,4-pentadiene-1,1,5,5-tetramine; Ranitidine Impurity I; Ranitidine Formaldehyde Adduct, 2,2'-Methylene Bis[Ranitidine]
Ranitidine-S-oxide	RBPL-R0504	73851-70-4	C ₁₃ H ₂₂ N ₄ O ₄ S; 330.4	Ranitidine S-Oxide; N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine; USP Ranitidine Related Compound C; Ranitidine EP Impurity C
Ranitidine impurity K	RBPL-R0505	61832-41-5	C ₄ H ₈ N ₂ O ₂ S; 148.18	N-Methyl-1-(methylthio)-2-nitro-ethenamine; 1-(Methylamino)-1-(methylthio)-2-nitroethene; 2-(Methylthio)-2-(methylamino)-1-nitroethene; 1-(Methylthio)-2-nitro-N-methylethyleneamine; Ranitidine EP Impurity K;
ROSUVASTATIN	RBPL-R0700			
Rosuvastatin lactone	RBPL-R0701	503610-43-3	C ₂₂ H ₂₆ FN ₃ O ₅ S; 463.52	N-[4-(4-Fluorophenyl)-6-(1-methylethyl)-5-[(1E)-2-[(2S,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethenyl]-2-pyrimidinyl]-N-methyl-methanesulfonamide; Rosuvastatin imp D
Rosuvastatin EP Impurity C	RBPL-R0702	1422619-13-3	C ₂₂ H ₂₆ FN ₃ O ₆ S; 479.52	5-Oxo Rosuvastatin; (3R,6E)-7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3-hydroxy-5-oxo-6-heptenoic Acid; 3-Hydroxy-5-keto Rosuvastatin; Rosuvastatin EP Impurity C (Calcium Salt)
RALOXIFENE	RBPL-R0800			
Raloxifene Related Compound C (N-Oxide)	RBPL-R0801	195454-31-0	C ₂₈ H ₂₇ NO ₅ S; 489.58	Raloxifene-N-oxide; [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-oxido-1-piperidinyl)ethoxy]phenyl]methanone;
RANOLAZINE	RBPL-R0900			
Ranolazine-N-oxide	RBPL-R0901	NA	C ₂₄ H ₃₃ N ₃ O ₅ ; 443.55	
Ranolazine-Bis N-oxide	RBPL-R0902	1246816-00-1	C ₂₄ H ₃₃ N ₃ O ₆ ; 459.54	Ranolazine Bis(N-Oxide); N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide 1,4-Dioxide

API IMPURITIES AND METABOLITES

Ranolazine impurity I	RBPL-R0903	5294-61-1	C ₁₄ H ₂₁ N ₃ O; 247.34	N-(2,6-Dimethylphenyl)-1-piperazineacetamide; 1-Piperazineaceto-2',6'-xylidide; 4-[(2,6-Dimethylphenyl)aminocarbonylmethyl]piperazine; N-(2,6-Dimethylphenyl)-2-piperazinyacetamide; RS 94287
RIZATRIPTAN	RBPL-R 1000			
Rizatriptan N10-Oxide	RBPL-R1001	260435-42-5	C ₁₅ H ₁₉ N ₅ O; 285.35	N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine N-Oxide; Rizatriptan EP Impurity H
RIVASTIGMINE	RBPL-R1400			
Rivastigmine EP Impurity A	RBPL-R1401	139306-10-8	C ₁₀ H ₁₅ NO; 165.23	NAP 226-90; (S)-3-[1-(Dimethylamino)ethyl]phenol; 3-[(1S)-1-(Dimethylamino)ethyl]phenol; Rivastigmine EP Impurity A; Rivastigmin USP Related Compound C
Rivastigmine Related Compound A	RBPL-R1402	32634-68-7	C ₂₀ H ₁₈ O ₈ ; 386.36	(+)-O,O'-Di-p-toluoyl-D-tartaric Acid; O,O'-Di-p-toluoyl-Dg-tartaric Acid; (2S,3S)-(+)-Di-O-4-toluoyltartaric Acid; 2,3-Bis-(4-methyl-benzoyloxy)-succinic Acid; Rivastigmine USP Related Compound A
Rivastigmine Hydrogen Tartrate EP Impurity H	RBPL-R1403	586-37-8	C ₉ H ₁₀ O ₂ ; 150.18	1-(3-methoxyphenyl)ethan-1-one;
RUPATADINE	RBPL-R1500			
Rupatadine impurity I	RBPL-R1501	2387-23-7	C ₁₃ H ₂₄ N ₂ O; 224.34	N,N'-Dicyclohexylurea; 1,3-Dicyclohexylurea; DCU; Dicyclohexylcarbodiimide; NSC 17013; NSC 30023; Lomustine USP Related Compound C
ROPINIROLE	RBPL-R1600			
Ropinirole USP RC A	RBPL-R1601	139122-19-3	C ₁₀ H ₁₁ NO ₂ ; 177.2	4-(2-Hydroxyethyl)-1,3-dihydro-2H-indolin-2-one; 4-(2-Hydroxyethyl)-1,3-dihydroindol-2-one; 1,3-Dihydro-4-(2-hydroxyethyl)-2H-indol-2-one; USP Ropinirole Related Compound A
SILDENAFIL	RBPL-S0100			

API IMPURITIES AND METABOLITES

N-desmethyl Sildenafil	RBPL-S0101	139755-82-1	C ₂₁ H ₂₈ N ₆ O ₄ S; 460.58	5-[2-Ethoxy-5-(1-piperazinyl sulfonyl) phenyl]-1,6-dihydro-1-methyl-3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one; UK 103320
Sildenafil impurity B	RBPL-S0102	1094598-75-0	C ₂₂ H ₃₀ N ₆ O ₅ S; 490.58	Sildenafil-N-oxide; 5-[2-Ethoxy-5-[(4-methyl-4-oxido-1-piperazinyl) sulfonyl]phenyl]-1,6-dihydro-1-methyl-3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one;
Sildenafil impurity D	RBPL-S0103	1357931-55-5	C ₁₇ H ₂₀ N ₄ O ₅ S ; 392.43	Desmethylpiperazinyl Sildenafil Sulfonic Acid ;3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxybenzenesulfonic acid ;
SOLIFENACIN	RBPL-S0200			
Solifenacin Impurity I (N-oxide)	RBPL-S0201	180272-28-0	C ₂₃ H ₂₆ N ₂ O ₃ ; 378.46	(1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylic Acid (3R)-1-Oxido-1 - azabicyclo[2.2.2]oct-3-yl Ester; Solifenacin-N-oxide
Solifenacin impurity A	RBPL-S0202	118864-75-8	C ₁₅ H ₁₅ N ; 209.29	(S)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline; (1S)-1,2,3,4-Tetrahydro-1-phenylisoquinoline; (+)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline; (S)-(+)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline;Solifenacin S Phenyl Tetrahydroisoquinoline Impurity; Solifenacin EP impurity A
Solifenacin EP Impurity E	RBPL-S0203	25333-42-0	C ₇ H ₁₃ NO; 127.19	(R)-(-)-3-Quinuclidinol; (3R)-1-Azabicyclo[2.2.2]octan-3-ol; R-(-)-Azabicyclo[2.2.2]octane-3-ol; (R)-3-Quinuclidol; (R)-3-Hydroxyquinuclidine; (3R)-Quinuclidin-3-ol
SERTRALINE	RBPL-S0300			
Sertraline Impurity G	RBPL-S0301	79617-95-1	C ₁₇ H ₁₈ Cl ₃ N; 342.69	Sertraline Enantiomer ; Sertraline (1R,4R)-cis-Isomer ; 1R,4R)-4-(3,4-Dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride;
Sertraline impurity B	RBPL-S0302	52758-05-1	C ₁₇ H ₂₀ ClN; 273.80	3,4-Dideschloro Sertraline HCl (USP) ; cis-3,4-Dideschloro Sertraline HCl ; Sertraline Phenyl Impurity ; cis-4-Phenyl-1,2,3,4-tetrahydro-N-methyl -1-naphthalen amine hydrochloride
Sertraline impurity D	RBPL-S0304	871838-58-3	C ₁₇ H ₁₈ ClN ;271.78	Sertraline 3-Chlorophenyl Analog ;4-Deschloro Sertraline ; cis-(1S)-N-Methyl-4-(3-

API IMPURITIES AND METABOLITES

				chloro phenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
Sertraline impurity C	RBPL-S0307	79646-00-7	C ₁₇ H ₁₉ ClN; 271.78	Sertraline EP Impurity C;(1R,4S)-4-etrahydronaphthalen-1-amine;cis-(1S)-N-Methyl-4-(4-chloro phenyl)-1,2,3,4-tetrahydro-1-naphthalenamine hydrochloride and enantiomer ;(1RS,4RS)-4-(4-Chlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride ;rac-cis-3-Dechloro Sertraline HCl
SULFASALAZINE	RBPL-S0400			
Sulfasalazine impurity D	RBPL-S0401	66364-70-3	C ₁₇ H ₁₄ N ₄ O ₃ S; 354.38306	2-[[4-(2-PyridylsulfaMoyl) phenyl]azo] hydroxybenzene (Sulfasalazine IMpurity D);4-[(2-Hydroxyphenyl)azo]-N-2-pyridinylbenzenesulfonaMide;4-[2-(2-Hydroxyphenyl)diazanyl]-N-2-pyridinyl benzene sulfonaMide;Sulfasalazine IMpurity D
Sulfasalazine impurity H	RBPL-S0402	69-72-7	C ₇ H ₆ O ₃ ; 138.12	Salicylic Acid; 2-Hydroxybenzoic Acid; 2-Carboxyphenol; 2-Hydroxybenzenecarboxylic Acid; 2-Hydroxybenzoic Acid; o-Carboxyphenol; o-Hydroxybenzoic Acid; Rutranex; Saligel; Salonil; Salvona Nanosal; Stri-Dex; Trans-Ver-Sal; Verrugon; Acetylsalicylic Acid EP Impurity C (Aspirin Impurity C)/ Mesalazine EP Impurity H
Sulfasalazine impurity J	RBPL-S0403	144-83-2	C ₁₁ H ₁₁ N ₃ O ₂ S; 249.29	Sulfapyridine; 4-Amino-N-2-pyridinylbenzenesulfonamide; 2-Sulfanilamidopyridine; 2-Sulfapyridine; 4-Amino-N-2-pyridinylbenzenesulfonamide; Adiplon; Coccoclase; Dagenan; Eubasin; Eubasinum; Haptocil; Sulfidine; Sulphapyridine; Thioseptal; Trianon
SIMVASTATIN	RBPL-S0600			
Simvastatin EP Impurity E	RBPL-S0601	75330-75-5	C ₂₄ H ₃₆ O ₅ ; 404.55	Lovastatin; (2S)-2-Methylbutanoic Acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl Ester; (+)-Mevinolin; 6α-Methylcompactin; Altacor; Antibiotic MB 530B; L 154803; Lostatin; Lovalip; Lovastatin Lactone; MK 803; MSD 803; Mevacor; Mevinacor; Mevinolin; Mevlor; Monacolin K; Monacolin K Lactone; Sivlor;

API IMPURITIES AND METABOLITES

				Simvastatin EP Impurity E
SUMATRIPTAN	RBPL-S0800			
Sumatriptan N-oxide	RBPL-S0801	212069-94-8	C ₁₄ H ₂₁ N ₃ O ₃ S; 311.4	Sumatriptan N-Oxide ; 3-[2-(Dimethyloxidoamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; GR 112504; Sumatriptan EP Impurity D;
SITAGLIPTIN	RBPL-S0900			
Sitagliptin Impurity A	RBPL-S0901	823817-58-9	C ₁₆ H ₁₅ F ₆ N ₅ O; 407.32	ent-Sitagliptin Phosphate; 7-[(3S)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine Phosphate; (S)-Sitagliptin Phosphate; Sitagliptin EP Impurity A;
Sitagliptin Impurity B	RBPL-S0902	1345822-87-8	C ₁₆ H ₁₆ F ₅ N ₅ O; 389.33	4-Desfluoro Sitagliptin; (R)-3-Amino-4-(2,5-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one-phosphate
Sitagliptin Impurity C	RBPL-S0903	1345822-86-7	C ₁₆ H ₁₆ F ₅ N ₅ O; 389.31	5-Desfluoro Sitagliptin; (R)-3-Amino-4-(2,4-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one-phosphate
Sitagliptin fumarate adduct	RBPL-S0904	2088771-60-0	C ₂₀ H ₁₉ F ₆ N ₅ O ₅ ; 523.39	Sitagliptin Maleate Adduct; 2-(((R)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-yl)amino)succinic acid
SORAFENIB	RBPL-S1000			
Sorafenib N-Oxide	RBPL-S1001	583840-03-3	C ₂₁ H ₁₆ ClF ₃ N ₄ O ₄ ; 480.82	4-[4-[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide 1-Oxide
SALICYLIC ACID	RBPL-S1100			
Salicylic Acid Related Compound A	RBPL-S1101	99-96-7	C ₇ H ₆ O ₃ ; 138.12	p-Salicylic Acid; p-Salicylic Acid; 4-Hydroxybenzoic Acid; 4-Carboxyphenol; Paraben-acid; p-Carboxyphenol; p-Hydroxybenzoic Acid; NSC 4961; USP Salicylic Acid Related Compound A

API IMPURITIES AND METABOLITES

Salicylic acid impurity B	RBPL-S1102	636-46-4	C ₈ H ₆ O ₅ ; 182.13	4-Hydroxyisophthalic Acid; 4-Hydroxy-1,3-benzenedicarboxylic Acid; 4-Hydroxy-m-phthalic Acid; Eupirina; NSC 2445; USP Salicylic Acid Related Compound B; Acetylsalicylic Acid EP Impurity B/ Salicylic Acid Related Compound B
Salicylic Acid EP Impurity C	RBPL-S1103	108-95-2	C ₆ H ₅ OH; 94.11	Hydroxybenzene; Phenol
TELMISARTAN	RBPL-T0100			
Telmisartan impurity F	RBPL-T0101	915124-86-6	C ₃₃ H ₃₁ N ₅ O; 513.63	4'-[(1,4'-Dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl][1,1'-biphenyl]-2-carboxamide; Telmisartan amide
Telmisatran related compound A	RBPL-T0102	152628-02-9	C ₁₉ H ₂₀ N ₄ ; 304.39	2-n-Propyl-4-methyl-6-(1-methyl benzimidazol-2-yl)-benzimidazole; Impurity A; 1,7'-Dimethyl-2'-propyl-2,5'-bi-1H-benzimidazole; 4-Methyl-6-(1-methyl benzimidazol-2-yl)-2-propylbenzimidazole
Telmisatran impurity D	RBPL-T0103	NA	C ₂₆ H ₂₄ N ₂ O ₄ ; 428.29	1-[(2-Carboxy[1,1-biphenyl]-4-yl)methyl]-4-methyl-2-propyl-1H-benzimidazole-6-carboxylic Acid
Telmisartan methylester	RBPL-T0104	528560-93-2	C ₃₄ H ₃₂ N ₄ O ₂ ; 528.6	2-(4-{[4-Methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid methyl ester
TRAMADOL	RBPL-T0200			
Tramadol-N-oxide	RBPL-T0201	147441-56-3	C ₁₆ H ₂₅ NO ₃ ; 279.37	(1R,2R)-rel-2-[(Dimethyloxidoamino) methyl]-1-(3-methoxyphenyl)-cyclohexanol; RWJ 38705;
Tramadol impurity A	RBPL-T0202	2914-77-2; 152538-36-8 (FB); 73806-49-2	C ₁₆ H ₂₅ N O ₂ · Cl H; 299.84	(1RS,2SR)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol; (1RS,2SR)-2-[(Dimethylamino)methyl]-1-(3-methoxy phenyl) cyclohexanol Hydrochloride; Tramadol related compound A
Tramadol impurity D	RBPL-T0203	NA; 185453-02-5 HCl; 80456-81-1 (FB)	C ₁₅ H ₂₃ NO ₂ ·HCl; 249.36 ; 285.82 HCl	O-desmethyl tramadol; (1RS,2RS)-2-[(dimethylamino)methyl]-1-(3-hydroxyphenyl)cyclohexanol;

API IMPURITIES AND METABOLITES

Tramadol Impurity C	RBPL-T0204	66170-31-8; 905592-54-3 (FB)	$C_{16}H_{23}NO$; 245.37	1,6-Dehydro Tramadol Hydrochloride; 2-(3-Methoxyphenyl)-N,N-dimethyl-2-cyclohexene-1-methanamine Hydrochloride; Tramadol Impurity C Hydrochloride
THIOCHOLCHICOSIDE	RBPL-T0300			
N-deacetyl-N-formyl Thiocholchicoside	RBPL-T0302	219547-29-2	$C_{26}H_{31}NO_{10}S$; 549.59	N-[(7S)-3-(β-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]formamide
N-deacetyl-3-demethyl Thiocholchicine	RBPL-T0303	97043-09-9	$C_{19}H_{21}NO_4S$; 359.44	(7S)-7-Amino-6,7-dihydro-3-hydroxy-1,2-dimethoxy-10-(methylthio)-benzo[a]heptalen-9(5H)-on
Thiocholchicoside S-oxide (Impurity J)	RBPL-T0304	1359973-79-7	$C_{27}H_{33}NO_{11}S$; 579.62	N-((7S)-1,2-Dimethoxy-10-(methylsulfinyl)-9-oxo-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-5,6,7,9-tetrahydro benzo[a]heptalen-7-yl)acetamide
3-o-desmethyl Thiocholchicine (Impurity C)	RBPL-T0305	87424-25-7	$C_{21}H_{23}NO_5S$; 401.48	3-Demethyl Thiocolchicine 3-O-β-D-Glucuronide;(7S)-7-(Acetylamino)-5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-3-yl β-D-Glucopyranosiduronic Acid;
Thiocolchicoside disulphoxide	RBPL-T0306	1359973-80-0	$C_{27}H_{33}NO_{12}S$; 595.62	10-S-Methylsulfonyl Thiocolchicoside; N-[(7S)-3-(β-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylsulfonyl)-9-oxobenzo[a]heptalen-7-yl]acetamide
Thiocholchicoside Impurity A (Colchicine)	RBPL-T0307	64-86-8	$C_{22}H_{25}NO_6$; 399.44	(S)-Colchicine >95%; N-[(7S)-5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; (-)-Colchicine; Colchineos; Colchisol; Colcin; Colsaloid; Condylon; NSC 757
TROSPIUM	RBPL-T0400			

API IMPURITIES AND METABOLITES

Trospium chloride related compound A	RBPL-T0401	76-93-7	C ₁₄ H ₁₂ O ₃ ; 228.24	Benzilic acid; α-Hydroxy-α-phenylbenzeneacetic Acid; 2,2-Diphenyl-2-hydroxyacetic Acid; 2,2-Diphenyl-2-hydroxyethanoic Acid; 2,2-Diphenylglycolic Acid; 2-Hydroxy-2,2-diphenylacetic Acid; Diphenylglycolic Acid; Diphenylhydroxyacetic Acid; Hydroxydiphenylacetic Acid; NSC 2830; α,α-Diphenyl-α-hydroxyacetic Acid; α,α-Diphenylglycolic Acid; α-Hydroxy-2,2-diphenylacetic Acid; α-Hydroxy-α-phenylbenzeneacetic Acid; α-Hydroxydiphenylacetic Acid; Trospium Chloride Related Compound A;
Trospium impurity D	RBPL-T0402	467-32-3	C ₂₈ H ₂₀ O ₄ ; 420.45	Benzilide; 3,3,6,6-Tetraphenyl-1,4-dioxane-2,5-dione; NSC 403081; NSC 677243
TORSEMIDE	RBPL-T0500			
Torsemide Impurity C (Related Compound C)	RBPL-T0501	58155-35-4	C ₁₅ H ₁₈ N ₄ O ₃ S; 334.39	N-1-Ethyl-1-demethylethyl Torsemide; Torsemide Related Compound C; N-[(Ethylamino)carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide
Torsemide Impurity D	RBPL-T0502	160972-33-8	C ₁₇ H ₂₂ N ₄ O ₃ S; 362.45	N-1-Butyl-1-demethylethyl Torsemide; USP Torsemide Related Compound B; N-[(Butylamino)carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide
TIMOLOL	RBPL-T0600			
Timolol impurity D	RBPL-T0601	NA	C ₆ H ₉ N ₃ O ₂ S; 187.22	4-Morpholino-1,2,5-thiadiazol-3-ol; Timolol related compound D
Timolol impurity B (maleate salt)	RBPL-T0602	158636-96-5	C ₁₃ H ₂₄ N ₄ O ₃ S; 316.43	3-(tert-butylamino)-2-(4-morpholino-1,2,3-thiadiazol-3-yloxy)propan-1-ol; Isotimolol (S); Timolol related compound B
Timolol impurity F	RBPL-T0603	30165-96-9	C ₆ H ₈ ClN ₃ OS; 205.67	3-Chloro-4-morpholino-1,2,5-thiadiazole; 3-Morpholino-4-chloro-1,2,5-thiadiazole; 4-(4-Chloro-1,2,5-thiadiazol-3-yl)morpholine; Timolol EP Impurity F; Timolol BP Impurity F; Timolol USP Related Compound F
TOLTERIDONE	RBPL-T0700			

API IMPURITIES AND METABOLITES

Tolteridone lactone	RBPL-T0701	40546-94-9	C ₁₆ H ₁₄ O ₂ ; 238.28	rac-6-Methyl-4-phenylchroman-2-one; 6-Methyl-4-phenyl-3,4-dihydro-1-benzopyran-2-one; 6-Methyl-4-phenylchroman-2-one; 6-Methyl-4-phenyl-3,4-dihydrocoumarin
Tolteridone impurity E	RBPL-T0702	480432-14-2	C ₁₉ H ₂₅ NO ; 283.41	4-Methyl-2-[3-[(1-methylethyl) amino]-1-phenylpropyl]phenol; N-Isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl propylamine; rac Desisopropyl Tolterodine
TAMSULOSIN	RBPL-T0800			
Tamsulosin impurity D	RBPL-T0801	80223-96-7	C ₁₉ H ₂₆ N ₂ O ₅ S ; 394.49	2-Methoxy-5-[(2R)-2-[[2-(2-methoxyphenoxy)ethyl] amino] propyl] benzene sulfonamide; Tamsulosin Methoxy Analog
Tamsulosin HCl impurity G	RBPL-T0802	80223-99-0; 106463-19-8 Racemate	C ₂₀ H ₂₉ ClN ₂ O ₅ S; 444.97	5-[2-[[2-(2-Ethoxyphenoxy) ethyl] amino] propyl]-2-methoxybenzenesulfonamide Hydrochloride; Flomax; Harnal; Omnic; Pradif; YM 12617-1; YM 617; Yutanal; rac Tamsulosin Hydrochloride
Tamsulosin impurity H	RBPL-T0803	1329611-47-3	C ₂₀ H ₂₇ NO ₃ ; 329.43	Tamsulosin impurity H; (2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-1-(4-methoxyphenyl)propan-2-amine; (R)-De(aminosulfonyl) Tamsulosin;
Tamsulosin impurity A	RBPL-T0804	918867-88-6	C ₃₀ H ₄₀ N ₂ O ₇ S; 572.71	N-[2-(2-Ethoxyphenoxy)ethyl]-(R)-Tamsulosin; 5-[(2R)-2-[Bis[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide; 5-((R)-2-[Bis[2-(2-ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzenesulfonamide; Tamsulosin EP Impurity A; Tamsulosin EP Impurity A (Supplied as HCl Salt) ; 5-[(2R)-2-[bis[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy benzene sulfonamide HCl ;
TAMOXIFEN	RBPL-T0900			
Tamoxifen-N-oxide	RBPL-T0901	75504-34-6	C ₂₆ H ₂₉ NO ₂ ; 387.51	(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine oxide
TIZANIDINE	RBPL-T1400			
Tizanidine impurity A	RBPL-T1401	51322-69-1	C ₉ H ₉ N ₅ S; 219.27	2,1,3-Benzothiadiazol-4-amine, N-(4,5-dihydro-1H-imidazol-2-yl)-

API IMPURITIES AND METABOLITES

Tizanidine impurity B	RBPL-T1402	51323-05-8	C ₇ H ₅ ClN ₄ S ₂ ; 244.72	N-(5-Chloro-2,1,3-benzothiadiazol-4-yl)-thiourea
Tizanidine impurity C	RBPL-T1403	1147548-83-1	C ₁₆ H ₁₄ Cl ₂ N ₁₀ S ₂ ; 481.39	1, 1'-Ethane-1,2-diylbis[3(5-chloro-2,1,3-benzothiadiazol-4-yl)guanidine
Tizanidine impurity D	RBPL-T1404	51323-03-6	C ₈ H ₇ ClN ₄ S ₂ ; 258.75	Methyl N-(5-Chloro-2,1,3-benzothiadiazol-4-yl)-carbamidodithioate
Tizanidine impurity E (Related compound A)	RBPL-T1405	30536-19-7	C ₆ H ₄ ClN ₃ S; 185.63	5-Chloro-2,1,3-benzothiadiazol-4-amine
Tizanidine impurity F	RBPL-T1406	1147548-85-3	C ₁₆ H ₁₁ Cl ₂ N ₉ S ₂ ; 464.35	N,N'-Bis(5-chloro-2,1,3-benzothiadiazol-4-yl)-N-(4,5-dihydro-1H-imidazol-2-yl)-guanidine; 1,3-Bis(5-chlorobenzo[c][1,2,5]thiadiazol-4-yl)-1-(4,5-dihydro-1H-imidazol-2-yl)guanidine; Tizanidine EP Impurity F
Tizanidine impurity H	RBPL-T1407	107-15-3	C ₂ H ₈ N ₂ ; 60.1	Ethylene Diamine ; Ethane-1,2-diamine
TOFACITINIB	RBPL-T1800			
Tofacitinib pyrimidine N-oxide	RBPL-T1801	NA	C ₁₆ H ₂₀ N ₆ O ₂ ; 328.37	Tofacitinib pyrimidine N-oxide
Tofacitinib N-Oxide	RBPL-T1802	2028267-73-2	C ₁₆ H ₂₀ N ₆ O ₂ ; 328.37	CP-690550 N-Oxide; (3R,4R)-4-Methyl-3-(methyloxido-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile
Tofacitinib impurity Q	RBPL-T1803	3680-69-1	C ₆ H ₄ ClN ₃ ; 153.57	6-Chloro-7-deazapurine; 4-Chloro-1H-pyrrolo[2,3-d]pyrimidine; 4-Chloropyrrolo[2,3-d]pyrimidine; NSC 64952
Tofacitinib impurity R	RBPL-T1804	479633-63-1	C ₁₃ H ₁₀ ClN ₃ O ₂ S; 307.76	4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine; 4-Chloro-7-[(4-methylphenyl)sulfonyl]- 7H-pyrrolo[2,3-d]pyrimidine; 4-Chloro-7-(4-methylphenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine;
TOPOTECAN	RBPL-T1900			
Topotecan RC-C	RBPL-T1901	7689-03-4	C ₂₀ H ₁₆ N ₂ O ₄ ; 348.35	(S)-(+)-Camptothecin; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-

API IMPURITIES AND METABOLITES

				b]quinoline-3,14(4H,12H)-dione; Topotecan USP Related Compound C
TENOXCAM	RBPL-T2000			
Tenoxicam impurity A	RBPL-T2001	504-29-0	C ₅ H ₆ N ₂ ; 94.11	2-Aminopyridine; 2-Pyridinamine; 1,2-Dihydro-2-iminopyridine; 2-Pyridylamine; NSC 431; Piroxicam EP Impurity A
TRIMEBUTINE	RBPL-T2100			
Trimebutine impurity B	RBPL-T2101	118-41-2	C ₁₀ H ₁₂ O ₅ ; 212.2	3,4,5-Trimethoxybenzoic Acid; Eudesmic Acid; Gallic Acid Trimethyl Ether; NSC 2525; Tri-O-methylgallic Acid; Trimethylgallic Acid
Trimebutine impurity C	RBPL-T2102	1916-07-0	C ₁₁ H ₁₄ O ₅ ; 226.23	Methyl 3,4,5-Trimethoxybenzoate; 3,4,5-Trimethoxybenzoic Acid Methyl Ester; Methyl Eudesmate; Methyl Gallate Trimethyl Ether; Methyl Tri-O-methylgallate; NSC 16955; Trimethylgallic Acid Methyl Ester
VERAPAMIL	RBPL-V0100			
Verapamil impurity I	RBPL-V0101	67812-42-4	C ₂₆ H ₃₇ ClN ₂ O ₄ ; 477.04	α-[3-[[2-(3,4-Dimethoxyphenyl) ethyl]amino]propyl]-3,4-dimethoxy-α-(1-methylethyl)- benzeneacetonitrile
Verapamil impurity K	RBPL-V0102	20850-49-1	C ₁₃ H ₁₇ NO ₂ ; 219.29	
Verapamil N-Oxide Hydrochloride	RBPL-V0103	NA	C ₂₇ H ₃₉ ClN ₂ O ₅ ; 507.06	Verapamil N-Oxide Hydrochloride
Verapamil impurity E (RC-F)	RBPL-V0104	93-03-8	C ₉ H ₁₂ O ₃ ; 168.19	3,4-Dimethoxybenzyl Alcohol; Veratryl Alcohol; (3,4-Dimethoxyphenyl)methanol; 3,4-Dimethoxybenzenemethanol; 3,4-Dimethoxybenzyl Alcohol; 3,4-Dimethoxyphenylmethyl Alcohol; NSC 6317; Veratralcohol; USP Verapamil Related Compound F; Verapamil EP Impurity E; Verapamil USP Related Compound F
Verapamil impurity G (RC-E)	RBPL-V0105	120-14-9	C ₉ H ₁₀ O ₃ ; 167.17	3,4-Dimethoxybenzaldehyde; 3,4-Dimethoxybenzenecarbaldehyde; 4-O-Methylvanillin; Methylvanillin; NSC 24521; NSC 8500; Protocatechualdehyde Dimethyl Ether;

API IMPURITIES AND METABOLITES

				Protocatechuic Aldehyde Dimethyl Ether; Vanillin Methyl Ether; Veratral; Veratric Aldehyde; Veratrum Aldehyde; Veratryl Aldehyde; USP Verapamil Related Compound E; Verapamil EP Impurity G; Verapamil Related Compound E
VENLAFAXINE	RBPL-V0200			
Desvenlafaxine	RBPL-V0201	93413-62-8; 386750-22-7-for succinate salt	C ₁₆ H ₂₅ NO ₂ ; 263.38	4-[2-(Dimethylamino)-1-(1-hydroxycyclo-hexyl)ethyl]phenol; DVS 233; Desvenlafaxine; O-Desmethylvenlafaxine; Pristiq; WY 45233;
Venlafaxine impurity F	RBPL-V0202	93413-79-7	C ₁₇ H ₂₆ ClNO; 295.85	(2RS)-2-(Cyclohex-1-enyl)-2-(4-methoxyphenyl)-N,N-dimethylethanamine hydrochloride ;
Venlafaxine impurity B	RBPL-V0203	323176-93-8 (base)	C ₁₄ H ₂₁ NO ₃ (base); 251.32	Venlafaxine Ester Impurity ; Ethyl (2RS)-3-(dimethylamino)-2-(4-methoxyphenyl)propanoate HCl
Venlafaxine N-Oxide	RBPL-V0204	1021933-95-8	C ₁₆ H ₂₅ NO ₃ ; 279.38	2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl)-N,N-dimethylethan-1-amine oxide
Venlafaxine impurity C	RBPL-V0205	130198-05-9; Free Acid: 93413-77-5	C ₁₅ H ₂₃ NO ₂ •HCl; 249.35	1-[2-Amino-1-(4-methoxyphenyl)ethyl]cyclohexanol Hydrochloride; (±)-1-[2-Amino-1-(4-methoxyphenyl)ethyl]cyclohexanol Hydrochloride; 1-[2-Amino-1-(p-methoxyphenyl)ethyl]cyclohexanol hydrochloride; N,N-Didesmethylvenlafaxine Hydrochloride; Venlafaxine EP Impurity C
VALSARTAN	RBPL-V0300			
Valsartan Methyl ester	RBPL-V0301	137863-17-3	C ₂₅ H ₃₁ N ₅ O ₃ ; 449.55	Valsartan Methyl Ester ; N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-Valine Methyl Ester; N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-Valine Methyl Ester; N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine Methyl Ester; Valsartan USP Related Compound E
Valsartan Isopropyl ester	RBPL-V0302	1245820-09-0	C ₂₇ H ₃₅ N ₅ O ₃ ; 477.6	Valsartan Isopropyl Ester ; N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine 1-Methylethyl Ester; (S)-Isopropyl 2-(N-((2'-(1H-Tetrazol-5-

API IMPURITIES AND METABOLITES

				yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate
Valsartan Ethyl ester	RBPL-V0303	1111177-30-0	C ₂₆ H ₃₃ N ₅ O ₃ ; 463.57	Valsartan Ethyl Ester; N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-L-valine Ethyl Ester
VALPROIC ACID	RBPL-V0400			
Valproic acid impurity L	RBPL-V0401	97-61-0	C ₆ H ₁₂ O ₂ ; 116.16	2-methylpentanoic acid; (±)-2-Methylvaleric acid, 2-Methylpentanoic acid, 2-Methylvaleric acid;
VORICONAZOLE	RBPL-V0500			
Voriconazole RC-C (Imp-A)	RBPL-V0501	86404-63-9	C ₁₀ H ₇ F ₂ N ₃ O; 223.18	2,4-Difluoro-α-(1H-1,2,4-triazolyl)acetophenone; 1-(2,4-Difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)-ethanone; 2',4'-Difluoro-2-(1H-1,2,4-triazol-1-yl)acetophenone; ((2S, 3R)-2-(2,4-Difluorophenyl) -3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol); USP Voriconazole Related Compound C; Voriconazole EP Impurity A; Voriconazole USP Related Compound C
Voriconazole RC-F (Imp-E)	RBPL-V0502	5872-08-2	C ₁₀ H ₁₆ O ₄ S; 232.3	DL-10-Camphorsulfonic Acid; (±)-7,7-Dimethyl-2-oxo-bicyclo[2.2.1]heptane-1-methanesulfonic Acid; (±)-2-Oxo-10-bornanesulfonic Acid; (RS)-10-Camphorsulfonic Acid; (±)-Camphor-10-sulfonic Acid; (±)-Camphorsulfonic acid; 2-Oxo-10-bornanesulfonic Acid; DL-Camphorsulfonic Acid; ((1RS,4SR)-7,7-Dimethyl-2-oxobicyclo[2.2.1]-hept-1-yl)methanesulphonic Acid); USP Voriconazole Related Compound F; USP Ecamsule Related Compound E; CSA; Voriconazole EP Impurity E
VIGABATRIN	RBPL-V0600			
Vigabatrin EP Impurity D	RBPL-V0601	56-12-2	C ₄ H ₉ NO ₂ ; 103.12	γ-Aminobutyric Acid; 4-Aminobutanoic Acid; 3-Carboxypropylamine; 4-Aminobutyric Acid; Aminalon; GABA; Gaballon; Gamarex; Gammalon; Gammalone; Gammar; Gammasol; Mielogen; Mielomade; NSC 27418; NSC 32044; NSC 45460; NSC 51295; Oryza GABA Extract HC 90; Pharma-GABA 20S; Pharmagaba;

API IMPURITIES AND METABOLITES

				Pharmagaba 20; Pharmagaba 20D; Piperidic acid; Piperidinic acid; γ-Aminobutanoic acid; ω-Aminobutyric Acid;
VALACICLOVIR	RBPL-V0700			
Valaciclovir Impurity A	RBPL-V0701	73-40-5	C ₅ H ₅ N ₅ O; 151.13	Guanine; 2-Amino-1,9-dihydro-6H-purin-6-one; 2-Amino-6-hydroxy-1H-purine; 2-Amino-6-hydroxypurine; 2-Aminohypoxanthine; 9H-Guanine; 2-Amino-hypoxanthine; Acyclovir Impurity B; Acyclovir Impurity B, Acyclovir EP RRT - 0.4; Aciclovir EP Impurity B; (Valaciclovir Impurity A)
Valaciclovir Impurity B	RBPL-V0702	59277-89-3	C ₈ H ₁₁ N ₅ O ₃ ; 225.2	2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; 9-[(2-Hydroxyethoxy)methyl]guanine; Acycloguanosine; Acicloftal; Cargosil; Gerpevir; Herpevir; Zovirax; Zyclir; Valaciclovir EP Impurity B; Acyclovir
ZIDOVUDINE	RBPL-Z0100			
Zidovudine related compound B	RBPL-Z0101	25526-94-7	C ₁₀ H ₁₃ ClN ₂ O ₄ ; 260.67	3-Chloro-3-deoxythymidine
Zidovudine impurity D	RBPL-Z0102	76-84-6	C ₁₉ H ₁₆ O; 260.33	Triphenylmethanol; α,α-Diphenylbenzenemethanol; BL 3756; Hydroxytriphenylmethane; NSC 4050; Triphenylcarbinol; Triphenylmethanol; Triphenylmethyl Alcohol; Tritanol; Trityl Alcohol; U 45483; α,α-Diphenylbenzenemethanol; Zidovudine EP Impurity D; Losartan Impurity G
ZIPRASIDONE	RBPL-Z0200			
Ziprasidone related compound B	RBPL-Z0201	1159977-56-6	C ₂₁ H ₁₉ ClN ₄ O ₂ S; 426.92	3-Oxo Ziprasidone; (5-(2-(4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindoline-2,3-dione); 5-[2-[4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1H-indole-2,3-dione
Ziprasidone impurity E (RC D)	RBPL-Z0202	1159977-04-4	C ₂₈ H ₂₄ ClN ₅ OS ₂ ; 546.11	3-(Benzo[d]isothiazol-3-yl)-5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; Ziprasidone Related Compound D; 3-(1,2-Benzisothiazolyl) Ziprasidone; Ziprasidone related compound D

API IMPURITIES AND METABOLITES

Ziprasidone Ring-opened Impurity	RBPL-Z0203	1159977-64-6	$C_{21}H_{23}ClN_4O_2S$; 430.95	Ziprasidone open ring impurity; Impurity C; 2-(2-amino-5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-4-chlorophenyl)acetic acid
Ziprasidone Deschloro Impurity	RBPL-Z0204	118305-72-9	$C_{21}H_{22}N_4OS$; 378.5	5-{2-[4-(1,2-Benzothiazol-3-yl)-1-piperazinyl]ethyl}-1,3-dihydro-2H-indol-2-one.
Ziprasidone N-Oxide	RBPL-Z0205	188797-76-4	$C_{21}H_{21}ClN_4O_2S$; 428.94	Ziprasidone N-Oxide; 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-oxido-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one
Ziprasidone S-Oxide	RBPL-Z0206	188797-80-0	$C_{21}H_{21}ClN_4O_2S$; 428.94	Ziprasidone Sulfoxide; 6-Chloro-1,3-dihydro-5-[2-[4-(1-oxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-2H-indol-2-one;
ZOLMITRIPTAN	RBPL- Z0300			
Zolmitriptan N-Oxide	RBPL- Z0301	251451-30-6	$C_{16}H_{21}N_3O_3$; 303.36	(4S)-4-[[3-[2-(Dimethyloxidoamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; Zolmitriptan USP Related Compound E
Zolmitriptan RC-G	RBPL- Z0302	152305-23-2	$C_{10}H_{12}N_2O_2$; 192.21	(S)-4-(4-Aminobenzyl)-2-(1H)-oxazolidinone; (4S)-4-[(4-aminophenyl)methyl]-2-oxazolidinone; 4S)-4-(4-Aminobenzyl)-1,3-oxazolidin-2-one; ZTR 5; Zolmitriptan USP Related Compound G
Zolmitriptan RC-H	RBPL- Z0303	1116-77-4	$C_{11}H_{23}NO_2$; 189.3	4-Dimethylaminobutyraldehyde Diethyl Acetal; 4,4-Diethoxy-N,N-dimethyl-1-butanamine; 1-(N,N-Dimethylamino)-4,4-diethoxybutane; 4,4-Diethoxy-N,N-dimethylbutanamine; 4,4-Diethoxy-N,N-dimethylbutylamine; 4-(Dimethylamino)butanal Diethyl Acetal; Zolmitriptan USP Related Compound H